var title_f39_18_40224="Lichen sclerosus in a 10 year old prepubertal girl";
var content_f39_18_40224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus in a 10-year-old prepubertal girl",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDykgknik2846mn429sUAcmuY+ksNIAbFGwdqfj1pO+O9ILCbMmoiMtjk1OgIyT0pNpYtsHI6GncfKQBdpOBk9zTiMdsE0K29VOCO2PQ0/IyMD2ouOwIM9QCPekC7SeBT8DaepPWgJyPXr7UMfKMTrint8xxz1xmpAvzYxgUj/IR2XFAcpDJHhgD1qKTI5wCD6VYYY5IOO+agl+VlVeQe/amjOWhBOQVGKrTDBBAJH86tS8cDioZ8Flx1PIpoykULlhuBx068VUm7n8quSAgvu5yaqSDDnn8K0RzyI4g8xUAAn06VrxjdbMMELzjFZMCO7MRxitzTvLQfvAWwMj/wCvW0DE5y5UbzuOCPWg5G1UO4evSnX+DO23kZyDSQjYAep9KmSCOpqBsIgY/Mi9hVkBWKI5G0EM2D1qK3gMmnyTkgfOFznmoNrPIyr+Hvio2Nr9xtwHWSR4/lGTx6CoEco69c+1SzK6xbwR83BqlKzA7s9P1poykT3ZWeDzGUbw2FOOVFU54xtxknHT6U9y62u7IEZf8aFlDR8gHArQzIoz8gB7VYjQLIZEADt1NVx8uDxzU0WNxPODWUjaJcwWwTzj3qyhGPl6/SoY16Y4B61YTh+fwxUs1RPEuVOw8jrU0SdT3psalX4PXipkVlkOcED0rM1ihwGRkt+FSg5x04qPktnIIFP5JGAcmg2SJDGoGT1P600pxg5xUmGAA3Kf6UGPj52BPpSuUkVZFwcD070iISCe2PWrG3vjNBG3IODSuFiuGwMEEGinhCRnJX2PNFGorFxgeKkjAJx7UxQM89qlQce/amUhNgz24phHNTgDBzTcYGKlsrlIwOOelAAKkdjT2HGO1Nx05qSrDCmMYPHXmkVR1IqXq2M8CiNGLHceKaDlIgNvqfrTjnAwCR3PpT2XBGKeV+8AAMGncLEXUZ9OtAwxODzTwMjj8cVGdwwQeO9CbEDngc4x7ZqGYDYdwOakDEPk9D+lMc5BATJz61aZElcrMuATk56VVnbG055HUVdly+TgcDpVK5QG3Mij584wKpK5hLRFJ+mTnH1quxBOetWCrPGM9qjjjLSA9qtHLK5VG4yqOQD0rc0uMTW7DPzDg4rMZcTcnAHSt/wvHE10yykohQ4OM/NW0dDJK7scjfLsuZFOQVPT0qOJyWGRgetavie2+z6ncJuD4bAcfxD1rNt+D6gc0p76Ewua0ErNEkX3UTJCj1p8sfCshyelVEk+bJ9atRnJwO1ZHQtUF2iLZI65KycdMYIrFnZhGFB4HNbkhY2M0JxgN5gPpWJdEkpgAY9K0jsZz3IpSTaRq7bVLcE1BGSG+Y4XNaF3bqLSI9WHJB7elZ6hgcY9sVRkiyqhm4OR/OrKJknjkVBGgUcn8auRhF6j8aiRtBE1sN4Cjkgjk1cVMOCvzGoIlCnCjlhxVhFIjUYGfWspG8SymCV7dsmpiMHJ/wAio2xuTHUdamUFpB0z2FQbxQ5Fxt+U7T60/wCXJHJPt0pQBjIYj2pAcZPAx+tTc1SFRTuOMU4hh94gqewFPRiOg3YOelLnPU8VNy7DAmWIPIx6UyTOevNSEjkA0gDEjOPcUA1ciUDHSipjHt4UZH1oouKxOqYHIyT0qYR7QO5NPZFXaTyaccZPH/6qbZaiRkdTTME8dxxUykHqOgqNVZmx29qkqxEw28dWo9KkZMMfakKnbgdKLgkR7cjjrUirhc7uaYAR8p6VLwCBnii47EZX5TuPFBZOpxj6U8jg4PB7CgrgZxnj160BYj24wF4GaZjqO+c+9PZSQDnnrQyNsyTnuDVEtEGHyOh9cdaayneMAnHFSDljjBYdaSTJXO7BHamjNorqMbz/ABZz1qvMVNrIjcsTx9e9WtpT5jzjmqLs6cMBk84rRGEymyDDc4OOT2q3bW4EKMfvY596hA3yhsY9q1Y1+QDFXFkRp3MS4jPm49DmtXw/c5uEiJGBkA4qpqsXzDHGah052guAY+T04rXocb92dix42iVdS+UkqU4OOtc1F04PevQvirZW1vqcTWTIYjFGG2NuUOUBOD35rzlGww64z2onboRtJotoxyBVlW28nvVRD83bnpVqV8BfoBisy7mhbqJQwUc7cYx2rCmjLXARfWtCzumgfcDzgj86itxm+DBNwz+dVHsE3fVEd3bMhVNwOBnPas5hiUN6V0mtfvL5ztKLtGAT04rBdcyIg/i61pJWMiaMbwTxjHc1MOFwQcelLbxbTgqCM8Ajip9oLEucAdcVkzojsLAuTwRkjAq7CMR7T9709arwxKV3jHHUnsKsphVXK5PY1mzaCLCHeRwBj9al2sjgn7x/LFQqgB3Z5PvVnoxLLz0zWTOiI5QWIKnjOOaf5QcsRyx6Y7U1S20YUBBzg1KMKBkY74FSbIaFYZweAOQaI2ygz3HB9acpLAkHAxzRwSMfdHrSYxpG3DLnOealUZwQOKTA65qT5QmOM0DSuM+uM0UbcdSAaKQWNBUDIDk8dqdIi4xk4J6CnQqSTyTj3qRlAy56DgCmaJFdU2k9CfXNDKFbqKlRMtkge4FOkhCopb8KVxkDptHXrUSgYJ5q2fmXkc9KhdFJG0nBoHYrhe/YnrQgBfAU8HAPr9KmAAJViSo9KYwAHyjFBNgAC7hg7v5U2TjAz2/WnIcDnketJnPLcY9P0pgRblUHAO7+H0pC3OAPxPepCcv1G7HWmEA8hTuz+I+lUiWRlfnwADn8qGA2jGSwPTFOAJJJJJHU+9AYkHtjHSmiGVXmCuVZTj1qlMEEhI79Part8mCACD8ueP5VRdSWGB0HNarQ55j4YSZMgZFaiIAgOOcVStgMAknjtV842g5Bzxj0oTNYRsjH1ZB1LEDPaqNtlBuByD6Vc1UMZAf4faoLZDkpgHByK1i+55tRe+afiCFZPD1nNHKJCQTIgGDGQcYP864mMEv16Gu9a0lfw1dyrzEjhPoSM1wyr5bkEd6qS0RnNWkT26HaAxyfXFaV5avB5YlXazKGAPcHpVJP9YBjj2rX1CQTpDJhgdgHzHPSpRSWlzCkykhGa6HwfbQzXG+5XdChXzCT2zzWHdjJNdJ4TlWLSL6T+JP1zQnZ3FGN2VfFckFxrd5JYQrFabz5MceThR6Z57d65pTmQOUKN/drduJ4xcyNHGBkbVHpWVIF+0Ed8fnWknczLcYbAwPxpxT5X52n1xVuGLEa464qGRSSVPA/nWLZ1xh7o2HIUgZwavoq8cfKB0FQRAA4GT7AdqlmbDA4wMdal7Fx0LA5XO3gcA1JBksemDxk9qRSuxQT0HHPX60DliuT71izpih43btxbI7mpVGW+UnA4xTFXcwDAkD8s1MjNz29Vx+tSaIYE2htx/XpShRjoeOvPWhscHcDUirtDDGT60ilqIFyQMZHr6Uq5IOBz3NOXHX86eqkgk9DSKSI1DtnavFFTIFC8g0UirF+IY75PQcVNJESODkg0+OIiQHcMetWFQoD0PHFMpIoqmGz36HHSpD80OR83PGeMU9kLNgHOOox+lLJ8qngYFBRXG1XOcYI/KkdSWyAB+FSIgLOSpPrURDkHnP86QWIZEZQxGOfUVGclx8uCOvpU8g2qSWzmo053sBz7ihCK7tgHaeg79qi3AZ/nUshDctxz+dV5CfmC529RVIzbHq+D/nrTS2SCzY7AioyGOACBnmlTJb5uOxyegqkZ3Jcny2THXBGO1REEHg52npjrUiEICHO0Hg01g3IPDA/pTW4MZOrNEzJghR3qksZdlZcYb9KuXAHzgjA4Bz3qskeyTrwD61qYtaj7cbZdpwfWruFHB71VgQednHGTirkg+XrjNCRtDYwtTb98AeBzxUSAnYVwMHk57VY1RSZd2MADB96jt8KOnBrRbHnyj75u22qTJ4Wu9KCqYPNM6ueoYrg/oBXAbiJdzDJzk11c0hXTp4wSM45HeuQckSMAeM1XQwq/EaMfXOO+K29UjEdnYNyDJDv5Huaw42wo9Ku3c7SqmWyEUKBSQ07Izrg9a1dClK2N8ij723isac/NgHmtPRZClvdqOr7frxSWjJW44RbvNk6BBnBrP2lrwsADzwK1JCxXaowG+9VK0j3XjsOm6rewW95I2LdCIhgZqFhlycEgVeRcL8vFVyv74gNtz39KyPQatFEK+Xk7ch/Udvan4VA2Rx1+lIEwN2DjPOaRh+9+XBBweecUmZFuDBVWC/NwOewqZ0z84IB757/AIVXtwxYBTlmPJ9vSp9p8xsAkqcA+tYs6VsP+Zs4O1cZHtSJlx7D+L1oAJXpkjhtvNOU9T8oB6Y70nYsVABHgEHOSKVHOcEdO1QjBBVSW9P8aeAQD6+3NSykTqdwx/KpFHy8nBz0zTImAwe9TKFY7n4BNSaIcjMi4z09aKVflyCc896KQGxCmQccY496mEZLAZ3AetRphdrBcp0ODnI9atqisfv8dTx1PpVGiRD5WTjIwTk47e9ReUFcnbuY/MCefwqxgGUjOVUYPanXCBo1wcE9T3pMpIobfmO4ep+tRv8AJht2F7Yq0Y8OCBUDLhBnGPegdiu29NzY3KfTg1ADuPcHk+4q1Om5RgnB5qvcZAPJ4GMChEtFRkyoyDjPWoGA3dSBjkCrbsfIABBZhyT2qnIwGCMEiqMpIfGucBxg57eg60nYkbevf0piBvN49zketS87S7KNucHmmQkNQN82Dx/KnxbS+WbAPfuT7UhBwxXAPf2FOt1QqXZRhRjB6iqiKRDdBl7fKOBzn86iRVYs2TnOARVmbkrG3CdST6+lVlDbBkgbjy3rW5kN4BDNwoOPerMbbk4NUWk++SCfSpbCQFCpOGJ71LKjJXsU9QBLtngDqKbbx7rdj6EVPqKcHOaitPnYAd6tHLJe8OvlYaZI2DtLBc9ulcfINjkAcmu7v0P9lONxOJQdnbpjNcZexskxx1PatOhyVlaQyCTLLntVtZN8oUcY5zVGEkNhkbPsK1tW0y80O+FvqERiuGRWeI8mPIyM++CKVhXKLgeYxNX9OABfrk4xWdFIJZD1H1FbOlKQJOeuAePelsVHVks+fLI5ziotJiwWJH41a1BvlYhQoPYdqfYJthFS3obQhedy2BhM9qqfekZ8HAqzNKEi4+8eAMVUDOQqAgd24+9+NStTpqSWxMxDRkJ8yAcn0quq4UjPy57UFS2Ahwo6+9ICWkABHy84HX8aTdzJFy3JjIyOHNWFyjtsyVPT3NUbc7pGLemT7VOshMmN2AO45rNnRF30JwpAycIuSM//AFqUDLHJPHPvSOSSpU/Jjv1Le9EZwHYcEYHPf61BY4DEp4OW646ClQgkbjgDgY71GcYOed3PBxQgcspJGM8g9QPahjROFAXmp1TjBFQqCcjGT1zU6KSwGSc/nUPU0RKisq8gZopPLPO3ew9RRSLN5Y38r5RyOoBqRfk2lixboBn+dRqGEKhfnx3z0/xqWVQoYY3g9F/xqjRIVC0gYhRndknuKTDdCpw3IHrU6IWU8hFwMn0FLnzMgqwIPUj+H2/wqWUU5sqwYhgMAKAKrSR7SXOT3GKvybWTG4liemarvgAsvzEZIyMikOxRYttUYJ61WMZaMuwwCcD/ABq8vCcnB6ZB7VVKZIwfw7mmiJFWVfkLDDAcZ6GqTgYAGOv61dnJUNlT7e9VSM5xkkk8Yq0ZSQikKzAdcYoQ4yuQCOCcdabgnnJAGT7VJGVyflBQ9BnpQIegG7cP9X1GfUd6VQNjEDHOee31pqAFctj2HapFJQMGAPBLj09/rVwJmQ3yiUgq454Jbjn/AAqqqstupIzk8DqcVaOZFQlRtOSSe59BTLzajK0YwCMYzmtjFoqybSMquFbgYqGPCyDHHY1YMexCWyCw49hUDLx7HoaCHo7jLjLghieCeTUdiQsgY9OlOY7QQcEU1Qu4YpmW7L8gWS0uiZNqqFIHrzXNXse9wf51vFsROuMgqRzWVNGWY5HT9Ku9omVSHNIrwKUxnAx0Iq9bzfab+ea6PnEIxLOSSTjAyagSPaMg1Ha5Z5GHHOKm9tSXCzsQyRjzMjjmtTThjI96qhQSTjPNX7NR5QO0/ewfShO5UadmM1VgNuec9cdafC4WEE4+lQ6n8xXA4A/Oq6zElV5AHUDvQy78rLLSea/f0zSM3JDc44HNNU7RyMg9jSRoTISRx6UhXuSJnk5BHXBpykCRuMAdxQqgx5VsMxxgdqWOPEgKg475qS0iWJNpVgPm7g1Kn3iUBVgSOemacyqwLc5GMHt+NTEruXLZz0x0/wD11MjWKGl2C/OBvB69MGmBm4Z8AA9x0p4U7SD931Pr71Hgbtozkd+vFZGoMu5uvPTGO1TDaONpx6ikClCCBkr+BNKDvOSOCOmetIpE0bANhcjI5HoKmUZ+4fmzVe3U9yc5x7VcgUkZXPXrUbFpXJFjcDjP40VKF9eKKCrG+gVG+fjk4x0P0p0rkoHIByckY5qvC5kXcRnjA44FTxMTGfmYljwaDoiWCUJICZDHPTrTUYKwEnQ8EAc4NSIhjA5HQHd160y5QoWIOXP8ROABQMrSBzP8gIG0jBxxTJAyqSuQAvyg+lTq6Kd/UjHHXd71Tto2C3AMjyK7F03fw/7I9R6VLDUqSjLK4K7u4x0qGYfMNnI9z3qyUzGQflOcqM/nUHlY4P8AD83XOKLkvUrSqd2Odx6j0qokeJPmA3Y6Nxn8avSuFkJ9uvXNUJPmbIPBPPP9KtGclYiGE3YILuceuPenKD5fAB44J+tK3J7YHJOMc0Icx7fYn8PWqIaHKVWPk4OeB9O5qxCryIxbaYxzk8Zb/CoIh8+H4IwOPSrdpcvbDcqxvCjZAkXIU+3pVwJkio5l2hSDh/mBA4wOv86jk2SBUAyQu4c9atTs95M0zhIw5OAOB9AO1VHC7W8scbupHWtjJFdpDn5+eOKgdiHCjHT9KkkLfeUnjjPpVfnzMldynr6UX1M5jZ0BPXvTUGCCe3FSS8/19qYq/MAeeeKbepCWpehiiksrhpDhwF2fnyf0rNRMsScdK2EIGkzKANxkGeOcAH8MVmqPl6c5onpFFQhd3KlzhI2PAA71DYBXiBXofSotZkPliJOrdaTR5Ng8tu3Sp6GVrzLjLgkjjNbWkhZtMljl3iON94K+uMVlyLla1tHspJ9J1O5jmVfsyozITy4JxwPainujSasYl+GY8DoOcVVtE3OW5NWtQYg5HcVBZ/LhTWjVmc0tZF3aMDjpUfzDG4jGeAP51I2dm7Hyj9TTGH3SDknt6USKSEhQl25ON3FW4SMuFLL2GOpqv80bEjaxK9Aev41bt/LMe6V9pA+XPUVmbR0JUUJG+CAOnHWjACEY24PTFEYXaCzZJ9uBUkPQghgzfKcjt61nI2iNcggjgbh0Pamj5RtGQfz/ADokBBKggkds/wBaQkF8ZxjuD19qjYuxIEyxzkEDr/SnxqyDcSGx1x/KmKc+oP481InONo69WPrUsaRNGcjBwuTjjtViIRrIY+pHBweh7VDFGC20nj0PpViNULsUTrwWA5OPU1LNETKHx9/P40UmF43kbu9FBVzagG1cArsHTPU1K2GDbcbumD0AquTvIVcD+EAjn61ZUMkLnIyBlQR1PoaGaplqA74lWR+QuQuOi9qgnLPGyqy7TkBjzSab5tzb+ddRiGXJIj3dB7/jmllCq4UsNq9eM0ik7kSRrGhRVwm3aCT/ADpqgs4RWCjGScdqsg+YSV5TPp1qAxItwrbcggjHfA6VLGU51Xfj5m2nAIqJlYkhdoJ64qZ4m85pR/EOCKZLGVQHgE9gM8UhMz2TOSwwDkE45qswyw5w2CPpir86lHPTnn8KrkSOcFQAewPetEQ0UpcF1UE4xk5HT3pq7Vdt3zL06c/SpnYZL9VPTPHFROhO1TnO7kk1SMmtRx++oTGT1AHXFSKGkwPvNySPT6+tJbnyhtKAgZBOf6+1PiwS+GGwthmPp6CriSyXyhJGp48xV+VM/eP0/PrVAbR8jDHUkjsM/wA60JclMwH5E6kccegqlOd/7pQFQHlsZwa36GdtSjKQFIBO5jmo+km3ggdqsLmOVWUnch6+nvVaQAMxBOe1JNkSQjrkehPNNRgSVGOOtKzYUA5JxTASH2j+I0dSDaWUf8IxNCvmc3Cuem3AXH1zmsc8JyMAVfDRjTpVLvvDghQPlx3JPr0rOufkj65yKcuhpHRMzJY/NdmP0FV41MU6kfStGJf3ajvUN7blRnr7isua7sN0bQUi6uHQcckc1o6KN8N8og8wrCXyMDYARk8/05rJsX3Q+/etPSoo5LiTzXZF8pmXaM5YdB/9etKekkRNXRkX7DgYOT1pltzgkdKS9wZeT3/GlhBxx+NaS3OG2pPvzx1XuKVV3AbD0NQqckZ6561bhDZ3LjGefepvdmkSWDYqBtis3OQeMU5Nuwbxux04qsxJk4xjPAznFOj+STnOGOSc8ipZZethtiYuSVPKg9Me1OADoRkEkZHY/jRGzEBuCg44GaGA+YllGey9azkbxI3b5NqjJPXIxQg2jIYYP6UpIxu+bAH8PU1HAVQE4O49Mnmo6F3LKHYduM/Snx4ZCN/PuOlMRwMMFz7g1MnYkE/1NSy4j0C4AzzjNXLcBcsCBxwBUCxrvOVPPUelSbAsZ8skEdmqWaIGUsSfMY0VaiYxxhV2/jiipsVY0JjtZMEHjGO496sw5IchgDxls1niQs+7BJI49KnNxFDGXkwFyMdjn3qmjSLsaZfyod5z+7HXHr7VXgDMTuO0Ankc8HtTY52+yk7kLA8qTyatRfMiqGywGW29P/1Ui0MI2sN2eDjHp7iiYDcJdykngb/SnoFYqGZSMZGRxUcxBYfMQdmMEdKmwWI7pSWBjAVSCQB2/GqsyHZnnjgLmrDEmHCn5NpBPP5VBIEVNvZh19DSsFzOdVNyBnC92Xk1EuAZCDwP1FWblVWQkA4xgY4/GocARF8jIbgHg1cSGirMmeOCcgjPp6VERhcD72cjqfxqdxgqVPJJwM1EwG/JI2qRgCrM2RhWT5edo+Vh2+n9asQPGFCspIHOz+9nsKhYu+4gAZ4x/ezT0hdiEDkY5HYg1pHcmRZjCq0iTKE4OD6ewx3qpOrrDvETIm/ar4+8cDjPt6VejQKj+flmZMh1HB9v/r1nTy54cuEUbo4wflUnqSPU1sYlOZFaT5W3JnkjgGoXBZ8YPtUueu4HGDye1RknGep9aklkUnykg81GMd8569akZiSecntxTMc5OM+tG5JYhyYJFz3Bqne9kHSrVpuclVAzjJz3qtdD94O9EnoXbQW2jypJGfSm3TkxvGAMe1W47aePTUumjX7PIxVX3gkkdQR1H1IqvJK80SRuXKR5CdMKDyR/WudaO52Sfu8pQ05wCVPWtvTZIUNw88TOohZUAbbtc9G98enesOJNt0R61euW8u3Yg4yMV0wVmcE37rM5yXkzyR61OgwvB/Goo12kjripHOEIx7iqbu7nGkOjXJOD83bPrUq/MdrOwI4PHT6U2IgEl0BJGD7e9Of5drEHceR70irWJFTY2E+ZjwD04qTAbCuwADZIxyRUPmnysbfn+vWrUC8hnXKg545zSZpEkjUkHPzA9OcZp4Uo3RfYZPJqQcsSgXaMZGeAaY6MAdx46ccY+lZvY3iBGS27HzDoahcgIcDJbkmpEkwpAG/Gec0rBm2/eB6n3qLlsdCfkG/ke4xVqHaqghQfSq6YGfMUe1SI/RdpYDuT0NSNFlGDHDfe9jU5Kxj7pPoe9QWqBAWPGOd1LPM7MjKBgelS9DaJOillBOfyopYpyq4BC+2KKm5RcZSPVSw+XJ605iAVWLB4zuHrSNvDZx/uk9velhCg7SenJqxkturorMGDKTlgf6VfcnClDknPUc+1VbVvMc7QoLDaParZXYyYY7l6H1Pek2aJj4oicl9yyP1GM81GTlsBmAxt3DqT6VLDJjJkYjB3e9RBlE6sUJYdQehrO40yQqE2KFIAXJDHk1UmKyR7mQqAADnoTUqzBJ253AtkHnGKbNmREXK/NnCg/wAQqgZTmVgAWwRwWOO3TFU2iVmbGTzjryD2rQbKy7JgwwcMT1H+NVJUKMcfJk4B68elUkRcq7dsgIA+UEj61E/EwGAT154A9quMp3t1VgOg9KqshC71JYnv0FUtTN6EbBXLFiQoGPp70gblG6vjA+n1p2zG7acBucnt9KltT5RLbgsm3GcZwPariQyWeed7VEmUxqDwoGMj0z2ArLn5lI3qMLjpgMfatG6uHniAlkZkjHysTkLk5OB/nNZFxMJmj+QJtXGAMZHqfc1rdGUivGxyTnIU9OuTRIMgNngdakkZPNQLujgODkjn3OKrsylSOpPIHp9aCRhBJyBTW+QerZ6Y4p4fPBJGOajcYI/iHekJ6EkH+s5zyM8VHNnLHHaliI4YdOlNfkmlJ6Gkehe01bPEz3rSRssRaIogcNIOit6Ke57Vr6JosGpaO32edzqiZkeFlCxiILkvvJ+9/s4rFjjUoFfkEZrY0a/fTby2uoFjaSFxIFlTehP+0vcVlB2aO2UXytxOZvofJu6iu3yqKe5rZ8S3a3ly7rb28O6V5MRJtA3fwj/ZHYdqwbkBQgUdB0rp0T0PMrJq6Yig/wAX8qc+MnHI7UmTtG45PTNBJPKjp7UGFrIU8HgkMeDmnKcDAP50nzEcgf0FTWyR/dYEep71LE1cQBfk3dB1NX45NsOzAwTwc9KpPuUnbyp6MB1FT23LbpfmQdady4ouIrLu8n5vakLMxAK9vXpTo3UE7VZU6Bc0rsFyuOnQ+tYyOhbEaoUYdMZz9KkCghcEEjuaQKFbnGMcZ9aUZYEZB7k9x7VBRNGpLAOFXaOnr9aljA8xdgHsCOnvUUGXcKFGOtW4wWuCTjAHHYUmaRQ932RsigfMcg55qNF3SDzFIA7VE7ADoQc8DNN81t+7J+p9KiRoixNjfxk0VFiOT5sgZ7YzRU3A2Hc7Bn5m29KW1w8bEfLj16mkuVAfZHyemPWiN8SBRjI6nNaJlssxsIpE+XAzycdKsSP5kucAoPxBOOKz3OZSoOP7oznHvWggVcq3BAHOfXtSaLTJVYLGHX727adwqPYrFHX1z1OAfSkdduVB+UnHc7v8KjeXAwOCxxnHAwahgOuF+V5OQ64JHc80kMqQ4aT77nDHOR9Kd5gUOqgbh1B6fSoJYvkRQ2dw3Y9M9qpMG9BbtJNsgwR3AHzZx2qqz7kZWDAqQABzx61dTD4VSCVX1ziofs8kcrRSSAl+hXp+f41aIepRuF8wsHB44wO+KAQGjLKB057AY7VbMLq5C5bPHI5/GqzmJJQANzHICdz9PpTRLKxRGAKtyuSQDn86S3jJ+ZuI+SCR39Kf8qTEvw56en0qeNOct0PCg8CqTIaIZooGMwjmPlIu0FhgZ9MeuayZAp4QDOfmJ9M1tywNHCchWJ/hHasidEQMoYGQt83+fStWyGkUp5HdyvJLE7m7e1QEgHC9xzUzIxUNyVzt+pqPK4KgZbuTSMmLtIUnNQyDBxzn+VPLsQM8gUxvvY6cc5qiWCbVTA5z+lKBkPiowhQCrCDO73qXqawFhmwoB/Knm4CHdn8KypbtEk2x8sOppUbedzH9ay5WdCrKxNfTl3A96qXDZdR3qNH869wM4Wprgfv8VrFWOKrLndw5AxjFOAG4cke56UJk4GKXAHr/ACqznYoHyA9cdSTT1y7YGc9ueaahKlsdehFIcdQQWzmlcCVSygq3Kk8HPSpRK8oVcjAPHGM1Wh3g4xyelW4RhSXGc1LZpFFqMDgEkn0Panc5x/D6elRxDch/vdsdasJkcnr7Vk2bpDUVg53fUmpliLbSjcd8d6Yg3sRjjuTU0Z3ttAyg64GMUi0hy/uoeCTzzipYo8JliRu7Dnj3qBVDzqP4AeTmp3kG8iPgZweKhu7NEQS4MuzPBHpzTUJOUIzj0pScS5Tn3prrtZSDxUtjLI+QAAdqKjBGOetFSBsRB8ht2AScE9c+1SSIFj4yCfmyOv0oWPLKwb5QOPT61R1aaaxT7WjAxxsFeNsAYPUg+taltpK5dH7pAV5L8e4qSN1aT5jjb0xx+FRRqq4deVxkE0+G3wWctjdyvHNMEywZ8jI24HGO+fpTQpG0EZJyw7gE054CqjuvByepFSRADYQcruztB71LKWpVj8wEMwGVO0k9Min7TKeZOOeAKszqHG5QGTPQHqaqMDuwCAS2MH09PwpXHYfEhDrxtBXIYdzVueNAIDHtb5Qsn+FUNpX5d/HUEjp61ZEyfY8AMXU/KPX1p8wrWGSrIRIc44JD92z0qpb232dYxCdpdfmHVj/n9a01iE8KtFyI+vHA+lRTqGlYnlh8p9fqKq4PUoSRBG2hlbHJZfX0piDLuwY5A4AB/MGrhxIwIG1c4yRyo/rUCJKCwLMcDA28DFUmQ0V5oX2YRwpbqp7f4msmRSrvucEk/Mcc59vet5GURvwHkzjeOijuf/r1iX4y6sAFjUYAH+etaXuZyRVfbuVX+UDp3wP8TVVlO3gc1O2MHtnjmo5AAME4I5Jz/Si5kysPvfKaG5OMc/WnMPu5445xSoPl5HNUSQyL2U7jjtVuFflyO4zVYZzwMbu9XrbBUfTvUs2px1OV1RHt7+QDhT8wqOO64w/pzW54is/NjWVFyyencVy5BYhV5JOAK1STVzhq81KbNzSE84vKBhc4FSXP/Hw351q6ZaiCyjj7/wAX1qheKPNYYye1SbSi4wVyJVyTk4bt9aWQEEgkk0zaDzuG0d/Wlc5bI47GmYMXPy5HJp4Xdy4H071ERIHTGzy+c8c+1TovByDnvUAh4JXBB4HAqdS2BjAJPJNQjLAKeRUysSgCqPl656CokzaJbTduIHAI4pQWIxt49ahibdw/JHT2qxESCSxIA6VBqiSMbYzjk+9KjE/IpI7n3pF27wSW2+p70b/m+QkHoOKTZaHoMED3qSYpuJA4qFFfrge3rSyPgDf1zisyr2HgoEJGefem5LAjIwKrsTnAPHpTgeOTntQkHMTq2wYopoKAD56Kdg5jfgVimGxtbn3P+AqtfWiXaRxysFt43EjLjJc+hPp3qypDPkHaAMjHoKniQZDAZIHHc5NM0avoyJsoiqvKjjmponwVIBOOp9aYUOWUc56nsBU9uwwdittBAGew9aaGMEmSA38fJ+tSQKrMzsCwHAA/z1p0qqipvyQTnpyfYUQKI02KxB3dB/WpZcdCQMI87OSTwfSqkp+cqSOSRkVYul2yfIcnA4qCaIoGYjpnkVBRUkJ8zGTt9PSpmjL2pZWBkBwAeKhOXTL5z1JHWkiZmOQ3QZbPb0poTZfs5cn92WyCAxYdP8alukUsQjnOfmP9aqhgjBlJAGMnP+eaZ5kgmUnOG55549DVJkkkysIVkDgn+LPQUyJ/KVuMiQbGUcZHpmpjcqVcbFC+46+1V5Y1w3JVV+bOematCYjSbo/LdwOCAmMcfhWLdO+9s8Dpn0rQlUiYlvnIzg9/rWfcgjkAdDVJmbM+RQpKk7sjj61DIi5OW5PNWJQpUY9eeaglUF9vTHU+9NMykRYwc9fbFNA3r8x+apNp2Z3c9j6UjjCjOBkda0Rmm7jF3HB6be1XrZRgce1VYgQw4BwPzq3ANq55zUs6aaJWj8xCMZHasm20WM6l5gGFX5sY6Gui0+JXuoY5ZFhR3UFz/CuQCfw5rqPE2h2On3Ik0i/W906VQY5W4dmHDArjj1HtVK9mOrCEpxTOSljMcAJGA3Sueu0Jfiur1qSNYIURtzBMnnIXmuXnB5xz60zKsiooz9aRy2QRz6ipCACCTkj2ocEHK4prY4ZIIweo28e9PAHbGfamIjHJGMd6m6NkcVDKiiSEAnDdO9T8DO3btPX2qFeScde9PjKo209/WszZIRCVclcn696tRkkMCoqBhgZHBH61PHjgnJH8PuallpD+TH229KWBssMjmqysWccD9asqg3Z6YqWWmTAnLE/lUTq5AyM7TmpMgbiOgHemCbeSAMYqUyugyNSWIbAFSmLaDtLH2xQAcklcAUb84AyD2zQgIyzJ8oK8eoop4fjlSfeiqCx0UaNsz6nr3qxGMcjGOiketROxCbBwTx+FSQFN21hxg554z6UM1GcDcCDjPFOV3RnPO3IGO2aZKuSzoQoHzMT/ACxT4kDIir1ODjrmgCVGJhDN6EDJztGacsyxZUEBtoGT79ak2KR8ueenbgVVkPnSYYjYBu2baB3B3G4YJOOw704yZSEbtwK88f59KhVCikADYw+76e9NVWMbvz8xyuBjI9fapaKTJfkdSAp+Y46/rVYopGI0C4PzY7n3qw+ETIGSOahZt7HacZ4PpmkhtkEjknaQu7PyipsBnyVYHOCQe5qtcRlHAXk+vrT1cROqs37w8gZ60xMuSqI7pNwUxHHHUH8PaomlKSt0KFs898Uk0mWDBj8vHPb3qC8lJjVTyQvDD1q0yWQXrh5lCDAPc8bqpkBgdrYBByeeauSx7xnG8ep7fSqLLltycEdaozZUkBb7owR1FMZSqMcc561M5yzckknrTJBgfPwPr+tNGbRACM8nOBSZGz5QeeBTwArAA59cilOGOMc5wuK1IW4xCQeW6cjAq0QYo4yD82c59qj2ggMBwG5FW4o/PmCgYweRUnZRRatDI8O1QpGc7sc5q/HqP2eG53iFnYYHmpuPvtPaoERbaKOOVtkkmShI7DqKp3itLGrKRxyBxx9a03Rpy6lK4m3HJ6elUphgYbvzVhwdyq45JxUMoDZyQWHGKlHJVjqVGwpxjBx2703YNvAIFTbT98nI9Kbgkeo9KdjjaGIT06L/ADqdAM5A+tRbSOAMjNTrwMZ4qGVEciYz6GpFHbGT7Ui8cAjFKRkc8Vmaj413ZOPlH86NwJKgEY5zTIwVz6d/elBXfyMr2xSZSsLHkbmJ57AU8uSRnvUcygklOB6U3KlV+bbik1cVy2WGOGJp0IBYkgZ7VUDkDCDdj0qdZQ33ccVNirk0jnv0P41Hg05ZgcgkZUdKCyuMN1znNCQwQgL97HsaKTaR93keuKKqwHQvnzmLDlu+egqwgBxnBGMDHOKgt1BJL4CnjOM5qUy4yVGHxgAdqDUZKVCfIcoP7vfNSQMdoDctuOR6elRqhDrvfauNxwuSKmQ7YGZR0OCaQyzJIVijOFyRgEjPFRLGhUyNyccAdKapPlBCCxx0/wA9qnXAtVjLZc56e/8A+qkhlRPmiYc8Ece1ODAIQRnDdOvFDuwD4/jPP1BqZUCsU4GQOtDHcpht6MoxjPp0HoKZlY2UhRnPfuTTyFHzO3yyMcYHp0ouXUxKxOGPtj2FTYVytM+GVjjpkZpG2EAbgSPmyaWaJipYncRwewqMbvl2gHI5zQNliToqD+ECop1jDAp8wPUZpsxfzAT1x261WM37zeFPTGKqImySFyQ6FtvUqp9apyurKGAIYHBz2p/mb5G/hx+f0pkzLJz0yMZ9fatDNsqyDJGTUYYDdkZFSPjbg8kj9ajWMsQpIBz19K0RmyPPB7k/rUwTCBQCZPUdKmt7SSQ4UHPQGtqy04Rx44J9T1qm7F06bbKFnZM3yFRk81etoFW43xKSG+YnHSr0lv5Yyi5ZVJYetU7fEUfylgXGR64qWz0aVOyNCfZNaFAck85Pc1z8IHnszhl3naGx8p9a29y5Urkr05qmkZjvGlEavGM7Ubkc030NlBWZnSQIZsMeDVWa3VJFzyh6YrZliBQbcl88jHAqJ7ESKrFtpHBx1p31OWrTTMJ7c7vk4qB0IYgcGtq6tSuMfMo71Ue1+cH9RVXPPlSsZ23HGTjocUKADwM/zq9LbbCd3PtVRlCNx696loycbCjHJY4IqWMNwXHXmq+SXxnJ7EVMyN5YxkHNZyQ1qLnLd8CjYucpw3tSKDnPUU5uOmOakYqhmGTyaSVAo9z1py4VeOKEK5wGpDQKFAAXr3NMb5SSWx/Whzjg8rnrRCBJJ8w6e9DAkiY7Tg5p4fLYKkD0FMkHI25H4U6NGdvvYPsKTVgTLMYG0bsZoqIMBwVP4GinYo6SOZQW2kMAvXHQ+1RWx+RnZssOgbuaaFxFK3AJOAPQVJH/AAgqVC89OB6GlY1JSAA0gPz9z7+n0qVJN0AG0gEZO4dTVQOWZsvuTdjirqqFTc/JB+VT2FFgEHACtuA55Azk+n5ZqaPD7n4CqOAT+AqEgmUAEA9BjmmF1jwcgdwPU0hiKfnJVSQO57VITuBXpu446+tMmLJ8rA7mPT/61IXCS7y21cHtTsBBMGd2IOFVeARyMd/8+tBUNy4yUGAP60+V1DKQCd2DjNMcsIssAdx5/wAKEhEGWkXCnow4Pv71FKrRyFAMAnk5qT+DcPuj5j9fSgnzbiQHPK8Hrj1ocRtleYbVdiSM4wD6VBGMykkDjkgenapLgsZ9vAj9h0FQzNsJwRjOPxoQhX5lwoxu6+/tUTYJ5JGOlSFw5AHyjHUVAeXyCSOwNULcj27ugPJzmtKy0wsgeQEc56dan0zT3lkEkgIx2rf8oeXgYzVXNYUupTggVSoRcY71eEQVc9260xE2NnquKeZN33c5HIpN3OqMLbDZPkLK6hlPUZqlFDGI5Cchl6fSr/EyhSPnzwaasKxliUZlxyKEbx0RGtoRFFtdDvAbA7Z9ajij23UiFgyNwCeladvYSSTuxDJGoztJ3EA1PLaCGfLu0kp4XkcH3rQHMwjBJH5jxgFejHGRUaxkIrdR+tbdzAFhZUVxggEZ4/GqbQbGAPIPNDM5PmMto1YMCeSM1Vltl27l+96CtJ4wdxPFRKo6jHy9KVzCcTGul3kEelZt1GRIWI+UVvypzkAdwRWVcIS54zVx1OSpDQzpFUcqQB2oQHacnNLIg3ENwD09qSM7WwDxUyRzbMeExggnjtSMQSCM8dqR+GHzEChCecAn3rOw7j2JIIzinIAE28bhTQfkwDyKbIyx4d2wAPSkMcSCvGCB1pwCr8y9O9Mk4UMOc96WE5XII4PNAE248DHHvT0YgdM/jUWfQGhH5x1H8qTBMlZznjdRR16Y/OigdzoPMUlQdoA9KlD77Uq20tI+76Dt+FUEydxCnnpj36CrSyFYVUBNjHcQfbgUzdk1sphRM8KfnyeM/wCFSHMhwqnaOSD3P19Ka7K8cZ5Xrjtx/wDXpI3kBydoLckHtjvQK4oQR7vmYO3UjkVH5h8xcBcnCpx09alcn7PuLbFJJBJxmq1s++4Ltj5QPbP09qLDuizJjILEk9CR+tNYEkKrANjPI6ZqC5kMY2qdp6+pxSbiBuwzZPzL7etArhI+4bAv3QOaY5V+N2OducdqQTxh3WQ4U/dHvmhyrzKNu2MDdjHI4oJuNVd5chiEHC/7VQMPLQOu5nZiCCcYqQsVBwAcjjtgVWuH4CnqODzmgLhO2UQYxu5yahRlLMTkpjCluPxqW7YzPkgbjgDHAAA6YqGQKyMe3Smg3GBjnIAI6c960dJhExfeuT2PpWfErNKgCYNdRpcAjhGFwcckUGsI3NK1RVhIx1HWkk4+hHTHWnM22MnBI9AOTTF3tGGKgH2PSg64KxTLb7gR5IUcY9alKFHC9FHT61TPmJeEtht44HpV6XLMu7gA9aR0bbD40y4xyepqYOUQqqAqOWqOPcsnpgZBHTFWmdRkAlAcU4kslkluWux5cISJ0Eblux+tWJjNJEDIAiJjccZOBwAPanswniXnDD7zMaryuZJOSZABy+7jIPC47gjvW0VcycxkrjDsEzGOuetUSvUuCSw79jSzTnbKowvYA/XpUPmBlyDyBzg96JIZE6YQ9feqzHaNvB4/KtIIrjLAg46Vl3JCTKpyM+3WskLRkUoQKeAT6isy6jGM85HNaMoACkeveqlwQV+b8yKtM56kbmQ8e9uelVmUCTHOavuPNwB1xVSeMxHdVvVHFNWZEw9M8etL5m3jbx2PrS/My7ucdxTCCUrNozEyyOccg89KCRuBIyvbmlJKgHOB0prMMZ4IH6VFguOdgwwpwe1RRPiTBB3d6fHsZtpyR1Bp7pvbj09MGgCSPLAsBwO2elPAJyfT2pkb/IMjnvj0p24AYJPPSkMYz/MchSfeihpADh1BYdzRTC50VsuDJLnCRDj2zSoySMhGY1GSOM/Qe9R+cphWIZA3ZbA4zVoMEVpHG3AARO/POaDW5NM+SHA4C4GeuT1/SoYwEiJ3MEJ6DqB1phfC7MhVUZPuTTGkAVIM8BizMBnmgdx0kjzHCg4A2rnsPamyKFVl3fLu6479qcFWOP5yc9QfSoiGwWY/MwJ2jsKB3JEWNkJHJHByM/jSI21NwIHJwc96InKL5Srl35LCmSJmLO7gfdoFcfgJIWV8Ho2P1qBWKFnyQDxj2PSnwsBCwbjOAc9TUShnVE3Ak5OP8+1ArhdyfuQoOXyMHP55qKX54spzwMmkmRA2UxwuNx7+pNNwqpFkdQSR9adhXIkYlcsOOgpVCjIYHaOvuaVgVUSKMAkgDr9ahdskJg4UUWHcv6ZgXGWIKnr/AIV1NoV2cDnsPSsTR7UNH5rcE8KO9bkURRMc59B1oZ1U1oTQnecDtyakICRksRyc+lNt4gDkEj196llh85/kIKAYz60jqiZdu0v255YehUx9OgPWpZFYySYQttXhRxmr8aKj4VcZ5yKSUBJUOM5BycdfrQacxHGP3S7l28fdzyKZlPMww+TcB65qWbDJtKfN6+oqvZ/PdKEPYjnpTRDZeeQqqkn5R2Izn8KrPdtsHlqMDjJq2bFm5ll4wTgc4qtNcW1sgAG5h3J71tEycuxTvFm8kzM2GB7LkZ+tUxkHLYDYqxe3plg/iIJzjGayku2ZxuUAjgEDrTewKRqJNIuGZi46cntVKV98j56g5pguCc7OCPWoUDtMzsSy4wRWTGiWUCQDHbmqs4O4Ejg8VKjbJNhXk5OfWluj8vykhiOKa1M5lIxKFJ7+tU7tMx5zVqWY87T8w61RmdtzKyjH1q07HJURTy+CRnHvTosgfKDx1pVU/NhiR3B60IuxvvbQexpWOd6CTKCuQM88j+tRAbfQ54p8nBOGyDzTVGF3Z/CosTcICFc8U6V+nYevvTC2SNv3h2x1p5VWXjg/lmlYLj+Dgg4Y9fenvgKM1ErbsALhh26ZpyAYI698VNir6DwAOMfmaKFBdQwXIIzzwaKLBc1rIY82WUswcAIo9QMVNLLuP7w4AwCT09zVcORGAB0wR/hUF20mCrcnOM5qrFXsWftDYWTBwD8nFTRPjLErjvntWfFlwJN4EacAHualttiyYySTyMtwKbVgTuWftRkiAK7QBxkUtuVZ3Zjyq8t1zUMhWToSFB49T/hSsCLWWUnYgxt9eegA+nNKw7j42wXLHaMZxnk04SMImOOWHQHgCqsbqINoBG9hnPXFTNIFLZQgEZX/AB/+tTFcbuYqGI+Yk/5/Ki4KFIwGG5uM47U1QWZVH+sY9R396gmb7mPvZwKAvYmbDxM2NqcAcdaYpTysv97P4Y9KR3TYEUEj9KrlRgDp2Oe5pibHB8ybFxjPHp9akEQ8xFViSecnv71CMrMFJ3OB0Har+kxiS43AErnjNKw4u7Oi0qNY4lBBLAdSelaBIzgL8o5IHp61FaxlogcYU9F9frViGPHJYkdeO1SzugPYHyyRnA7etTQ4RFC4GBzUdunzSKpz2BP0qS8QIbfyzhSo3L6Gi2lzdS1sRyg5UjAAOd3pUUmHzwSuM0+QErg8cdD/ADqnK5TCg7s0kWRs7lmAYFSPypttIAp2A/L+dQtIoJwfl6NS27lUkZThM8E9R9K1SMZSL4mkfILkHOMelUrkQx56M2erHv8ASmi6ULsgyWb05JNRpZOwM965VCCQAM/hVohySQTXxkhdQ4XIwdo5NY8k5EnC/IPTg1Yv7i2hi3Dy0foFHpWT9pRmDDBB6+9W1bQyVQ0beUNncNp54q4pAO4HgDBHrWTFKvy8HrzxV23fLZHToRWTRqpixuDyeM+tMuAcEZ3L608MpkdRz7VFISYyM/SpSFJmeyknI9eaSYoYBhcOOuP61KVABJOA36VVcgOc8qe+aa03MakiFkJAbOQRmkG3uMg1Iw5yv6VEqnzCabOWTI5NvVelRK3JDAY65HepJDksCeexpmSVAIwR7UMybGyMAP5UeYcDH3vQ0kowAOG9MUiZ+Xsuc5x0pCuSocnB+8OelTSDAHByRnIqILkgfjx2NOJfbhjkDn6UFD4XwgDn5qKTYOxNFS0O5prKVTnGB8wB5yfeoMbnPOQeSTzj/wCvSyvsjVD95/mY+1Rb/lAOdi8kD1q0O5LJyidBj+H09j7mpICoT5hhv4m9vQCq8R88qhJzuwqAZyf71SLKqOwVckfdJ5/GhgmWJDl1CjCDknvTCr3IAyB1J56Uj5A25OOp+tKCoPIOGGCaQ7iIgbG0YwOM1YDqYmeQsR2HdvxqAkDquMdiajZvugdB0HpTsO4+NgBIzn5jwMevp9KbI26PjGR39KbIy7W256cZNNLARsp5PU+5/wAKLE3FjIILsST0qNnDY68dTijcV5C5BHAHb601M7sE4PehIV7kkBdCSD87DBOO1dDo8IVN7Y29BjqT6CsHc8rBmb7o2j2HoK6zRod1irkgt0J7LRI2o7l1HYgFsGVhjA/hFTorsn3cbepByKjVcAkBhHnlu7VbjYPGGQbU6Bajc7oj44wqnJJPXjvUE5AULjJzx7VJ5yABGP1AqtdyhfmCMSOCaTNUSSNlATjnvWbcyBIyCGUDrntVgyffweAcVm37rKNpyMHIJ70JDbIJHAiO0jnnPWp9PH2m32LwQcGsudXAyDz14ptrqX2JWWXdnOeBW0Uc8mdTHbQW6E4DY7jgmuN8ba/JGI7WI7XI+YDjaKmvfFChGKxux9+BXA3s8l5eSzy8uzZPt7VtFKOp52Lr2SjHdmnZys+Gzuz3PNakDjjcAc1z1mzQtn+Hrit+0eOVeB82OlZjozui6HAJG7qMg+tWopTGuVG5uAQDyKphfk3HOM9vSp4eOxznKtUtHXF3LCjEpZcdc4/rTpXQg88nrULE49fpVfcDLz+VTsVuT5ByrVWli+U7SPoalkTK5HUd6YpGAT2prUymyBfUjp6VWkcjcVPFWrhhnKGqZ/i5x7UPQ5WIgLLk4we1NdjyPToaRDtOelPl3M4J4JoZncizzuyS3pin7QckDPfFIRgg5w2aTGXOD3pCJgwdcg4Pr/iKcMcA84qBumB94dzViMK0WScNS2HcRgueQT+OKKGyDztz70Ux3LAPmsxY5HUmolcFSMcE8n0/+vTC4VAuSN3IPrTS21VbGCvQe/rVKImyRZDE5ChvMbuOoqaIKuDkjHUj19qgt/Vm68n1P19qDLuY9dg746miwJl3OYtuTuY5Of4RQHWOPCcMeARVcFfLEa9Ty3PNTIcI7HIOMLjqaSViuYUuBkEfMaWUrsBH3unHSmwKHLYPGM5+lQqSz4zkdeO1MLgoIyc5Hcn1/rT3UCMFWLSHqTRIOMgnIprEpGcnrwP8aa1E3YaD8oKZBIzx2p7AjgcngmoFJBwOD6+hqR8jByWyc9OfrQSmW7aNmlAxgZzntXZads+zJuXPYL2b2rkNPfdKoPOBgD/Peuwtd4VYoQfMIyT3X/AVEjrols72Zt4zt6jGABT0IRQd3bp7UijGY4SHCnlv4R7moJZPkcR59SxqTsgFqymIscFz6dqhm++WLt0xgn5c+uPX3plmhiiy3Unj86ZO25Qo+VuePWpkagzqFKgDnn3NUpwxTj73v6CplOGAIIwDhv5iqtywGWDMB045zVRE2VNwlYc85NUL5QqNnGetXm/dsTk4xkGs69O8nqc9PrWiOao7GDd5duBgGqlvbr9sKEZVhj8a13jHmD+6OaikiEfkygYJO4fnWkdTzKsbu5USD5Gz95Dg1ctAA5GeQM0+RFF2Qudkgzz6/wD66fbLgOpHSlJWZrDQvROcbG69PrUyMAAASVX7wPaqvTAOMYwKmHys3U8dfX61LOuBMjEEknK1Vkys7begOPzqyfuckAEVVDkAgjPoKiWxqmXDnYO4qN14ogdio7HHT0omfI6EU4mEyk64yATjNQSYVjtAwe9T3Jwc45qs+T9KTOeREU75zU3mhlwB25FRc54IxTWPzhhwKDJse/QDsemKjRiTjIyvf1FDsXXrg9sUvQgkFT6+tArjunIPHrUsJyMHpnJ5qAH+9+XYikY7WBHP1qrCRc8wLwSfaiq8ZQr8xYGiiwwLb3DEdOtI77pBjOO1RLkLk5+nrT1BxuHfpVEXJDxJgNuB+9gfpUkZVcljkA/hUcIAYkttUDlu4pAQygkYXt/jSC5MuWY4PzZ5P9KmUlCFAYMepPXFQRuByFwO5PQU9GCo/J3HA5NBaJVkYLsTucH6VGxMTMpz059qEcK24A/Q02QljuOcmmDY8MWIB6sabM5JyTyCPpmmbuQOjDvSE5POcdl96BXuSMD8ijPA596IsFySTtxj61Hgsw5xz+VTxAeb04PT6UAjU0mEhw44U9DXTpkI0UZ2KeZJPT2rB0wEAE4CqflUc5zW4rMxCkEoMYjHc+9RI7qRcWTEQjT5Ix3PBaobgsYwseQp9aUAli8jAqPToT6CmsxfDtlB0C46VB1RYiscHjOBioCxYkkfU+lOkO0nYTtP61AwLswyQMZ4PWky7kUkhZTt6EkjPeqjkk4OGJPOKtyJnGB0GKpOdvTjn60RBkc3y5PUjiqUoBVpC3PTB9atyAZBzgnoPWqs5+XaB90cn1rdHNMoOAA59sU2+AEECjOQDmpZABD3qHVWxLCCf4cmri9GclRbEM33YXHXFTZw4OB83OahVs24XoQ2eanUbo2AwTWZUUWFO5Rx26VLAcHBzmoImO0cdqmjPzCkdESbbtUKOR2zUCod3zDirQ5ximNtQ/Jn8alosSP0Hy+jelLKp+tKi/LuIx7etPkyVwKcTKZm3YyMjg+lUpWJKg5FaV6EABBycc9qypG2kH3okcshHPbpTBndgHIPUelSSAn7+M1GCd3y5/CkzNjiCOp60FicdsetMDHkkU+PLqTkEZzQmIF+YkE8dqeAUbDHP8qiGUk4/I1KGByN3TnmrEmSrgDpRUcUh28bOv8AEKKQ7kYJ3hRyB1H9KdI3O1TgHqff/Cq7Pt+VeGHcUuc8E446d8VRlcnwChIb5B39aMEADoe4z0pnmDaVAwR3pQw2qg4J5NAXRMhAAOAMmpZBtYKcFV5OPWo05b5QfQA00tiQgA0i7kjgswA4z0J7Ch5AFQds/nUTtk7efemSMMKAMEcc00K5Oso645PCimurD5gQSeAKaQQCc8DpQuGVcHn3p2ESpwrFhg8DiplBH3u3QnvVY7gox+JNTxZIy5ye4zQy4s2NMlYOqk4B9e1dGkgeMLHwgHJHVvrXM6YAD85+U9feuhtlwNzkbWP3BUSO2iyxuPyj5cDoo+6tNZ85zyf0FP3bjgDC/wB0envTJGDqcfdHXngVkdaK6vucgA7v0pykAEDk96HztwDgetNPzAAD8qCxhYnLHoTxVOcBW7e1TzuEkAI6VDN8zDHQ85qooUioSCS3Yciqkjb2Y9DVyYDYRx61R7e9aGMiK5UCNBnI71nai264i9dtaV1lThuR1rIu3Bni9KuOzOOt0JY/uH61ZhwsgqBD8pHfPpU0f+sBNQaRLEXO7HQGpc4ao14PsRTwc0jaJNGTkgVIy5WoVO1s5qXdlaW5TdgHYUcruz37UhwACeabI24H9KpGMmUbxsg9+az50Bxu/StC8cFT2PrWa5Uc9KUu5yyYrOMjcMj2qLHORzSF/lIFORwMgDgn86ggRckkg06L7x7UgG3p0NOIAXPQ0ASy4ZAR97NNUAg4OfWmo4xgHn1NPIAIJ6H9KpMQipx94D60U0yAEhgSaKBFSNwpy/3R+tOEm6RmY4Hc1U3gsQuCo70/dnHPA59q0scykWSe/JXsKlzgAkZz2qtGwyCef61K8hJJyc0ikywshBJJ59RTY5SrE8njAqssuScHjHAp6cgevfNND5iyo6tk+mKac4Ddc9KjBJYEk4FPRixLcKB096LDuPwWIBO0AZp0RGSTw2O9V5JDvIzwaeGyOvtn1p2uHMWCQMZHy55NS2/zc9QOnvUAKlVTufSpkfGcDBFJmkWaWmtiZcHLds9q6iIOYSEIGeWc1yumtH5mHXLdsV1VsSYvvcBeT/Spkjsose5AQqOF7k9TTQwETbQMjpu/maaz7gC2eOc01zjAKg8dKyO6IP8AOG3HA7kUByuBjtxTV+bLE9uaRmye3FIohuFDvk9etRldvOeOpFTHBYcVDcDC5YnOORWkUJmfcEl27ZNQbct+OPpU0vzsBn34qMgcYzkc1Rm7Fe6++wJ6ViXWRcR4xnnrW1LyCaybviRCPWmclVaE0ZzmphyVx+dQREY4qwgBHHWkVHYs57U4HkA1CpO7BqU4wDUs1WxKuM8+tKxwcCoiRketLuJ+vc0A2SZ3cNkd/pTM+xpN2OSaN4AJJ61SOeTM+8bk4/EVUk+U5I/Op74BmBJxg54NUpJA3HOKJI5nIWVwQNoxScAcGkyQc1GWGeBx7VFhXLSFSoFDnt0Paq4cqQVzjNTB8/eGcUWC4IM9ART3dsjBBXpjFRqw3cn3pznsDg0JCvoID6sAfcUVE23dyCfpRTJuZyuQSOB6+1SKwwFAyO59arJuxlhzUjts+7yxFbHLcnVxn7vapQy7Cuec5NVQflBJwvrTlbLZA/GlYaZYJ56YyOKkQkJ/tHiq4YnB7dqckmSOaLDUizzxupwYrnByx5FR7txBbp3p+eBjr3p2HzAOXy3Q8kVIDgcYqEdeOfSrAA2Be55PtQUmIv31XJzjqBUoIGQDyDTI196enL8YxmixUdDT05sSovH1rq7X/UKARj1zXFWjbZU9Cea7LT5A0O0jp0FQ0dtGRYfaowuCOxqBye+SepqfO9icjJ9O1QSqf4VwO1ZNHfGRFkgk5znGPSoZGZA2cc1IpJAY9+1RTnPB7jFFi7iq+0HvjtVe4lJ68880ueACaikICNgDb/OrQmxnVietRs3UY6jtTgwximMxGfSmZSZXlGEPPArHvvvKcY5rWk/u4GOeKyNQYhRnnmmc9V6EkOOKspyDVS3OVHrVpTxxU2Kg9CfOMUMX2/uwuePvdKapOADxT8gHFFhuVhWPPHSl3Ed+Kj53cEUpOVJz0pIlyJFfg8cVEZBg7vwoflCQc+1VHfPftWljCUiG6kDHFVpAFAGckdadJjJLZz2qA88A0mc7aHLzyTkUmNpJXgHtTBnOM0jAjgc+1RYVyQHPToOtLkjtkVH/AAgjg96EY9zzTsBPjI4PvjNNDnGAc45xTCP7vH40Ljr+FNILjwxxx0NFM3443DFFKwXMoOTxx70eYCOM4NV1JJx3PenhgRn0rc5LliOQy9cbe2KlLDOB171FE3GSMHHQU9SCVH5mkxol3YAA5J61Kq/KDxk8VACA+0cinbznAwB3NCQXLIznkY9KchJ5qFSSAKer4Y7QOenvTsFydAByetWNwXoOo9OlVo8E896kHGRu780WLiyVmwM5HNCNkAdAKb1yBjFOBwq7SDTZaZPaj98gzxn8q7Oz+SFcdT2riLYHzl+vWuwsZBtC5rNo66UjSUjAx165qK4O8Yz27DFDyKq7QcN9KZI5IOBiocTshIh3lcgcD61DKc9KfL+vrVeTtxzU9DXmGv8AKp45qHJCqCOvJqRmZjkYx3z1qNxkE5waEJyI92HxjIpkjdeeKC+MAnOOpqNmzmqRDZGw5DelY+pH92P96tduMisfVeB6DrTRhV+Edbn5RVtc44rPtn+QYq6rY6UiYyLG44PGSO1IH+YZNRNJjoOfemBueaYORYDbXIBpc5Uk9KrmQE/dwR6nNRSTndjPB4xTUTKVQsNKAML+dUJbjlkweKWeUJxxgiqazAEggc1WxhKdx5cnCjBFNXaW+bj6VCJsN6/Wk35+7wPU1FiEybIzgUE4xn8MVGxC8knFJuIXpxSsUSg9KMnNRDIHB470gYYH1oC5YYkjrTUbAIP05pm7B68UrHpzx2piuDgls4zRUZcZ+YHPtRQHMf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure-of-eight pattern of vulvar and perianal hypopigmentation in a 10-year-old girl with lichen sclerosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Paradise JE. Vaginal bleeding. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GF, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40224=[""].join("\n");
var outline_f39_18_40224=null;
var title_f39_18_40225="Infected bulla";
var content_f39_18_40225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected bulla in paraseptal emphysema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left upper lobe cavity with a moderately thick wall, representing an infected bulla in a patient with marked paraseptal emphysema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40225=[""].join("\n");
var outline_f39_18_40225=null;
var title_f39_18_40226="Alopecia areata 4";
var content_f39_18_40226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patchy hair loss is seen in this patient with alopecia areata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman, W, Jaeger, E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, Second Edition, Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40226=[""].join("\n");
var outline_f39_18_40226=null;
var title_f39_18_40227="Ropivacaine: Patient drug information";
var content_f39_18_40227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ropivacaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=see_link\">",
"     see \"Ropivacaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/59/10165?source=see_link\">",
"     see \"Ropivacaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naropin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naropin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ropivacaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11999 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40227=[""].join("\n");
var outline_f39_18_40227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219215\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219216\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016101\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016100\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016105\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016106\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016108\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016103\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016110\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=related_link\">",
"      Ropivacaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/59/10165?source=related_link\">",
"      Ropivacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_18_40228="Carboplatin: Patient drug information";
var content_f39_18_40228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carboplatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     see \"Carboplatin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/10/43174?source=see_link\">",
"     see \"Carboplatin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carboplatin Injection;",
"     </li>",
"     <li>",
"      Carboplatin Injection - LIQ IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701720",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carboplatin, cisplatin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11756 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-189.41.172.26-AECD3C225B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40228=[""].join("\n");
var outline_f39_18_40228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146189\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026963\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026965\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026964\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026969\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026970\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026972\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026967\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026974\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=related_link\">",
"      Carboplatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/10/43174?source=related_link\">",
"      Carboplatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_18_40229="Ketamine: Pediatric drug information";
var content_f39_18_40229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"    see \"Ketamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/36/10820?source=see_link\">",
"    see \"Ketamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ketalar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ketalar&reg;;",
"     </li>",
"     <li>",
"      Ketamine Hydrochloride Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       General Anesthetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Some neonatal experts do not recommend the use of ketamine in neonates; an increase in neuronal apoptosis has been observed in neonatal animal studies (Patel, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Limited data available; dose not established; titrate dose to effect; further studies needed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adjunct to anesthesia: 0.5-2 mg/kg/dose has been reported. A study of 23 patients [mean age: 3.2 years (9 days to 7 years)] undergoing MRI received a fixed dose of 0.5 mg/kg of ketamine prior to propofol bolus and infusion. A single case report describes ketamine (1-2 mg/kg) adjunct use with sevoflurane in a one-day old neonate (GA: 33 weeks) undergoing pacemaker placement (Castilla, 2004; Tomatir, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Procedural sedation/analgesia: Full-term neonates: 0.2-1 mg/kg/dose; may repeat 0.5 mg/kg/dose as needed; use most frequently reported in cardiac catheterization and ROP corrective procedures (Jobeir, 2003; Lyon, 2008; Pees, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"      see \"Ketamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose to effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 6-10 mg/kg for 1 dose (mixed in cola or other beverage) given 30 minutes before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 3-7 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Range: 0.5-2 mg/kg, use smaller doses (0.5-1 mg/kg) for sedation for minor procedures; usual induction dosage: 1-2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Sedation: 5-20 mcg/kg/minute; start at lower dosage listed and titrate to effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 3-8 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Range: 1-4.5 mg/kg; usual induction dosage: 1-2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults: Maintenance: Supplemental doses of",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of initial dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ketalar&reg;: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F185765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Use 100 mg/mL I.V. solution and mix the appropriate dose in 0.2-0.3 mL/kg of cola or other beverage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Administer slowly, do not exceed 0.5 mg/kg/minute; do not administer faster than 60 seconds; maximum concentration for slow I.V. push: 50 mg/mL;",
"     <b>",
"      Note:",
"     </b>",
"     Do not inject 100 mg/mL concentration I.V. without proper dilution; dilute with an equal volume of SWI, NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     W to produce 50 mg/mL concentration for slow I.V. push. Maximum concentration for intermittent or continuous infusion: 2 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F185770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Cefepime, ceftazidime, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bupivacaine, bupivacaine with fentanyl, clonidine, clonidine with tetracaine, dexamethasone sodium phosphate, fentanyl, lidocaine, lidocaine with morphine, meperidine, midazolam.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, doxapram.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Morphine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; do not mix with barbiturates or diazepam as precipitation may occur",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anesthesia, short surgical procedures, dressing changes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ketalar&reg; may be confused with Kenalog&reg;, ketorolac",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F185769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia/tachycardia, hyper-/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Intracranial pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema (transient), morbilliform rash (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea, salivation increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at the injection site, exanthema at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Skeletal muscle tone enhanced (tonic-clonic movements)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, intraocular pressure increased, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Airway obstruction, apnea, bronchial secretions increased, respiratory depression, laryngospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, dependence with prolonged use, emergence reactions (includes confusion, delirium, dreamlike state, excitement, hallucinations, irrational behavior, vivid imagery)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketamine or any component; patients in whom a significant elevation in blood pressure would be hazardous (eg, patients with elevated intracranial pressure, hypertension, aneurysms, thyrotoxicosis, CHF, angina, or psychotic disorders)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with gastroesophageal reflux. Use with caution and decrease the dose in patients with hepatic dysfunction. Use with caution in patients with a full stomach, patients should fast (ie, be NPO) for an appropriate time before being sedated for elective procedures. Use with caution in patients with elevated CSF pressure, chronic alcoholics, and in acutely intoxicated patients. Do not use as sole anesthetic in surgery or diagnostic procedures of the pharynx, larynx, or bronchial tree or in surgical procedures involving visceral pain pathways",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use only by or under the direct supervision of physicians experienced in administering general anesthetics. Resuscitative equipment should be available for use; respiratory depression or apnea may occur with rapid administration rates or with large doses. Postanesthetic emergence reactions which can manifest as vivid dreams, hallucinations and/or frank delirium occur in 12% of patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; these reactions are less common in patients &lt;15 years of age and &gt;65 years and when given intramuscularly. Emergence reactions may occur up to 24 hours postoperatively and may be reduced by minimization of verbal, tactile, and visual patient stimulation during recovery, or by pretreatment with a benzodiazepine (using lower recommended doses of ketamine). Severe emergent reactions may require treatment with a small hypnotic dose of a short or ultra-short acting barbiturate. Prolonged use may cause physical dependence (withdrawal symptoms on discontinuation) and tolerance. Cardiac function should be continuously monitored in patients with hypertension or cardiac decompensation. Animal data suggests that exposure of the developing brain to anesthetics like ketamine (especially during the critical time of synaptogenesis) may  result in long-term impairment of cognitive function (Patel, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5994626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Ketamine crosses the placenta and can be detected in fetal tissue. Ketamine produces dose dependent increases in uterine contractions; effects may vary by trimester. The plasma clearance of ketamine is reduced during pregnancy. Dose related neonatal depression and decreased APGAR scores have been reported with large doses administered at delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiovascular effects, heart rate, blood pressure, respiratory rate, transcutaneous O",
"     <sub>",
"      2",
"     </sub>",
"     saturation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces dissociative anesthesia by direct action on the cortex and limbic system; does not usually impair pharyngeal or laryngeal reflexes",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anesthesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 3-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Within 30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analgesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Within 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Following single dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anesthesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 12-25 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analgesia: I.M.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recovery:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 1-2 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via N-dealkylation, hydroxylation of cyclohexone ring, glucuronide conjugation, and dehydration of hydroxylated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alpha: 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 2.5 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/36/10820?source=see_link\">",
"      see \"Ketamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; do not engage in such activities for at least 24 hours after ketamine anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used in combination with anticholinergic agents to decrease hypersalivation; should not be used for sedation for procedures that require a total lack of movement (eg, MRI, radiation therapy) due to association with purposeless movements",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Castilla M, Jerez M, Ll&aacute;cer M, et al, \"Anaesthetic Management in a Neonate With Congenital Complete Heart Block,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2004, 14(2):172-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/14962334/pubmed\" id=\"14962334\" target=\"_blank\">",
"        14962334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cote CJ, &ldquo;Sedation for the Pediatric Patient: A Review,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1994, 41(1):31-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/8295806/pubmed\" id=\"8295806\" target=\"_blank\">",
"        8295806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutstein HB, Johnson KL, Heard MN, et al, &ldquo;Oral Ketamine Premedication in Children,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1992, 76(1):28-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/1729932/pubmed\" id=\"1729932\" target=\"_blank\">",
"        1729932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jobeir A, Galal MO, Bulbul ZR, et al, \"Use of Low-Dose Ketamine and/or Midazolam for Pediatric Cardiac Catheterization,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2003, 24(3):236-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/12545318/pubmed\" id=\"12545318\" target=\"_blank\">",
"        12545318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyon F, Dabbs T, and O'Meara M, \"Ketamine Sedation During the Treatment of Retinopathy of Prematurity,\"",
"      <i>",
"       Eye (Lond)",
"      </i>",
"      , 2008, 22(5):684-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel P and Sun L, \"Update on Neonatal Anesthetic Neurotoxicity: Insight Into Molecular Mechanisms and Relevance to Humans,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2009, 110(4):703-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/19276968/pubmed\" id=\"19276968\" target=\"_blank\">",
"        19276968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pees C, Haas NA, Ewert P, et al, \"Comparison of Analgesic/Sedative Effect of Racemic Ketamine and S(+)-Ketamine During Cardiac Catheterization in Newborns and Children,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2003, 24(5):424-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/14627307/pubmed\" id=\"14627307\" target=\"_blank\">",
"        14627307",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saarenmaa E, Neuvonen PJ, Huttunen P, et al, \"Ketamine for Procedural Pain Relief in Newborn Infants,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2001, 85(1):F53-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, Phipps S, Smith B, et al, &ldquo;Oral Ketamine Premedication to Alleviate the Distress of Invasive Procedures in Pediatric Oncology Patients,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(4):537-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/1408506/pubmed\" id=\"1408506\" target=\"_blank\">",
"        1408506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD and Rasmussen GE, &ldquo;Pain Management and Sedation in the Pediatric Intensive Care Unit,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1994, 41(6):1269-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/7984386/pubmed\" id=\"7984386\" target=\"_blank\">",
"        7984386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomatir E, Atalay H, Gurses E, et al, \"Effects of Low Dose Ketamine Before Induction on Propofol Anesthesia for Pediatric Magnetic Resonance Imaging,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2004, 14(10):845-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/18/40229/abstract-text/15385013/pubmed\" id=\"15385013\" target=\"_blank\">",
"        15385013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13398 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40229=[""].join("\n");
var outline_f39_18_40229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185725\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185726\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053466\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675070\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053458\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185708\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185693\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185765\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053471\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185770\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053461\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053470\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185772\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185769\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053475\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053457\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053456\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185759\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185702\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994626\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053465\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053455\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053473\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053474\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053463\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053476\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=related_link\">",
"      Ketamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/36/10820?source=related_link\">",
"      Ketamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_18_40230="Bilateral 4th nerve palsy";
var content_f39_18_40230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Bilateral superior oblique palsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A patient with a bilateral fourth nerve palsy demonstrates a reversing hypertropia (left hypertropia in right gaze and a right hypertropia in left gaze in the middle panels right and left). The primary position deviation is not readily apparent because of the bilateral palsy (middle row center panel). There is underaction of both superior oblique muscles (right lower and left lower panels). There is overaction of the inferior oblique muscle bilaterally (right upper and left upper panels).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40230=[""].join("\n");
var outline_f39_18_40230=null;
var title_f39_18_40231="Management of struvite or staghorn calculi";
var content_f39_18_40231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of struvite or staghorn calculi",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40231/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40231/contributors\">",
"     Glenn M Preminger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40231/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40231/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40231/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40231/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40231/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/18/40231/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staghorn calculi refer to branched stones that fill all or part of the renal pelvis and branch into several or all of the calyces. They are most often composed of struvite (magnesium ammonium phosphate)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    apatite. These stones are often referred to as 'infection stones' since they are strongly associated with urinary tract infections with urea splitting organisms. Cystine stones, although much less common, may also develop into staghorn calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small struvite",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    apatite stones can grow rapidly over a period of weeks to months into large staghorn calculi involving the calyces and entire renal pelvis. If left untreated, this can lead to deterioration of kidney function and end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, since the stones often remain infected, there is a risk of developing sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, most patients require definitive surgical treatment.",
"   </p>",
"   <p>",
"    There are several alternative surgical treatments for staghorn calculi. The American Urological Association Nephrolithiasis Guidelines Panel reviewed the existing literature to determine the optimal application of these different treatment modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The current discussion is largely based on this Panel's recommendations for the management of staghorn calculi; the pathogenesis and clinical manifestations of struvite stones as well as the management of renal and ureteral calculi in general, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Limitations of the data",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limitations that must be considered when interpreting and adopting guidelines for the optimal treatment of staghorn calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from randomized controlled studies comparing treatment options are very limited.",
"     </li>",
"     <li>",
"      There is no uniform system of categorizing staghorn calculi, no standard method of describing the collecting system, and no widely accepted system of reporting the size of staghorn calculi.",
"     </li>",
"     <li>",
"      The indications for hospitalization may vary in different countries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These limitations lead to difficulty in interpreting or comparing procedural outcomes reported in the literature. In addition, most of the studies that evaluated the use of shock wave lithotripsy for struvite stones were based upon results with the unmodified Dornier HM-3, the most powerful machine available at the time the guidelines were created. Future studies may report on other lithotriptors, as monotherapy or in combination with other modalities, which might demonstrate dissimilar efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are seven alternatives for managing staghorn calculi, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical therapy alone",
"     </li>",
"     <li>",
"      Open surgery",
"     </li>",
"     <li>",
"      Laparoscopic surgery",
"     </li>",
"     <li>",
"      Percutaneous nephrolithotomy (PNL)",
"     </li>",
"     <li>",
"      Shock wave lithotripsy (SWL)",
"     </li>",
"     <li>",
"      Combination of PNL and SWL",
"     </li>",
"     <li>",
"      Combination of PNL and ureteroscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical therapy with one of the procedures listed above, most commonly PNL, is usually required to treat struvite stones. Medical therapy alone is",
"    <strong>",
"     not",
"    </strong>",
"    preferred except in patients who are too ill to tolerate, or who refuse, stone removal.",
"   </p>",
"   <p>",
"    This section briefly reviews these options as they relate to management of struvite stones. Greater detail regarding the surgical options is provided elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Medical therapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical treatment of struvite stones is rarely successful. Bacteria live within interstices of the stone where antimicrobial agents may not penetrate, and create a persistently alkaline local environment promoting stone growth. Nevertheless, if a bacterium has been identified in culture, chronic administration of a culture-specific antimicrobial agent can sometimes prevent further stone growth, and should be initiated.",
"   </p>",
"   <p>",
"    Other strategies include dietary phosphorus reduction (but this therapy is burdensome and often constipating), and administration of urease inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27027?source=see_link\">",
"     acetohydroxamic acid",
"    </a>",
"    (AHA, Lithostat). Urease inhibitors can cause complete, non-competitive inhibition of urease production. Stone growth can be arrested in 80 percent of patients versus only 40 percent of patients in placebo-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/5\">",
"     5",
"    </a>",
"    ]. However, 20 to 60 percent of patients receiving AHA experience significant side effects such as palpations, edema, nausea, vomiting, diarrhea, headache, loss of taste, hallucinations, rash, abdominal discomfort, anemia and reticulocytosis (all reversible).",
"   </p>",
"   <p>",
"    Prior to 1980, surgery was not advocated for removal of staghorn stones since they were unlikely to be symptomatic except for bacteriuria. However, few patients do well with observation alone. Among 177 consecutive patients with a staghorn calculus, for example, renal-related death occurred in 67, 3, and zero percent of patients who refused treatment, who were treated without complete clearance of stone fragments, or who had complete clearance of fragments, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, medical therapy alone is not considered the preferred option except in patients who are too ill to tolerate, or who refuse, stone removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/7\">",
"     7",
"    </a>",
"    ]. Routine surveillance every three to four months to monitor stone growth is mandatory for patients on medical therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of a renal stone is the \"gold-standard\" to which all other forms of stone removal are compared. Yet, open surgery for management of staghorn calculi is rarely indicated today. A variety of specific open surgical operations on the kidney may be performed to remove a staghorn calculus. Depending upon anatomy, a pelviolithotomy, extended pyelotomy, nephrostomy, anatrophic nephrolithotomy, partial nephrectomy, or even nephrectomy may all play a role.",
"   </p>",
"   <p>",
"    The most common open operative stone removal procedure performed today is anatrophic nephrolithotomy, which involves an incision of the renal parenchyma along an avascular plane to gain access to the calyceal system. The development of this technique, and the demonstration that patients with infected stones could be made stone free, made this surgical approach the standard of care throughout the 1960s and 1970s.",
"   </p>",
"   <p>",
"    Open surgical stone removal is now relatively uncommon in the treatment of struvite stones, except for removal of a unilateral, chronically infected, shrunken, and poorly functioning kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/9\">",
"     9",
"    </a>",
"    ]. It may also be the only reasonable treatment option for very large or complex stones, or in morbidly obese individuals in whom endoscopic and fluoroscopic techniques are difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. There have been a number of series reporting the use of laparoscopic techniques to perform anatrophic nephrolithotomy. These data are limited by the small number of patients treated in this fashion and the lack of studies comparing laparoscopic anatrophic nephrolithotomy to established endoscopic techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Percutaneous nephrolithotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNL became popular as a primary technique for stone removal in the early 1980s. This procedure allows for removal of large volume stones. The technique has been greatly improved with refinements in flexible and rigid nephroscopes, and laser or pneumatic lithotripsy via the nephroscope. A more extensive discussion of this technique is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Staghorn calculi are generally best managed by PNL, despite the frequent requirement for repeat procedures. PNL was previously recommended in conjunction with SWL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/4,9\">",
"     4,9",
"    </a>",
"    ], but results with PNL alone have surpassed those with combination PNL and SWL as refinements in PNL techniques and instruments have been made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are some unquestioned advantages to PNL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the stone can be accessed, it can almost always be removed.",
"     </li>",
"     <li>",
"      Direct inspection of the collecting system allows identification and removal of small fragments.",
"     </li>",
"     <li>",
"      Repeated inspections are possible because the tract can be kept open indefinitely.",
"     </li>",
"     <li>",
"      The process is relatively rapid, with success or failure being obvious immediately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospitalization is usually from one to five days, with most patients returning to light activity after one week. One disadvantage of PNL is that the expertise required for this operation is not widely available. Thus, these complex patients are best treated by specialized \"stone experts\" generally located at major teaching hospitals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Shock-wave lithotripsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;SWL has historically been an accepted treatment for most stones, and is still used for the majority of smaller stones. There are several reasons for the popularity of SWL: it is generally considered to have few short-term complications; its noninvasive nature has much appeal; and the technique is widely available. However, it often requires general or regional anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some disadvantages with SWL in the management of staghorn calculi, given inferior stone free rates (compared with PNL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ], and it may result in a significant perinephric hematoma, residual stones in the ureteral tract, sepsis, renal trauma, and colic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Multiple treatments may often be required, and ancillary procedures directed toward the management of fragments are often necessary. In addition, multiple SWL treatments may subsequently impair renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/10/27812?source=see_link\">",
"     \"Renal complications of extracorporeal shock wave lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend SWL monotherapy as first line therapy for the management of most patients with staghorn calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. The exception is in patients with small stone burdens (stone area less than 500 mm2) who have normal collecting system anatomy (eg, no hydroureteronephrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. If SWL monotherapy is used, a stent should be placed to ensure adequate drainage of the kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Combination of PNL and SWL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are managed by using both PNL and SWL on the same stone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/9,16\">",
"     9,16",
"    </a>",
"    ], particularly when the stone is large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fragments are inaccessible by PNL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/17\">",
"     17",
"    </a>",
"    ]. This technique combines the main advantage of PNL (which is the rapid removal of large volumes of an easily accessible stone), with the advantage of SWL (the easy treatment of small volumes of stone that are difficult or dangerous to access using PNL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the combined technique, the surgeon first utilizes PNL, making every effort to remove as much stone as possible. Any residual stones are treated one or two days later with SWL. Because subsequent passage of these fragments cannot be predicted, a second percutaneous procedure is then performed, removing all residual stones. The likelihood of success is greatest with small, nonobstructing stones and lowest with large obstructing stones that essentially form a cast of the renal pelvis and calyces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, newer PNL techniques and instruments may make the addition of SWL to PNL unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adjunctive procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous nephrostomy tube placement may be necessary at some point in the management of staghorn stones. Nephrostomy tubes are placed routinely in patients undergoing PNL, and are also frequently used for drainage of infected stone fragments or pain relief following SWL.",
"   </p>",
"   <p>",
"    Ureteral stent insertion prior to SWL of staghorn calculi is used routinely. In many cases, a double-pigtail stent is placed and left indwelling for days or weeks to maintain drainage while fragments pass.",
"   </p>",
"   <p>",
"    Ureteroscopy is sometimes performed in patients undergoing PNL. With this technique, the ureteroscopic component provides the ability to remove peripheral stones, avoiding the need for multiple nephrostomy tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Irrigation (chemolysis) of the collecting system, with solutions such as a citric acid mixture (Renacidin&reg;), to dissolve remaining fragments of infected stones, particularly after PNL, has been advocated by some clinicians. Chemolysis is not a common procedure today, since its use prolongs hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Post-procedure monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic monitoring (every 6 to 12 months) with urologic imaging (eg, computed tomography [CT]) is indicated after successful therapy, since new stone formation can occur, occasionally affecting the contralateral kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/23\">",
"     23",
"    </a>",
"    ]. This is most likely to occur in women with pure struvite stones and recurrent urinary tract infections, and in patients with a ureteral diversion or any other condition resulting in recurrent bacteriuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes relevant for determining the appropriate modality of treatment for staghorn calculi are the stone-free rate, requirement for repeat primary, secondary or adjunctive procedures, and complication rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Stone-free rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stone-free rate following surgical stone removal is perhaps the most quantifiable and meaningful determinant of successful treatment. Given that the majority of these complex stones contain bacteria, the only way to subsequently sterilize the patients&rsquo; urine is to completely remove all stone material.",
"   </p>",
"   <p>",
"    Nevertheless, the renal stone literature is clouded by studies that count patients with small residual fragments (so-called \"clinically insignificant\" residual fragments) as successes. In addition, the method of assessing the stone-free state has a significant impact on the number of patients who are reported free of stones following surgery. As an example, stone-free rates are probably overestimated if the only method of ascertainment is a plain abdominal radiograph, as done in the majority of studies that examined this issue related to staghorn calculi. The removal of all fragments is best confirmed by CT without contrast, which can detect stones as small as 1 mm in diameter. CT scanning is more sensitive than plain radiographs, renal ultrasonography or nephrotomography. However, nephrostomy tubes may obscure residual stone fragments.",
"   </p>",
"   <p>",
"    Stone-free rates are greatly dependent upon stone burden, in particular if SWL and PNL are used rather than open surgery. Lower rates are reported with complete staghorn calculi (filling virtually the entire pelvis and calyces) compared to partial staghorn calculi.",
"   </p>",
"   <p>",
"    Stone-free rates are also higher with procedures that are more invasive. As an example, stone-free rates are approximately 50 percent for SWL, and over 75 to 80 percent for open surgery and PNL (100 percent in some reports of open surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3,25-27\">",
"     3,25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although stone free rates over 75 percent are achievable using PNL, these patients often require repeat procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3,4,19,28\">",
"     3,4,19,28",
"    </a>",
"    ]. As an example, in a prospective randomized trial of 50 staghorn calculi, SWL monotherapy (23 stones) was compared with combined initial PNL followed by SWL (27 stones) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/28\">",
"     28",
"    </a>",
"    ]. The stone-free rate at six months was significantly greater with combination therapy (74 versus 22 percent). Stone-free rates without a 'second look' PNL are lower (66 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. &ldquo;Aggressive PNL&rdquo; with multiple nephrostomy tracts appear to improve stone-free rates, while minimizing the need for second look nephroscopy procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If absolute stone-free rates are used to ultimately decide the most appropriate mode of stone removal, PNL and open surgery provide the \"best\" results. However, between PNL and open surgery, PNL generally has the advantages of lower patient morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Residual stone fragments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A persistent stone-free state is also dependent upon complete removal of all large stone fragments. As an example, the persistence of fragments more than 5 mm in size at three months is associated with a very high incidence of progressive stone growth (seven of nine in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/31\">",
"     31",
"    </a>",
"    ]. On the other hand, the stone-free and infection-free rate at three years is approximately 90 percent if all fragments are removed during the initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistently sterile urine and prevention of stone growth can be achieved in some patients with small residual stone particles. Finely pulverized stone material is susceptible to sterilization by appropriate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition to antibiotics, patients with small fragments that persist eight weeks or more after SWL may benefit from the administration of 40 to 60 mEq of potassium citrate per day to increase urinary citrate excretion; this therapy also appears to benefit patients with calcium oxalate stone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Potassium citrate administration will minimize growth of the fragments, thereby promoting their spontaneous passage.",
"   </p>",
"   <p>",
"    For patients with small fragments that persist eight weeks after the procedure, we suggest appropriate antibiotic treatment and administration of 40 to 60 meq of potassium citrate per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Repeat procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may require a repeat procedure (with same or different modality), or an adjunctive procedure (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Adjunctive procedures'",
"    </a>",
"    above). Analyzing the number of repeat procedures associated with various treatment options for staghorn calculi can be difficult, since some adjunctive procedures are considered an essential part of the primary procedure. The American Urological Association Nephrolithiasis Guidelines Panel changed its position with the 2004 guidelines, and now considers adjunctive procedures part of the primary procedures if they are performed in the same session [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before 1979, when open surgery was the only modality available to treat staghorn calculi, it was unusual to perform more than one procedure per patient to remove all stone material. Surgical stone removal by anatrophic nephrolithotomy still generally requires only one procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3,18\">",
"     3,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with different modalities require multiple procedures to removal all fragments, which vary with the initial modality (on average) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3,18,19\">",
"     3,18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients treated with PNL require one to two separate procedures.",
"     </li>",
"     <li>",
"      Combination PNL plus SWL often requires three procedures.",
"     </li>",
"     <li>",
"      SWL alone requires three to four procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With all procedures, the size and complexity of the stone in large part determines the success rate and need for repeat procedures.",
"   </p>",
"   <p>",
"    Retreatment rates, that is the rate at which the instrument must be reinserted through the tract during PNL to remove residual stones, varies from 10 percent in simple situations to 40 to 50 percent for more complicated problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute complications of surgical methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential acute complications related to stone removal procedures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perforation of the renal pelvis",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Hydrothorax/pneumothorax",
"      </span>",
"     </li>",
"     <li>",
"      Perirenal hematoma",
"     </li>",
"     <li>",
"      Significant blood loss",
"     </li>",
"     <li>",
"      Vascular injury",
"     </li>",
"     <li>",
"      Colon injury",
"     </li>",
"     <li>",
"      Urinoma or prolonged urine leak",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Pneumothorax",
"     </li>",
"     <li>",
"      Hydrothorax",
"     </li>",
"     <li>",
"      Pulmonary embolus",
"     </li>",
"     <li>",
"      Stent migration",
"     </li>",
"     <li>",
"      Renal impairment",
"     </li>",
"     <li>",
"      Wound infection",
"     </li>",
"     <li>",
"      Secondary unplanned interventions",
"     </li>",
"     <li>",
"      Transfusion requirement",
"     </li>",
"     <li>",
"      Nephrectomy",
"     </li>",
"     <li>",
"      Death",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall acute complication rate is possibly lowest for PNL, and highest for open surgery and SWL, but rates for individual complications vary greatly depending on the procedure.",
"   </p>",
"   <p>",
"    In a review of the literature, the rate of significant acute complications ranged from 13 to 19 percent for all four modalities of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. There were instances of nephrectomy or renal loss with all four modalities.",
"   </p>",
"   <p>",
"    Compared with SWL, the more invasive modalities (open surgery and PNL) have higher rates of transfusion (from 5 to 50 percent versus one percent or lower for SWL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The mean rate of transfusion for PNL, combination treatment and open surgery has been estimated to be approximately 20 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. In one review of 1854 patients who underwent PNL, 228 patients required transfusions (mean 3.6 units, range one to ten units), and 24 patients required angioembolization to control renal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/37\">",
"     37",
"    </a>",
"    ]. Size of the stone was the only factor associated with risk of massive bleeding.",
"   </p>",
"   <p>",
"    The rate of death related to any of the procedures is very low (0.5 to 1 percent for open surgery versus less than 0.1 percent for SWL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/4\">",
"     4",
"    </a>",
"    ], and is more likely to occur in those with significant comorbidity or who develop sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Septic complications are more common with SWL alone than with combination SWL and PNL or open procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Long-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term complications associated with the techniques utilized to remove staghorn calculi include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stone recurrence",
"     </li>",
"     <li>",
"      Growth of residual stone fragments",
"     </li>",
"     <li>",
"      Renal impairment",
"     </li>",
"     <li>",
"      Loss of the kidney following surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the frequency of these long-term complications. There is a risk of renal loss, albeit small, with all modalities of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ]. With long-term follow-up in the summary report, 1.4 to 2 percent of patients undergoing an open procedure had renal impairment, and 3.7 percent eventually lost their kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a summary report, long-term complications were evaluated in over 1500 patients who underwent an open procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/4\">",
"     4",
"    </a>",
"    ]. The open surgery group had a stone recurrence rate of 10.4 percent. Only a small number of patients had growth of their residual stone, yielding a stone growth rate of 1 percent.",
"   </p>",
"   <p>",
"    For SWL and PNL, stone recurrence and growth rates would be expected to be similar to an open procedure, since the method of removal should not have an effect on the propensity for recurrent stone formation or growth or residual stone fragments. Early stone recurrence rates were estimated to be approximately six percent for SWL alone and PNL alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/9,19\">",
"     9,19",
"    </a>",
"    ], and with follow-up of over three years, 23 percent for combination SWL and PNL treatment for large staghorn calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staghorn calculi refer to branched stones that fill all or part of the renal pelvis and branch into several or all of the calyces. They are most often composed of struvite (magnesium ammonium phosphate)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    apatite. These stones are strongly associated with urinary tract infections and persistent infection of the stone.",
"   </p>",
"   <p>",
"    Staghorn calculi can lead to sepsis, deterioration of kidney function and end-stage renal disease if left untreated. Since medical therapy alone is usually not successful, most patients require definitive surgical treatment.",
"   </p>",
"   <p>",
"    The major surgical alternatives for staghorn calculi include percutaneous nephrolithotomy (PNL), shock wave lithotripsy (SWL), the combination of PNL and SWL, and open surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations apply to adult patients with a non-cystine, non-uric acid staghorn calculus, who have two equally well-functioning kidneys or a solitary kidney with normal kidney function. In addition, it is assumed that the medical condition of the patient is such that they could tolerate anesthesia and any of the four modalities of treatment.",
"   </p>",
"   <p>",
"    Given the poor outcomes associated with non-removal of staghorn calculi, we recommend that all newly diagnosed patients undergo a stone removal procedure (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Treatment options'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that percutaneous nephrolithotomy (PNL) be used as the first line of treatment for most patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      PNL should be the final procedure in patients who require combination therapy with PNL and SWL, to ensure that stone fragments are removed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Combination of PNL and SWL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest SWL as monotherapy,",
"      <strong>",
"       with",
"      </strong>",
"      placement of adequate drainage of the kidney prior to the procedure (usually a ureteral stent), only in selected patients with small stone volumes who have normal collecting system anatomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with small fragments that persist eight weeks after the procedure, we suggest appropriate antibiotic treatment and administration of 40 to 60 mEq of potassium citrate per day (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Residual stone fragments'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Given that outcomes with percutaneous nephrolithotomy are similar to open surgery, but with lower morbidity, we recommend open surgery (anatrophic nephrolithotomy) only in very selected circumstances, as follows (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a large stone burden, especially if the collecting system anatomy is very distorted, in whom a reasonable number of less invasive procedures would not be expected to successfully remove the stone.",
"     </li>",
"     <li>",
"      Morbidly obese individuals in whom endoscopic and fluoroscopic techniques are difficult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a staghorn stone in a non-functioning or poorly functioning kidney, especially if it is chronically infected, nephrectomy is a reasonable treatment option.",
"   </p>",
"   <p>",
"    Subsequent to successful treatment, periodic monitoring (every 6 to 12 months) should be undertaken, since new stones may occur, occasionally affecting the contralateral kidney. Urologic imaging with plain abdominal radiographs or a non-contrasted renal CT scan and 24-hour urinary testing will help determine stone recurrence and the adequacy of medical stone management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=see_link&amp;anchor=H724201#H724201\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\", section on 'Radiologic monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\", section on 'The complete metabolic evaluation'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/1\">",
"      Cranidis AI, Karayannis AA, Delakas DS, et al. Cystine stones: the efficacy of percutaneous and shock wave lithotripsy. Urol Int 1996; 56:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/2\">",
"      Jungers P, Joly D, Barbey F, et al. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004; 44:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/3\">",
"      Preminger GM, Assimos DG, Lingeman JE, et al. Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol 2005; 173:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/4\">",
"      Segura JW, Preminger GM, Assimos DG, et al. Nephrolithiasis Clinical Guidelines Panel summary report on the management of staghorn calculi. The American Urological Association Nephrolithiasis Clinical Guidelines Panel. J Urol 1994; 151:1648.",
"     </a>",
"    </li>",
"    <li>",
"     Wong H, Riehl RL, Griffith DP. Medical management and prevention of struvite stones. In: Kidney stones: Medical and surgical management, Coe FL, Favis MJ, Pak CC, et al (Eds), Lippincott-Raven, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/6\">",
"      Teichman JM, Long RD, Hulbert JC. Long-term renal fate and prognosis after staghorn calculus management. J Urol 1995; 153:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/7\">",
"      Gupta M, Bolton DM, Gupta PN, Stoller ML. Improved renal function following aggressive treatment of urolithiasis and concurrent mild to moderate renal insufficiency. J Urol 1994; 152:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/8\">",
"      Cohen TD, Preminger GM. Struvite calculi. Semin Nephrol 1996; 16:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/9\">",
"      Honeck P, Wendt-Nordahl G, Krombach P, et al. Does open stone surgery still play a role in the treatment of urolithiasis? Data of a primary urolithiasis center. J Endourol 2009; 23:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/10\">",
"      Kaouk JH, Gill IS, Desai MM, et al. Laparoscopic anatrophic nephrolithotomy: feasibility study in a chronic porcine model. J Urol 2003; 169:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/11\">",
"      Simforoosh N, Aminsharifi A, Tabibi A, et al. Laparoscopic anatrophic nephrolithotomy for managing large staghorn calculi. BJU Int 2008; 101:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/12\">",
"      Rodrigues Netto N Jr, Claro Jde A, Ferreira U. Is percutaneous monotherapy for staghorn calculus still indicated in the era of extracorporeal shockwave lithotripsy? J Endourol 1994; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/13\">",
"      Auge BK, Preminger GM. Update on shock wave lithotripsy technology. Curr Opin Urol 2002; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/14\">",
"      Zhu S, Dreyer T, Liebler M, et al. Reduction of tissue injury in shock-wave lithotripsy by using an acoustic diode. Ultrasound Med Biol 2004; 30:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/15\">",
"      Zhou Y, Cocks FH, Preminger GM, Zhong P. Innovations in shock wave lithotripsy technology: updates in experimental studies. J Urol 2004; 172:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/16\">",
"      Lam HS, Lingeman JE, Mosbaugh PG, et al. Evolution of the technique of combination therapy for staghorn calculi: a decreasing role for extracorporeal shock wave lithotripsy. J Urol 1992; 148:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/17\">",
"      Streem SB, Geisinger MA. Combination therapy for staghorn calculi in solitary kidneys: functional results with long-term followup. J Urol 1993; 149:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/18\">",
"      Assimos DG, Wrenn JJ, Harrison LH, et al. A comparison of anatrophic nephrolithotomy and percutaneous nephrolithotomy with and without extracorporeal shock wave lithotripsy for management of patients with staghorn calculi. J Urol 1991; 145:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/19\">",
"      Gleeson M, Lerner SP, Griffith DP. Treatment of staghorn calculi with extracorporeal shock-wave lithotripsy and percutaneous nephrolithotomy. Urology 1991; 38:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/20\">",
"      de la Rosette JJ, Tsakiris P, Ferrandino MN, et al. Beyond prone position in percutaneous nephrolithotomy: a comprehensive review. Eur Urol 2008; 54:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/21\">",
"      Scoffone CM, Cracco CM, Poggio M, Scarpa RM. Endoscopic combined intrarenal surgery for high burden renal stones. Arch Ital Urol Androl 2010; 82:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/22\">",
"      Ferrandino MN, Monga M, Preminger GM. Adjuvant therapy after surgical stone management. Adv Chronic Kidney Dis 2009; 16:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/23\">",
"      Kristensen C, Parks JH, Lindheimer M, Coe FL. Reduced glomerular filtration rate and hypercalciuria in primary struvite nephrolithiasis. Kidney Int 1987; 32:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/24\">",
"      Cohen TD, Streem SB, Lammert G. Long-term incidence and risks for recurrent stones following contemporary management of upper tract calculi in patients with a urinary diversion. J Urol 1996; 155:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/25\">",
"      Lam HS, Lingeman JE, Barron M, et al. Staghorn calculi: analysis of treatment results between initial percutaneous nephrostolithotomy and extracorporeal shock wave lithotripsy monotherapy with reference to surface area. J Urol 1992; 147:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/26\">",
"      Stanley KE, Winfield HN. Management of staghorn calculi: percutaneous nephrolithotripsy versus extracorporeal shock-wave lithotripsy. Semin Urol 1994; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/27\">",
"      Streem SB, Yost A, Dolmatch B. Combination \"sandwich\" therapy for extensive renal calculi in 100 consecutive patients: immediate, long-term and stratified results from a 10-year experience. J Urol 1997; 158:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/28\">",
"      Meretyk S, Gofrit ON, Gafni O, et al. Complete staghorn calculi: random prospective comparison between extracorporeal shock wave lithotripsy monotherapy and combined with percutaneous nephrostolithotomy. J Urol 1997; 157:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/29\">",
"      Desai M, Jain P, Ganpule A, et al. Developments in technique and technology: the effect on the results of percutaneous nephrolithotomy for staghorn calculi. BJU Int 2009; 104:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/30\">",
"      Preminger GM. High burden and complex renal calculi: aggressive percutaneous nephrolithotomy versus multi-modal approaches. Arch Ital Urol Androl 2010; 82:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/31\">",
"      Beck EM, Riehle RA Jr. The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. J Urol 1991; 145:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/32\">",
"      Segura JW. Surgical management of urinary calculi. Semin Nephrol 1990; 10:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/33\">",
"      Pode D, Lenkovsky Z, Shapiro A, Pfau A. Can extracorporeal shock wave lithotripsy eradicate persistent urinary infection associated with infected stones? J Urol 1988; 140:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/34\">",
"      Cicerello E, Merlo F, Gambaro G, et al. Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J Urol 1994; 151:5.",
"     </a>",
"    </li>",
"    <li>",
"     Cicerello E, Merlo F, Maccatrozzo L, et al. Urolithiasis 2000, Rodgers AL, Hibbert BE, Hess B, et al (Eds), University of Cape Town, Cape Town, South Africa 2000. p.592.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/36\">",
"      Kang DE, Maloney MM, Haleblian GE, et al. Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy. J Urol 2007; 177:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40231/abstract/37\">",
"      Srivastava A, Singh KJ, Suri A, et al. Vascular complications after percutaneous nephrolithotomy: are there any predictive factors? Urology 2005; 66:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7368 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-F1D7113C53-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40231=[""].join("\n");
var outline_f39_18_40231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Limitations of the data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Medical therapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Open surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Percutaneous nephrolithotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Shock-wave lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Combination of PNL and SWL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adjunctive procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Post-procedure monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stone-free rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Residual stone fragments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Repeat procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute complications of surgical methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Long-term complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25577?source=related_link\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/10/27812?source=related_link\">",
"      Renal complications of extracorporeal shock wave lithotripsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_18_40232="Vestibular schwannoma (acoustic neuroma)";
var content_f39_18_40232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vestibular schwannoma (acoustic neuroma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     John K Park, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     Peter McLaren Black, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     David M Vernick, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     Naren Ramakrishna, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40232/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/18/40232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular schwannomas (also known as acoustic neuromas, acoustic schwannomas, acoustic neurinomas, or vestibular neurilemomas) are Schwann cell-derived tumors that commonly arise from the vestibular portion of the eighth cranial nerve (",
"    <a class=\"graphic graphic_figure graphicRef55465 \" href=\"mobipreview.htm?4/63/5110\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Vestibular schwannomas account for approximately 8 percent of intracranial tumors in adults and 80 to 90 percent of tumors of the cerebellopontine angle (CPA). In comparison, they are rare in children, except for patients with neurofibromatosis type 2 (NF2). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20712?source=see_link\">",
"     \"Neurofibromatosis type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical presentation, diagnosis, and management of patients with vestibular schwannomas will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of vestibular schwannomas is about one per 100,000 person-years. However, the incidence appears to be increasing, due at least in part to the incidental diagnosis of asymptomatic lesions with the widespread use of magnetic resonance imaging (MRI) and computed tomography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As an example, a retrospective analysis of 46,000 MRI scans done for other reasons identified eight unsuspected vestibular schwannomas (0.02 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/1\">",
"     1",
"    </a>",
"    ], and autopsy studies suggest that the prevalence may be even higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median age at diagnosis is approximately 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/2\">",
"     2",
"    </a>",
"    ]. The tumors are unilateral in more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/5\">",
"     5",
"    </a>",
"    ], affecting the right and left sides with equal frequency. Bilateral vestibular schwannomas are primarily limited to patients with neurofibromatosis type 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20712?source=see_link&amp;anchor=H7#H7\">",
"     \"Neurofibromatosis type 2\", section on 'Vestibular schwannomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953390426\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral vestibular schwannomas are one of the characteristic clinical features of neurofibromatosis type 2 (NF2). Studies in NF2 patients led to the identification of the neurofibromin 2 gene, which is located on chromosome 22. The NF2 gene produces merlin, also known as schwannomin, a cell membrane-related protein that acts as a tumor suppressor. Biallelic inactivation of the NF2 gene is found in most sporadic vestibular schwannomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20712?source=see_link\">",
"     \"Neurofibromatosis type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=see_link&amp;anchor=H537377066#H537377066\">",
"     \"Risk factors for brain tumors\", section on 'Neurofibromatosis type 2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to NF2, other risk factors that have been associated with the development of vestibular schwannomas in epidemiologic studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to loud noise, either in the workplace or from loud music, has been associated with an increased risk of vestibular schwannoma in two case-control studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]. A relationship to the duration of exposure was observed in one study, in which those with twenty or more years of occupational exposure had over a 10-fold increase in risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/8\">",
"       8",
"      </a>",
"      ]. Experimental studies of tissue injury and repair following acoustic trauma support the biological plausibility of this association [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Childhood exposure to low-dose radiation for benign conditions of the head and neck has been associated with an increased risk of vestibular schwannoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. In a series of 3112 children irradiated between 1939 and 1962, 41 vestibular schwannomas were identified with a latent period of 20 to 55 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/12\">",
"       12",
"      </a>",
"      ]. The increase in risk was proportional to the dose of radiation to the cerebellopontine angle (relative risk per Gy 1.14). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=see_link&amp;anchor=H8#H8\">",
"       \"Risk factors for brain tumors\", section on 'Radiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a history of parathyroid adenoma may have an increased risk for developing vestibular schwannomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/13\">",
"       13",
"      </a>",
"      ]. The reason for this association is unclear.",
"     </li>",
"     <li>",
"      Some but not all studies have shown an increased incidence of various brain tumors, including vestibular schwannomas, associated with the use of cellular telephones. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=see_link&amp;anchor=H11#H11\">",
"       \"Risk factors for brain tumors\", section on 'Cellular telephones and radiofrequency radiation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular schwannomas arise from perineural elements of the Schwann cell in the affected nerve and are similar pathologically to peripheral schwannomas found in other parts of the body. They occur with equal frequency on the superior and inferior branches of the vestibular nerve (",
"    <a class=\"graphic graphic_figure graphicRef55465 \" href=\"mobipreview.htm?4/63/5110\">",
"     figure 1",
"    </a>",
"    ); only rarely are they derived from the cochlear portion of the VIII nerve.",
"   </p>",
"   <p>",
"    Microscopically, zones of alternately dense and sparse cellularity, called Antoni A and B areas respectively, are characteristic of vestibular schwannomas (",
"    <a class=\"graphic graphic_picture graphicRef51843 \" href=\"mobipreview.htm?33/61/34776\">",
"     picture 1",
"    </a>",
"    ). Malignant degeneration is extremely rare with only six cases having been reported. Immunohistochemical staining for S100 protein is usually positive in both the benign and the rare malignant forms of this tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with vestibular schwannoma can be due to cranial nerve involvement, cerebellar compression, or tumor progression.",
"   </p>",
"   <p>",
"    The clinical presentations of these tumors are illustrated by a series of 1000 vestibular schwannomas treated at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinical manifestations in this series included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cochlear nerve &mdash; Symptomatic cochlear nerve involvement occurred in 95 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/15\">",
"       15",
"      </a>",
"      ]. The two major symptoms were hearing loss and tinnitus. Hearing loss was present in 95 percent but only two-thirds of these patients were aware of this limitation. The hearing loss was usually chronic, with an average duration of about four years. Occasionally, vestibular schwannomas can present with sudden sensorineural hearing loss. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=see_link\">",
"       \"Sudden sensorineural hearing loss\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Tinnitus was present in 63 percent with an average duration of three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/15\">",
"       15",
"      </a>",
"      ]. The incidence of tinnitus was higher in hearing than in deaf patients but was also present in 46 percent of deaf patients.",
"     </li>",
"     <li>",
"      Vestibular nerve &mdash; Involvement of the vestibular nerve occurred in 61 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/15\">",
"       15",
"      </a>",
"      ]. Affected patients frequently acknowledged having unsteadiness while walking, which was typically mild to moderate in nature and frequently fluctuated in severity. True spinning vertigo was uncommon because these slow growing tumors cause gradual rather than acute asymmetries in vestibular function. In this setting, the central vestibular system can often compensate for the gradual loss of input from one side.",
"      <br/>",
"      <br/>",
"      The most nondescript vertiginous sensations, such as brief tilting or veering, can suggest the presence of a vestibular schwannoma. The decision whether to obtain an MRI for a patient with these symptoms depends upon clinical judgment, with no good data in the literature about the likelihood that someone with such symptoms harbors a schwannoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"       \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trigeminal nerve &mdash; Trigeminal nerve disturbances occurred in 17 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/15\">",
"       15",
"      </a>",
"      ]. The most common symptoms were facial numbness (paresthesia), hypesthesia, and pain. The average duration of symptoms was 1.3 years; the symptoms usually occurred after hearing loss had been present for more than two years and vestibular symptoms for more than one year. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=see_link\">",
"       \"Trigeminal neuralgia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Facial nerve &mdash; The facial nerve was involved in 6 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/15\">",
"       15",
"      </a>",
"      ]. The primary symptoms were facial paresis and, less often, taste disturbances.",
"     </li>",
"     <li>",
"      Tumor progression &mdash; Other presenting signs can be the result of tumor progression, leading to pressure on adjacent posterior fossa structures. Very large tumors can press on the cerebellum or brainstem and result in ataxia. Brainstem compression, cerebellar tonsil herniation, hydrocephalus and death can occur in untreated cases. The functions of the lower cranial nerves can also become impaired, leading to dysarthria, dysphagia, aspiration, and hoarseness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vestibular schwannoma is generally suggested by the presence of asymmetric sensorineural hearing loss (which should be confirmed by audiometry) or other cranial nerve deficits. Such symptoms may lead to imaging with MRI or CT. Vestibular schwannomas account for 80 to 90 percent of posterior fossa lesions that are identified in this way.",
"   </p>",
"   <p>",
"    The differential diagnosis includes meningioma, which accounts for 4 to 10 percent of cases. Other less common causes of such lesions include facial nerve schwannomas, gliomas, cholesterol cysts, cholesteatomas, hemangiomas, aneurysms, arachnoid cysts, lipomas, and metastatic tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing tests are typically abnormal due to involvement of the acoustic nerve. The Weber and Rinne tests may be useful in suggesting asymmetric sensorineural hearing impairment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of hearing loss in adults\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further neurologic examination may reveal other cranial nerve deficits. A decreased or absent ipsilateral corneal reflex and facial twitching or hypesthesia may occur as cranial nerves V and VII become affected. Other cranial nerve deficits are uncommon unless the tumor is large. Romberg, Hall-Pike, and other common office balance tests are typically normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Audiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Audiometry is the best initial screening laboratory test for the diagnosis of vestibular schwannoma, since only 5 percent of patients will have a normal test. Pure tone and speech audiometry should be performed in an acoustically shielded area. Test results typically show an asymmetric sensorineural hearing loss, usually more prominent in the higher frequencies. Hearing loss does not necessarily correlate with tumor size. The speech discrimination score is usually markedly reduced in the affected ear and out of proportion to the measured hearing loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of hearing loss in adults\", section on 'Formal audiologic assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many other auditory tests have been used historically to try to diagnose vestibular schwannomas. These include acoustic reflex testing, impedance audiometry, and Bekesy audiometry. They have limited accuracy and diagnostic value, and their utility has diminished with the advent of brainstem-evoked response audiometry",
"    <span class=\"nowrap\">",
"     (AER/ABR).",
"    </span>",
"   </p>",
"   <p>",
"    Brainstem-evoked response audiometry can be used as a further screening measure in patients with unexplained asymmetries in standard audiometric testing. Test results show a delay in nerve conduction time on the affected side, reflecting the probable presence of a tumor. Prior to magnetic resonance imaging (MRI), ABR was the most accurate screening modality. In centers experienced with its use, the test shows abnormalities in 90 to 95 percent of patients with tumors. However, the false negative rate can be as high as 30 percent with small vestibular schwannomas, and there is a 10 percent false positive rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vestibular testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular testing has limited utility as a screening test for the diagnosis of vestibular schwannoma because of the accuracy of evoked response audiometry. When testing is performed, a decreased or absent caloric response on the affected side may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure of choice is magnetic resonance imaging (MRI), which can detect tumors as small as 1 to 2 mm in diameter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86508 \" href=\"mobipreview.htm?28/29/29142\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/17\">",
"     17",
"    </a>",
"    ]. When brainstem testing is abnormal or the suspicion for a vestibular schwannoma is high for another reason, MRI scanning with gadolinium contrast should be performed, including millimeter sections through the internal auditory meatus. If a patient cannot tolerate MRI, high resolution CT scanning with and without contrast is an alternative.",
"   </p>",
"   <p>",
"    Vestibular schwannomas are seen on MRI and CT scans as enhancing lesions in the region of the internal auditory canal with variable extension into the cerebellopontine angle. CT scans with bone windows can also be of prognostic significance as the extent of widening of the IAC and the extent of tumor growth anterior and caudal to the IAC are predictive of postoperative hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fast spin echo MRI may be useful as a screening test due to its low cost compared to gadolinium MRI, noninvasiveness, and high sensitivity and specificity. In one study of 25 patients and 50 ears, there were 11 true positives and 39 true negatives on gadolinium MRI. There were no false positives or false negatives with fast spin echo MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/19\">",
"     19",
"    </a>",
"    ]. This test is useful when performed specifically for evaluation for a vestibular schwannoma, not as a general screen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major treatment options for patients with a vestibular schwannoma are surgery, radiation therapy, and observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery generally results in satisfactory long term control of vestibular schwannomas; however, one group has reported a 10 year recurrence rate for partially resected schwannomas of 20 percent and a similar rate for incompletely resected tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953390685\">",
"    <span class=\"h3\">",
"     Surgical techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three standard operative approaches. Selection of a particular approach is determined by a number of factors, including the size of the tumor and whether or not preservation of hearing is a consideration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retromastoid suboccipital (retrosigmoid) - The suboccipital approach can be used for any size tumor with or without attempted hearing preservation.",
"     </li>",
"     <li>",
"      Translabyrinthine - The translabyrinthine approach has been recommended for acoustic tumors larger than 3 cm and for smaller tumors when hearing preservation is not an issue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Middle fossa - The middle fossa approach is suitable for small (&lt;1.5 cm) tumors when hearing preservation is a goal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many institutions, a team consisting of a neurosurgeon and an otologist perform the procedure. The experience of both the surgeon and the hospital are important in optimizing the surgical outcome and minimizing the risk of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953390863\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete tumor removal is feasible in almost all patients and there are few if any recurrences when tumor removal is complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. However, the outcome is less favorable in patients who undergo subtotal removal in an attempt to preserve anatomical continuity of the facial or acoustic nerves. Regrowth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrence, which is usually asymptomatic, occurs in up to 15 percent of cases when initial resection is incomplete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of surgical morbidity, which includes hearing loss, facial weakness, and vestibular disturbances, depends upon tumor size. Facial nerve function can be preserved in most patients even with large tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/26,29,30\">",
"     26,29,30",
"    </a>",
"    ], and serviceable hearing can be preserved in many patients. However, only rarely does hearing improve after vestibular schwannoma surgery. Intraoperative facial nerve and auditory monitoring have alerted surgeons to potential injury, thereby improving the final outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes that are achievable with an experienced team can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 179 patients, 97 to 99 percent of patients had complete tumor removal without evidence of recurrence at a mean follow up duration of 70 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/23\">",
"       23",
"      </a>",
"      ]. Normal or near normal facial movement was present in 94 to 97 percent of patients with small tumors and 28 to 57 percent with large tumors; in addition, 45 to 82 percent of patients with good hearing and small tumors retained their hearing. Treatment complications consisted mainly of cerebrospinal fluid leakage which occurred in 15 percent of patients; there were two deaths (1 percent).",
"     </li>",
"     <li>",
"      Similar results were noted in another report of 1000 patients who were treated at a single institution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/24\">",
"       24",
"      </a>",
"      ]. Ninety-eight percent of tumors were completely removed; in the other 21 patients, deliberate partial removal was performed in severely ill patients for decompression of the brainstem or in an attempt to preserve hearing in the last hearing ear. Anatomic preservation of the facial nerve and the cochlear nerve was achieved in 93 and 68 percent, respectively. Major neurologic complications included tetraparesis in one patient, hemiparesis in 1 percent, lower cranial nerve palsies in 5.5 percent, and cerebrospinal fluid fistulas in 9.2 percent. There were 11 deaths (1.1 percent) occurring at 2 to 69 days postoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent headaches are another significant complication following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a quality of life analysis of 1657 patients treated surgically, 46 percent reported headaches occurring more than once a day, and these were often severe enough to cause disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/31\">",
"     31",
"    </a>",
"    ]. The headaches eventually resolved in about one-half. Postoperative headaches were more commonly associated with the retrosigmoid surgical approach, and tended to be more frequent and severe in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953390905\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of complications in addition to damage to cranial nerves VII and VIII are associated with microsurgery. These were analyzed in a literature review that included over 32,000 patients who underwent surgical resection of a vestibular schwannoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall mortality rate was 0.2 percent.",
"     </li>",
"     <li>",
"      Cerebrospinal fluid leaks were observed in 8.5 percent, of which one-third resolved with conservative treatment. This complication was significantly more frequent in patients who underwent a translabyrinthine approach, although at least one report has suggested that technical modifications can decrease this complication with this approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/25\">",
"       25",
"      </a>",
"      ]. The frequency of cerebrospinal fluid leaks was not related to tumor size.",
"     </li>",
"     <li>",
"      Non-audiofacial neurologic complications were seen in 9 percent of cases.",
"     </li>",
"     <li>",
"      Vascular complications, primarily hemorrhage, were observed in 1 percent of cases.",
"     </li>",
"     <li>",
"      Infections were reported in 4 percent of cases, most of which were meningitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy approaches that have been used in patients with vestibular schwannoma include stereotactic radiosurgery, stereotactic radiotherapy, and proton beam therapy, as well as conventional fractionated radiation therapy.",
"   </p>",
"   <p>",
"    There are no randomized trials comparing different radiation therapy approaches, and data are only available from observational studies. A critical review of the literature concluded that equivalent local control can be achieved with each of these approaches and that treatment decisions could be based upon the availability of expertise and technology, as well as patient specific factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiosurgery (SRS) is a technique that utilizes multiple convergent beams to deliver a high single dose of radiation to a radiographically discrete treatment volume, thereby minimizing injury to adjacent structures. This can be accomplished with either the gamma knife or a linear accelerator. Radiosurgery is a viable treatment option for selected patients with smaller tumors (&lt;3 cm) or for enlarging tumors in patients who are not candidates for surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the largest experiences with SRS comes from 829 patients with vestibular schwannoma treated at the University of Pittsburgh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/35\">",
"     35",
"    </a>",
"    ]. The overall tumor control rate was 97 percent at ten years. No radiation-related second neoplasms were observed in this series, although others have reported such cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the original report of 162 patients from the University of Pittsburgh, normal facial and trigeminal nerve function was preserved at five years in 79 and 73 percent of patients, respectively, using radiation doses of 18 to 20 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/38\">",
"     38",
"    </a>",
"    ]. By comparison, with the decreased radiation doses (13 Gy) used in the more recent extended series, the risk of new facial weakness was less than one percent, the risk of trigeminal sensory loss was three percent, and the percentage of patients with preservation of hearing increased from 50 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/35,39\">",
"     35,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a concern that scarring following SRS may complicate subsequent microsurgery should the tumor recur. In a series of 20 cases in which surgical salvage was performed following recurrence after radiosurgery, approximately one-half were determined to have greater difficulty for resection or facial nerve preservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vestibular schwannomas in patients with neurofibromatosis type 2 (NF2) present a particular challenge because lesions are frequently bilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/41\">",
"     41",
"    </a>",
"    ]. Although these patients have a higher risk of hearing loss that those without NF2, SRS represents an important alternative to conventional surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of further decrease in auditory acuity secondary to SRS and the role of radiation dose and toxicity is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of cranial stereotactic radiosurgery\", section on 'Vestibular schwannoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Stereotactic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractionated stereotactic radiotherapy (SRT), utilizes focused doses of radiation given over a series of treatment sessions. The intent is to reduce radiation injury to critical neural structures while preserving tumor control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple series have demonstrated the general safety and efficacy of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/34,44-48\">",
"     34,44-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study, 200 patients with 202 vestibular schwannomas were treated with SRT (n=172) or SRS (n=30) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/44\">",
"       44",
"      </a>",
"      ]. For patients treated with SRT, the median dose was 57.6 Gy, given in 1.8 Gy fractions. At a median follow-up of 75 months, the 5 and 10-year local control rates were both 96 percent and there was no significant difference between the two treatment techniques. In patients with serviceable hearing prior to SRT, the hearing preservation rate was 78 percent at five years.",
"     </li>",
"     <li>",
"      In another single institution series using a different schedule, 496 patients were treated at a single institution between 1995 and 2007 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/48\">",
"       48",
"      </a>",
"      ]. A dose of 25 Gy in five fractions or 30 Gy in 10 fractions was used (89 and 11 percent of cases, respectively). Analysis of the 385 patients with imaging follow-up at least 18 months after diagnosis found a therapeutic failure rate of 3 percent, as defined by progressive tumor growth requiring surgical intervention. However, 30 percent of these patients experienced some tumor growth, and 9 percent had a long-term twofold or greater increase in tumor volume after treatment. Patients with a small tumor (volume less than 1 cm",
"      <sup>",
"       3",
"      </sup>",
"      ) were more likely to experience tumor growth than those with larger tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Proton beam therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proton beam therapy may provide maximal local tumor control while minimizing cranial nerve injuries. The physical characteristics of the beam result in the majority of the energy being deposited at the end of a linear track (the Bragg peak), with the dose falling rapidly to zero beyond the Bragg peak. Thus, the use of proton beam therapy permits the delivery of high doses of RT to the target volume while limiting the \"scatter\" dose received by surrounding tissues.",
"   </p>",
"   <p>",
"    In one report of 88 patients who were treated with fractionated proton beam therapy, the two- and five-year local control rates were 95 and 94 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/49\">",
"     49",
"    </a>",
"    ]. Salvage therapy was necessary in five (radiosurgery in one, craniotomy in one, and shunting for hydrocephalus in three). Seven of 21 patients with functional hearing retained serviceable hearing ability, while facial and trigeminal nerve function was preserved in 91 and 89 percent of patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since vestibular schwannomas are typically slow growing, observation with follow-up MRI scans every 6 to 12 months may be warranted in carefully selected patients.",
"   </p>",
"   <p>",
"    The growth rate of untreated tumors during observation was illustrated by a single institution series of 386 patients who were initially managed with observation between 1990 and 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients were reimaged at one year and subsequently followed based upon rate of growth. Indications for conservative management varied but included age &gt;60 years, significant comorbidity, small tumor size, lack of symptoms, risk of further hearing loss, or patient preference. Overall, 59 percent of patients had an annual tumor growth rate &lt;1",
"    <span class=\"nowrap\">",
"     mm/year,",
"    </span>",
"    although 39 patients (12 percent) had tumor growth &ge;3 mm at one year.",
"   </p>",
"   <p>",
"    A review of the literature identified 21 studies that included 1345 patients who were managed conservatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/51\">",
"     51",
"    </a>",
"    ]. With an average follow-up of 3.2 years, 43 percent of tumors showed evidence of growth, 51 percent remained stable, while 6 percent had evidence or regression without treatment. Hearing loss occurred in one-half of the 347 individuals in whom it was assessed longitudinally. In 15 of the studies, 20 percent of 1001 individuals eventually required treatment with either surgery or radiation, due to either tumor growth on imaging or symptom progression.",
"   </p>",
"   <p>",
"    Observation may be particularly appropriate in elderly patients who are poor candidates for immediate intervention. However, if there are signs or symptoms of tumor progression, age should not be considered a contraindication to surgery or an indicator of adverse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one series of 61 elderly patients, for example, complete removal was achieved in all but two, there was no mortality, and the facial nerve and hearing were preserved in 95 and 41 percent, respectively.",
"   </p>",
"   <p>",
"    Observation is associated with a risk of progressive hearing loss. If hearing preservation is an important consideration, early treatment should be encouraged.",
"   </p>",
"   <p>",
"    Studies on the natural history of small vestibular schwannomas have helped to define the risk factors for further hearing loss. A review of the literature identified 34 studies that included 982 patients with vestibular schwannomas &lt;25 mm in diameter, who had functional hearing and were managed with observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/54\">",
"     54",
"    </a>",
"    ]. Those patients with a tumor growth rate &le;2.5",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    had a significantly higher rate of hearing preservation compared with those with a higher tumor growth rate (75 versus 32 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single-institution prospective study identified 59 patients over a 22 year period who had vestibular schwannomas with serviceable hearing and were managed with serial observation from presentation until hearing loss developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40232/abstract/55\">",
"     55",
"    </a>",
"    ]. None of these patients underwent either surgery or radiation therapy during the period of observation. For patients whose tumors exhibited rapid growth (ie, &gt;2.5",
"    <span class=\"nowrap\">",
"     mm/year)",
"    </span>",
"    at any time during the observation period, the median time to hearing loss was seven years, and all of these patients had lost hearing in less than 10 years. Hearing loss generally developed within one to two years of the onset of rapid tumor growth. In contrast, the median time to hearing loss was 15 years in those with tumors that never exhibited rapid growth.",
"   </p>",
"   <p>",
"    For patients with vestibular schwannomas in whom preservation of residual functional hearing on the involved side is important, these data suggest that careful serial imaging is needed, and therapeutic intervention is indicated if there is evidence of rapid tumor growth (ie, &gt;2.5",
"    <span class=\"nowrap\">",
"     mm/year),",
"    </span>",
"    regardless of tumor size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach for follow-up studies after diagnosis and treatment is uncertain, and there are no data to support specific recommendations. Because of the potentially slow growth of these tumors, prolonged follow-up is necessary. The following represents an empiric approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients being managed with observation, yearly scans for 10 years, with scans subsequently every three to five years if there has been no growth. Audiometry should also be performed on a regular basis, if preservation of hearing is an important consideration.",
"     </li>",
"     <li>",
"      For patients who underwent surgery, yearly scans for 8 to 10 years, and less frequently thereafter if no residual tumor is present.",
"     </li>",
"     <li>",
"      For patients treated with RT, yearly scans for 10 years and then every two years if no growth seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/20/44353?source=see_link\">",
"       \"Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vestibular schwannomas (acoustic neuromas) account for 80 to 90 percent of cerebellopontine angle tumors (CPAs) in adults. The most common clinical manifestations of vestibular schwannomas are unilateral sensorineural hearing loss, often in association with tinnitus. Symptoms may also be due to involvement of other cranial nerves. Diagnosis of a CPA tumor is based upon MRI or CT imaging. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with large tumors, young age,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant hearing impairment, we suggest early rather than delayed therapeutic intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Both surgery and various radiation therapy techniques represent acceptable options for patients undergoing treatment. The choice of therapy should be based upon the availability of teams with appropriate expertise in treating vestibular schwannomas, as well as patient-specific factors. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For older patients with small tumors and limited hearing loss, we suggest observation with serial imaging and audiometry (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, such patients should be monitored at least annually for evidence of tumor progression. Rapid tumor growth (&gt;2.5",
"      <span class=\"nowrap\">",
"       mm/year),",
"      </span>",
"      rather than the absolute size of the tumor, may serve as a useful indicator for therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Observation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Posttreatment follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/1\">",
"      Lin D, Hegarty JL, Fischbein NJ, Jackler RK. The prevalence of \"incidental\" acoustic neuroma. Arch Otolaryngol Head Neck Surg 2005; 131:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/2\">",
"      Propp JM, McCarthy BJ, Davis FG, Preston-Martin S. Descriptive epidemiology of vestibular schwannomas. Neuro Oncol 2006; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/3\">",
"      Tos M, Stangerup SE, Cay&eacute;-Thomasen P, et al. What is the real incidence of vestibular schwannoma? Arch Otolaryngol Head Neck Surg 2004; 130:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/4\">",
"      Eldridge R, Parry D. Vestibular schwannoma (acoustic neuroma). Consensus development conference. Neurosurgery 1992; 30:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/5\">",
"      Edwards CG, Schwartzbaum JA, L&ouml;nn S, et al. Exposure to loud noise and risk of acoustic neuroma. Am J Epidemiol 2006; 163:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/6\">",
"      Sughrue ME, Yeung AH, Rutkowski MJ, et al. Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. J Neurosurg 2011; 114:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/7\">",
"      Preston-Martin S, Thomas DC, Wright WE, Henderson BE. Noise trauma in the aetiology of acoustic neuromas in men in Los Angeles County, 1978-1985. Br J Cancer 1989; 59:783.",
"     </a>",
"    </li>",
"    <li>",
"     Preston-Martin S, Mack WJ. Neoplasms of the nervous system. In: Cancer Epidemiology and Prevention, 2nd, Shottenfeld D, Fraumeni JF (Eds), Oxford University Press, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/9\">",
"      Ryals BM, Rubel EW. Hair cell regeneration after acoustic trauma in adult Coturnix quail. Science 1988; 240:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/10\">",
"      Hamernik RP, Turrentine G, Roberto M, et al. Anatomical correlates of impulse noise-induced mechanical damage in the cochlea. Hear Res 1984; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/11\">",
"      Schneider AB, Ron E, Lubin J, et al. Acoustic neuromas following childhood radiation treatment for benign conditions of the head and neck. Neuro Oncol 2008; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/12\">",
"      Shore-Freedman E, Abrahams C, Recant W, Schneider AB. Neurilemomas and salivary gland tumors of the head and neck following childhood irradiation. Cancer 1983; 51:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/13\">",
"      B&auml;cklund LM, Grand&eacute;r D, Brandt L, et al. Parathyroid adenoma and primary CNS tumors. Int J Cancer 2005; 113:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/14\">",
"      Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/15\">",
"      Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery 1997; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/16\">",
"      Doyle KJ. Is there still a role for auditory brainstem response audiometry in the diagnosis of acoustic neuroma? Arch Otolaryngol Head Neck Surg 1999; 125:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/17\">",
"      Wilson DF, Hodgson RS, Gustafson MF, et al. The sensitivity of auditory brainstem response testing in small acoustic neuromas. Laryngoscope 1992; 102:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/18\">",
"      Matthies C, Samii M, Krebs S. Management of vestibular schwannomas (acoustic neuromas): radiological features in 202 cases--their value for diagnosis and their predictive importance. Neurosurgery 1997; 40:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/19\">",
"      Marx SV, Langman AW, Crane RC. Accuracy of fast spin echo magnetic resonance imaging in the diagnosis of vestibular schwannoma. Am J Otolaryngol 1999; 20:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/20\">",
"      Sughrue ME, Kaur R, Rutkowski MJ, et al. Extent of resection and the long-term durability of vestibular schwannoma surgery. J Neurosurg 2011; 114:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/21\">",
"      Lanman TH, Brackmann DE, Hitselberger WE, Subin B. Report of 190 consecutive cases of large acoustic tumors (vestibular schwannoma) removed via the translabyrinthine approach. J Neurosurg 1999; 90:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/22\">",
"      Barker FG 2nd, Carter BS, Ojemann RG, et al. Surgical excision of acoustic neuroma: patient outcome and provider caseload. Laryngoscope 2003; 113:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/23\">",
"      Gormley WB, Sekhar LN, Wright DC, et al. Acoustic neuromas: results of current surgical management. Neurosurgery 1997; 41:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/24\">",
"      Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them. Neurosurgery 1997; 40:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/25\">",
"      Falcioni M, Mulder JJ, Taibah A, et al. No cerebrospinal fluid leaks in translabyrinthine vestibular schwannoma removal: reappraisal of 200 consecutive patients. Am J Otol 1999; 20:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/26\">",
"      Darrouzet V, Martel J, En&eacute;e V, et al. Vestibular schwannoma surgery outcomes: our multidisciplinary experience in 400 cases over 17 years. Laryngoscope 2004; 114:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/27\">",
"      Ohta S, Yokoyama T, Nishizawa S, Uemura K. Regrowth of the residual tumour after acoustic neurinoma surgery. Br J Neurosurg 1998; 12:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/28\">",
"      Cerullo L, Grutsch J, Osterdock R. Recurrence of vestibular (acoustic) schwannomas in surgical patients where preservation of facial and cochlear nerve is the priority. Br J Neurosurg 1998; 12:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/29\">",
"      Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): the facial nerve--preservation and restitution of function. Neurosurgery 1997; 40:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/30\">",
"      Anderson DE, Leonetti J, Wind JJ, et al. Resection of large vestibular schwannomas: facial nerve preservation in the context of surgical approach and patient-assessed outcome. J Neurosurg 2005; 102:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/31\">",
"      Ryzenman JM, Pensak ML, Tew JM Jr. Headache: a quality of life analysis in a cohort of 1,657 patients undergoing acoustic neuroma surgery, results from the acoustic neuroma association. Laryngoscope 2005; 115:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/32\">",
"      Schankin CJ, Gall C, Straube A. Headache syndromes after acoustic neuroma surgery and their implications for quality of life. Cephalalgia 2009; 29:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/33\">",
"      Sughrue ME, Yang I, Aranda D, et al. Beyond audiofacial morbidity after vestibular schwannoma surgery. J Neurosurg 2011; 114:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/34\">",
"      Murphy ES, Suh JH. Radiotherapy for vestibular schwannomas: a critical review. Int J Radiat Oncol Biol Phys 2011; 79:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/35\">",
"      Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 2005; 102 Suppl:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/36\">",
"      Link MJ, Cohen PL, Breneman JC, Tew JM Jr. Malignant squamous degeneration of a cerebellopontine angle epidermoid tumor. Case report. J Neurosurg 2002; 97:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/37\">",
"      Shin M, Ueki K, Kurita H, Kirino T. Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet 2002; 360:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/38\">",
"      Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med 1998; 339:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/39\">",
"      Chopra R, Kondziolka D, Niranjan A, et al. Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 2007; 68:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/40\">",
"      Roche PH, R&eacute;gis J, Dev&egrave;ze A, et al. [Surgical removal of unilateral vestibular schwannomas after failed Gamma Knife radiosurgery]. Neurochirurgie 2004; 50:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/41\">",
"      Subach BR, Kondziolka D, Lunsford LD, et al. Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2. J Neurosurg 1999; 90:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/42\">",
"      Ito K, Shin M, Matsuzaki M, et al. Risk factors for neurological complications after acoustic neurinoma radiosurgery: refinement from further experiences. Int J Radiat Oncol Biol Phys 2000; 48:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/43\">",
"      Phi JH, Kim DG, Chung HT, et al. Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer 2009; 115:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/44\">",
"      Combs SE, Welzel T, Schulz-Ertner D, et al. Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas. Int J Radiat Oncol Biol Phys 2010; 76:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/45\">",
"      Williams JA. Fractionated stereotactic radiotherapy for acoustic neuromas. Int J Radiat Oncol Biol Phys 2002; 54:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/46\">",
"      Koh ES, Millar BA, M&eacute;nard C, et al. Fractionated stereotactic radiotherapy for acoustic neuroma: single-institution experience at The Princess Margaret Hospital. Cancer 2007; 109:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/47\">",
"      Andrews DW, Suarez O, Goldman HW, et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution. Int J Radiat Oncol Biol Phys 2001; 50:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/48\">",
"      Kapoor S, Batra S, Carson K, et al. Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience. Int J Radiat Oncol Biol Phys 2011; 81:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/49\">",
"      Weber DC, Chan AW, Bussiere MR, et al. Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. Neurosurgery 2003; 53:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/50\">",
"      Bakkouri WE, Kania RE, Guichard JP, et al. Conservative management of 386 cases of unilateral vestibular schwannoma: tumor growth and consequences for treatment. J Neurosurg 2009; 110:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/51\">",
"      Smouha EE, Yoo M, Mohr K, Davis RP. Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. Laryngoscope 2005; 115:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/52\">",
"      Pulec JL. Acoustic neuroma surgery in geriatric patients. Ear Nose Throat J 1999; 78:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/53\">",
"      Samii M, Tatagiba M, Matthies C. Acoustic neurinoma in the elderly: factors predictive of postoperative outcome. Neurosurgery 1992; 31:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/54\">",
"      Sughrue ME, Yang I, Aranda D, et al. The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg 2010; 112:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40232/abstract/55\">",
"      Sughrue ME, Kane AJ, Kaur R, et al. A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg 2011; 114:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5222 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40232=[""].join("\n");
var outline_f39_18_40232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H953390426\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Audiometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vestibular testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H953390685\">",
"      - Surgical techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H953390863\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H953390905\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Stereotactic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Proton beam therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5222\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5222|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/29/29142\" title=\"diagnostic image 1\">",
"      MRI vestibular Schwannoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5222|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/63/5110\" title=\"figure 1\">",
"      Anatomy VIII cranial nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5222|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/61/34776\" title=\"picture 1\">",
"      Acoustic neuroma Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=related_link\">",
"      Complications of cranial stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20712?source=related_link\">",
"      Neurofibromatosis type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/20/44353?source=related_link\">",
"      Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=related_link\">",
"      Sudden sensorineural hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_18_40233="Management of toxic plant ingestions in children";
var content_f39_18_40233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of toxic plant ingestions in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40233/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40233/contributors\">",
"     Brian Bates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40233/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40233/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/18/40233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H38616816\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children are frequently exposed to potentially toxic plants, both in the home and outdoors. While these exposures rarely result in clinically significant poisoning, it is important for healthcare providers to be aware of the limited number of plants that have the potential to cause serious clinical effects. Most young children are asymptomatic or have minimal gastrointestinal toxicity after exploratory plant ingestions (eg, picking berries off a bush). Serious poisoning is associated with large ingestions of highly toxic plant species (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ), which typically occurs in the setting of suicidal ingestion, foraging mistakes, or intentional recreational use.",
"   </p>",
"   <p>",
"    Defining which clinical findings predominate, initiating general supportive care, and administering any specific treatments are the key steps in the initial management for toxic plant ingestions. The management of toxic plant ingestions in children will be reviewed here. Evaluation and clinical manifestations of potentially toxic plant ingestions or poisonous mushrooms, the management of toxic mushroom poisoning, and contact dermatitis caused by poison ivy are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link\">",
"       \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link\">",
"       \"Clinical manifestations and evaluation of mushroom poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42615?source=see_link\">",
"       \"Management of mushroom poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link\">",
"       \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/44/20168?source=see_link\">",
"       \"Poison ivy (Toxicodendron) dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3216162\">",
"    <span class=\"h1\">",
"     APPROACH AND DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient management and disposition after ingestion of a potentially toxic plant depends upon the plant ingested, the amount ingested, and the clinical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic children with small ingestions of confirmed nontoxic or minimally toxic plant species (",
"      <a class=\"graphic graphic_table graphicRef52103 \" href=\"mobipreview.htm?30/14/30957\">",
"       table 2",
"      </a>",
"      ) do not require any treatment unless significant symptoms develop. (See",
"      <a class=\"local\" href=\"#H38616864\">",
"       'Mucosal irritation'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H38616840\">",
"       'Gastroenteritis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Asymptomatic children with ingestions of unknown or potentially highly toxic plants (",
"      <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"       table 1",
"      </a>",
"      ), particularly consumption of large amounts, should receive medical evaluation, gastrointestinal decontamination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      if accomplished within one hour, and observation for four to six hours. In most instances, the child will remain asymptomatic and be discharged home. (See",
"      <a class=\"local\" href=\"#H38616906\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      below.).",
"     </li>",
"     <li>",
"      Symptomatic patients with ingestions of highly toxic plants (",
"      <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"       table 1",
"      </a>",
"      ) should receive timely supportive care, gastrointestinal decontamination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      if accomplished within one hour of ingestion, and for plant ingestion other than those that cause mucosal irritation (eg, philodendron, dieffenbachia [dumbcane]), antidotal therapy if necessary, and hospital admission. In addition to medical management, patients who ingest highly toxic plants with suicidal intent or for recreational purposes warrant evaluation for mental illness or drug abuse. (See",
"      <a class=\"local\" href=\"#H38616832\">",
"       'Supportive care'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H38616906\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H38616914\">",
"       'Antidotes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616832\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for children with toxic plant ingestion are primarily derived from case series and reports and are based upon physical findings. Many exploratory plant ingestions in young children ultimately involve consumption of nontoxic species that require",
"    <strong>",
"     no therapy",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_table graphicRef52103 \" href=\"mobipreview.htm?30/14/30957\">",
"     table 2",
"    </a>",
"    ). Gastrointestinal irritation is the most common clinical effect associated with toxic plant ingestion in children and is typically self-limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H6473972#H6473972\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Nontoxic'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H7184699#H7184699\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Minor gastrointestinal irritation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical findings and identification of the ingested plant are helpful in determining specific management. A regional poison control center should be contacted to assist with likely plant species ingested based upon clinical findings, identification of any available plant material, and treatment of specific toxic effects. Most poison control centers maintain active call lists of botanists who are knowledgeable concerning local prevalence of plant species and can assist in identification. To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients who have ingested highly toxic plants (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ) or who present with signs of serious toxicity, the clinician should rapidly perform an initial assessment of clinical findings and support airway, breathing, and circulation as needed. Antidotes are often necessary in symptomatic children who have ingested plants that cause anticholinergic, cardiac glycoside, or cyanide poisoning. (See",
"    <a class=\"local\" href=\"#H38616914\">",
"     'Antidotes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616864\">",
"    <span class=\"h2\">",
"     Mucosal irritation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who chew plants of the Araceae family (eg, philodendron, dieffenbachia [dumbcane]) and other plants that contain calcium oxalate raphides (intracellular sharp projections) may develop mucosal irritation and swelling. However, most young children are asymptomatic or have only mild irritation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H6474230#H6474230\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Mucosal irritation and swelling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For symptomatic patients, treatment consists of [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Washing the skin around the mouth with soap and water",
"     </li>",
"     <li>",
"      Treatment of pain (eg, mild pain: oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum single dose 800 mg every six hours; moderate pain: oral hydrocodone and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      [0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of hydrocodone], maximum single dose 5 mg; severe pain IV",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum single dose 10 mg)",
"     </li>",
"     <li>",
"      Oral administration of cold milk, ice cream, popsicles, or ice to patients who can swallow",
"     </li>",
"     <li>",
"      Administration of glucocorticoids (eg, IV",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      0.25 to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose 10 mg) to patients with drooling or significant lip, tongue, or oral swelling &nbsp;",
"     </li>",
"     <li>",
"      Endotracheal intubation in patients with severe upper airway obstruction (eg, stridor, aphonia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sniffing position) (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"mobipreview.htm?17/26/17837\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64481 \" href=\"mobipreview.htm?41/54/42860\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/3\">",
"       3",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616840\">",
"    <span class=\"h2\">",
"     Gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vomiting and diarrhea may be caused by ingestion of any of the toxic plants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Vomiting may be safely treated with antiemetics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously, maximum single dose 4 mg) without increasing the amount of absorbed toxin. Antispasmodic agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/31/8692?source=see_link\">",
"     loperamide",
"    </a>",
"    ) should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with diarrhea. Intravenous fluids should be given based upon the clinical assessment of losses and evidence of volume depletion. Patients with signs of shock should receive prompt fluid resuscitation (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"mobipreview.htm?41/12/42178\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616877\">",
"    <span class=\"h2\">",
"     Cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, a variety of bradyarrhythmias and tachyarrhythmias can occur after ingestions of a number of toxic plants (eg, oleander, death camus, azalea, monkshood, yew, false hellebore) (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H13413116#H13413116\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Cardiac arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3925410\">",
"    <span class=\"h3\">",
"     Bradyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradyarrhythmias caused by plants that contain cardiac glycosides warrant treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific Fab (see",
"    <a class=\"local\" href=\"#H38616938\">",
"     'Cardiac glycoside poisoning'",
"    </a>",
"    below). Children with clinically significant bradyarrhythmias (eg, complete atrioventricular block) following ingestion of other plant species should first be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. If bradycardia with hypotension persists, then the patients should receive epinephrine or cardiac pacing (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon calcium channel blocking activity in an animal model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/8\">",
"     8",
"    </a>",
"    ], some medical toxicologists have proposed calcium infusion as a potential treatment for bradyarrhythmias after human yew poisoning that are refractory to the above measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3925800\">",
"    <span class=\"h3\">",
"     Tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia or fibrillation and torsades de pointes are features of monkshood (aconitine), false hellebore, and yew toxicity (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ). Ventricular arrhythmias may be initially treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    (stable patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/9\">",
"     9",
"    </a>",
"    ]. Cardioversion (unstable patients) or defibrillation (pulseless patients) may also be performed according to Pediatric Advanced Life Support guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"mobipreview.htm?11/37/11860\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"mobipreview.htm?41/30/42470\">",
"     algorithm 3",
"    </a>",
"    ) but are frequently ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports suggest potential benefit from the following treatments:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      &ndash; Monkshood, false hellebore, and yew toxins bind to sodium channels. Rapid administration of 1 to 2",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"      of sodium bicarbonate followed by a continuous infusion of approximately 1",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"      per hour was associated with clinical improvement in an adult with large yew seed ingestion, widening of the QRS interval, and refractory ventricular tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34262?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Magnesium sulfate (20 to 50",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum single dose 2 g) is suggested for patients with torsades de pointes or other polymorphic ventricular arrhythmias caused by monkshood (Aconitum species) poisoning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/11\">",
"       11",
"      </a>",
"      ]. Magnesium administration has also been associated with successful conversion of ventricular bigeminy and prolonged QTc interval to sinus rhythm in an adult with a large ingestion of monkshood (Aconitum napellus) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Extracorporeal membrane oxygenation (ECMO)",
"      </strong>",
"      &ndash; A case report described the successful use of ECMO to support the circulation of a patient with resistant ventricular tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/13\">",
"       13",
"      </a>",
"      ]. Although ECMO was associated with maintenance of hemodynamic stability while permitting time for toxin metabolism in this case, this therapy is highly invasive and is usually not warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616885\">",
"    <span class=\"h2\">",
"     Nicotinic poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of nicotinic plants (eg, poison hemlock [Conium maculatum]) cause muscarinic signs (eg, vomiting, diarrhea, bronchorrhea, salivation, wheezing) and nicotinic effects (muscle fasciculations, paralysis, coma, and seizures) (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H13414429#H13414429\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Nicotinic poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscarinic findings should be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/7\">",
"     7",
"    </a>",
"    ]. The dose of atropine should be titrated to dry bronchial secretions without causing significant anticholinergic symptoms (eg, delirium, flushing, elevated temperature). Suggested dosing is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Management of seizures, muscle weakness, and paralysis consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seizures should be treated with benzodiazepines (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      ). If seizures persist, then",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"       phenobarbital",
"      </a>",
"      should be administered as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"       fosphenytoin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      is less effective for toxin-induced seizures (",
"      <a class=\"graphic graphic_table graphicRef55368 \" href=\"mobipreview.htm?29/20/30029\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with significant muscle weakness and respiratory failure should be treated with endotracheal intubation and ventilation. The duration of ventilatory support depends upon the amount of plant ingested but is typically less than 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/58/39845?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      in the setting of nicotinic poisoning may cause longer than expected paralysis and should be avoided.",
"     </li>",
"     <li>",
"      Patients with serious nicotinic plant poisoning should also have repeated evaluation of serum creatine kinase, urinalysis, and urine myoglobin to monitor for the development of rhabdomyolysis and myoglobinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/14\">",
"       14",
"      </a>",
"      ]. The primary treatment goals are similar to rhabdomyolysis from other causes and are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fluid repletion with isotonic (normal) saline (20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour up to 1 to 2 L per hour) &ndash; The emergency provider should closely monitor the urine output with the goal of a minimum urine output of 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour up to 200 mL per hour. Alkalinization of the urine or the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      to increase diuresis should not be used since they may be associated with adverse effects and the efficacy of these strategies is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link&amp;anchor=H25398992#H25398992\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Bicarbonate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link&amp;anchor=H25398999#H25398999\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Loop diuretics and mannitol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia) &ndash; Management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be",
"      <strong>",
"       avoided",
"      </strong>",
"      unless severe symptoms (eg, tetany) are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link&amp;anchor=H25399014#H25399014\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Treatment of metabolic abnormalities'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15407390\">",
"    <span class=\"h3\">",
"     Green tobacco sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Green tobacco sickness refers to nicotine toxicity caused by dermal absorption from tobacco leaves in field workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15\">",
"     15",
"    </a>",
"    ]. Factors associated with green tobacco sickness include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Working in tobacco fields when the crop is wet (eg, early morning dew, during or shortly after a rainstorm, or days with high ambient humidity) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nonsmoking workers due to less tolerance to nicotine when compared to smokers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Younger age with children and adolescents at highest risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Green tobacco sickness may have rapid onset while the worker is in the field or can be delayed for several hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15\">",
"     15",
"    </a>",
"    ]. Typical clinical findings consist of nausea, vomiting, dizziness, headache, and muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Less commonly, diaphoresis, salivation, copious bronchial secretions, diarrhea, and fluctuations in heart rate and blood pressure may occur. Rarely, seizures have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Green tobacco sickness typically resolves within three days.",
"   </p>",
"   <p>",
"    The diagnosis of green tobacco sickness is based upon a history of tobacco leaf exposure and clinical findings. If the diagnosis is in doubt, elevated blood, urine, or salivary cotinine levels can confirm the diagnosis in nonsmokers and smokers with mild to moderate use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. However, toxic cotinine levels have not been well established in heavy tobacco users.",
"   </p>",
"   <p>",
"    In most patients, treatment requires prevention of further exposure and supportive care as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove the worker from the field",
"     </li>",
"     <li>",
"      Have the worker shower and change clothing",
"     </li>",
"     <li>",
"      Encourage adequate hydration and rest",
"     </li>",
"     <li>",
"      Give antiemetics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      ) and intravenous fluids to patients with persistent vomiting",
"     </li>",
"     <li>",
"      Prevent the worker from returning to the tobacco field until all signs and symptoms have resolved",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     Atropine",
"    </a>",
"    is suggested for patients with moderate to severe salivation, diaphoresis, vomiting, diarrhea, or copious bronchial secretions as for other nicotinic plants (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Seizures should be treated with benzodiazepines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    ). If seizures persist, then",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    should be administered as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    is less effective for toxin-induced seizures (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"mobipreview.htm?29/20/30029\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616848\">",
"    <span class=\"h2\">",
"     Agitation, delirium, and/or hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system excitation with hallucinations may occur after ingestion of plants that contain lysergic acid diethylamide (LSD) congeners or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    and related anticholinergic toxins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H7184754#H7184754\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Hallucinations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H13413131#H13413131\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Anticholinergic poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with these findings should initially receive benzodiazepines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    typical maximum single dose 2 to 4 mg) and be placed in a quiet room. Physical restraints may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44584?source=see_link&amp;anchor=H23#H23\">",
"     \"Intoxication from LSD and other common hallucinogens\", section on 'Agitation and dysphoria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"     Physostigmine",
"    </a>",
"    may be appropriate for selected patients with severe anticholinergic plant poisoning. (See",
"    <a class=\"local\" href=\"#H38616922\">",
"     'Anticholinergic poisoning'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3926807\">",
"    <span class=\"h2\">",
"     Hypoglycemia and encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who ingest unripe ackee fruit (Blighia sapida), commonly found in West Africa and the Caribbean, may develop a Reye-like syndrome with vomiting, hypoglycemia, encephalopathy, and seizures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H7709856#H7709856\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Hypoglycemia and encephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is primarily supportive with close monitoring of the serum glucose and timely treatment of hypoglycemia with dextrose (eg, rapid infusion of 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    [2.5 to 5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of dextrose 10 percent in water] to maintain the serum glucose above 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.33",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616892\">",
"    <span class=\"h2\">",
"     Status epilepticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of Cicuta species (water hemlock) or Oenanthe crocata (hemlock water dropwort) is associated with recurrent seizures that may not be amenable to standard anticonvulsant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. Seizures should be treated with benzodiazepines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    ) and if seizures persist,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    is less effective for the treatment of toxin-induced seizures (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"mobipreview.htm?29/20/30029\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/7\">",
"     7",
"    </a>",
"    ]. A continuous infusion of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    , depending upon hemodynamic stability, may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H1792745#H1792745\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Status epilepticus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30505?source=see_link&amp;anchor=H37#H37\">",
"     \"Management of status epilepticus in children\", section on 'Refractory seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with status epilepticus after plant poisoning should also have repeated evaluation of serum creatine kinase, urinalysis, and urine myoglobin to monitor for the development of rhabdomyolysis and myoglobinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/7\">",
"     7",
"    </a>",
"    ]. The primary treatment goals are similar to rhabdomyolysis from other causes and are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid repletion with normal saline infusion (20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour up to 1 to 2 L per hour) &ndash; The emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour up to 200 mL per hour. Alkalinization of the urine or the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      to increase diuresis may be associated with adverse effects and the efficacy of these strategies is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link&amp;anchor=H25398992#H25398992\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Bicarbonate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link&amp;anchor=H25398999#H25398999\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Loop diuretics and mannitol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia) &ndash; Management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be avoided unless severe symptoms (eg, tetany) are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link&amp;anchor=H25399014#H25399014\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Treatment of metabolic abnormalities'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616906\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL DECONTAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients who are alert and present for care within one hour of a highly toxic plant ingestion be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) (1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    maximum single dose 50 to 100 g by mouth or nasogastric tube). AC should",
"    <strong>",
"     not",
"    </strong>",
"    be given in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving AC. The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H10032558#H10032558\">",
"     \"Decontamination of poisoned children\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendation for AC administration following highly toxic plant ingestion derives from indirect evidence of benefit in volunteers who ingested other substances and in animal studies, as well as from evidence of benefit following ingestions of other medications. Plant toxins, like most complex xenobiotics, bind well to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    . Because diarrhea often occurs after toxic plant ingestion, the use of a cathartic (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    ) with AC should be",
"    <strong>",
"     avoided",
"    </strong>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H10032467#H10032467\">",
"     \"Decontamination of poisoned children\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H27#H27\">",
"     \"Decontamination of poisoned children\", section on 'Cathartics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that children who ingest nontoxic or minimally toxic plants (",
"    <a class=\"graphic graphic_table graphicRef52103 \" href=\"mobipreview.htm?30/14/30957\">",
"     table 2",
"    </a>",
"    ) not receive AC. Plants that are nontoxic or minimally toxic (eg, philodendron, dieffenbachia, poinsettia) do not causes serious effects that are prevented by AC. Thus,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    administration is",
"    <strong>",
"     not",
"    </strong>",
"    necessary and the risk of aspiration, although low, may outweigh the benefits. (See",
"    <a class=\"local\" href=\"#H38616864\">",
"     'Mucosal irritation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H38616840\">",
"     'Gastroenteritis'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    We recommend that patients who ingest potentially toxic plants",
"    <strong>",
"     not",
"    </strong>",
"    undergo gastric emptying by gastric lavage or syrup of ipecac. This recommendation is based upon randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syrup of ipecac may also cause more symptoms than no gastric emptying in children who ingest nontoxic or minimally toxic plants. As an example, a poison center-based trial of 96 children who ingested fewer than six potentially toxic berries found that administration of syrup of ipecac led to more vomiting, diarrhea, and sedation than observation alone (100 versus 0 percent for vomiting, 39 versus 10 percent for diarrhea, and 20 versus 4 percent for sedation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3927241\">",
"    <span class=\"h1\">",
"     ELIMINATION ENHANCEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, plant toxins are",
"    <strong>",
"     not",
"    </strong>",
"    amenable to elimination enhancement including multiple dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC), hemodialysis, or charcoal hemoperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/2,4,7\">",
"     2,4,7",
"    </a>",
"    ]. However, the efficacy of MDAC in yellow oleander (Thevetia peruviana) ingestion is not clear since two randomized trials had different results. In the largest trial of 1647 patients poisoned by yellow oleander, MDAC provided no mortality benefit when compared with a single dose of AC or placebo (6.3 versus 6.8 percent, odds ratio 0.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/22\">",
"     22",
"    </a>",
"    ]. This is in contrast to a smaller trial in 401 patients who ingested yellow oleander in which MDAC was associated with a significant reduction in mortality compared to single dose AC (2.5 versus 8.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616914\">",
"    <span class=\"h1\">",
"     ANTIDOTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most serious plant poisonings, supportive care is the mainstay of treatment. However, antidotal therapy may be life-saving in selected patients with anticholinergic, cardiac glycoside, or cyanide poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616922\">",
"    <span class=\"h2\">",
"     Anticholinergic poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with anticholinergic poisoning and delirium that is not responsive to treatment with benzodiazepines receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"     physostigmine",
"    </a>",
"    . Patients who ingest plants with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    and related anticholinergic toxins (eg, jimson weed [Datura stramonium]) often develop severe agitation and delirium that may not be well controlled by supportive measures such as physical restraints or benzodiazepines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Administration of physostigmine (0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV slowly over five minutes, maximum single dose 0.5 mg) to such patients can result in rapid return to baseline mental status and avoid serious complications of anticholinergic poisoning including hyperthermia, tachycardia with hemodynamic instability, seizures, or rhabdomyolysis. &nbsp;",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"     physostigmine",
"    </a>",
"    is uncommonly used and unfamiliar to many clinicians, practitioners may chose to consult with a medical toxicologist or regional poison center. In the United States, the nearest available poison control center can be reached by calling 1-800-222-1222. The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Successful and safe use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"     physostigmine",
"    </a>",
"    after jimson weed poisoning has been documented in several case reports and series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Before physostigmine is given, the patient should be placed on a cardiac monitor, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    and resuscitative equipment should be available at the bedside. Physostigmine should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with known or suspected cyclic antidepressant poisoning or to patients with a QRS interval that is &ge;100 msec. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link&amp;anchor=H11#H11\">",
"     \"Anticholinergic poisoning\", section on 'Antidotal therapy with physostigmine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616938\">",
"    <span class=\"h2\">",
"     Cardiac glycoside poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple cardiac glycosides similar to digitalis or digitoxin, are found in a number of common ornamental plants (eg, common oleander [Nerium oleander], yellow oleander [Thevetia peruviana], foxglove [Digitalis purpurea]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/2,4,26\">",
"     2,4,26",
"    </a>",
"    ]. Toxicity includes vomiting, diarrhea, abdominal pain, weakness, confusion, hyperkalemia, and bradyarrhythmias, especially high grade atrioventricular block. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H7184730#H7184730\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Cardiac glycosides (eg, oleander, foxglove)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3215304\">",
"    <span class=\"h3\">",
"     Indications for digoxin-specific Fab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     Digoxin",
"    </a>",
"    -specific antibodies (Fab) fragments bind to naturally occurring cardiac glycosides, including those found in plants, and reverses toxicity in human poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/2,4,27\">",
"     2,4,27",
"    </a>",
"    ]. We recommend that children who ingest cardiac glycoside-containing plants (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ) and develop life-threatening arrhythmias (eg, atrioventricular node",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe sinus node block) or serum potassium &gt;5.0 to 5.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    receive digoxin-specific Fab fragments.",
"   </p>",
"   <p>",
"    The following evidence supports the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific Fab fragments for patients with serious plant-derived cardiac glycoside poisoning:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of 66 patients with yellow oleander (Thevetia peruviana) poisoning found faster resolution of bradyarrhythmias and elevated potassium in patients who received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      -specific Fab fragments versus placebo (71 versus 16 percent at eight hours) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case reports have also documented successful treatment of cardiotoxicity with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      -specific Fab fragments in patients who ingested foxglove extract, common oleander (Nerium oleander), and an herbal extract containing an unknown plant-derived cardioactive steroid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/29-32\">",
"       29-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Quantitative",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    or digitoxin serum levels obtained in patients poisoned with plants that contain cardiac glycosides do not correlate with clinical toxicity and",
"    <strong>",
"     should not",
"    </strong>",
"    be used to calculate the Fab fragment dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3215311\">",
"    <span class=\"h3\">",
"     Dose of digoxin-specific Fab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because binding of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific Fab fragments to naturally occurring cardiac glycosides is less efficient than in patients with digoxin or digitoxin poisoning, doses of digoxin-specific Fab fragments higher than typically given for digoxin poisoning may be necessary to achieve comparable efficacy. As an example, experts suggest that patients with common oleander (Nerium oleander) or yellow oleander (Thevetia peruviana) poisoning receive a starting dose of 400 mg (10 vials) of digoxin-specific Fab fragments over 20 minutes followed by 400 to 800 mg (10 to 20 vials) infused over four to eight hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/27\">",
"     27",
"    </a>",
"    ]. These higher doses of digoxin-specific Fab fragments may be associated with a higher frequency of adverse allergic reactions (eg, hives, angioedema, bronchospasm). Thus, the clinician should have parenteral epinephrine,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or similar antihistamine, and glucocorticoids (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ) immediately available during digoxin-specific Fab fragment administration.",
"   </p>",
"   <p>",
"    This dosing regimen for oleander poisoning is based, in part, upon a dose-finding study and subsequent trial of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific Fab fragments in patients with yellow oleander poisoning. Findings from this study include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      10 of 12 patients who received doses of 800 to 1600 mg (20 to 40 vials) of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      -specific Fab fragments had conversion of arrhythmia to normal sinus rhythm or reversal of hyperkalemia compared with 1 of 4 patients who received a dose of 400 mg (10 vials).",
"     </li>",
"     <li>",
"      The subsequent trial demonstrated significantly faster reversal of clinical toxicity (bradyarrhythmia, elevated potassium) among the 34 patients who received 1200 mg (30 vials) of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      -specific Fab fragments when compared with the 32 patients who received placebo (71 versus 16 percent at eight hours).",
"     </li>",
"     <li>",
"      Adverse allergic reactions (eg, pruritus, hives, angioedema, bronchospasm) occurred in 23 percent of patients who received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      -specific Fab fragments during the dosing study or the trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific Fab fragments used for oleander poisoning may not be appropriate for poisoning with other naturally occurring plant and animal cardiac glycosides, such as lily of the valley and bufotoxin. Use of digoxin-specific Fab fragments in such poisonings is empiric. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23043?source=see_link&amp;anchor=H7#H7\">",
"     \"Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity\", section on 'Cardiac glycoside poisoning other than digoxin or digitoxin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Yellow oleander poisoning is a common method of suicide in developing countries in Southeast Asia. Thus,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific Fab fragments are not always available for treatment of serious poisoning. In resource-limited settings experts suggest the following modification for treatment of serious cardiac glycoside poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40233/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Give insulin with dextrose infusion for serum potassium &gt;5.5",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Do",
"      <strong>",
"       not",
"      </strong>",
"      give calcium.",
"     </li>",
"     <li>",
"      Treat severe atrioventricular block with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      and, if not responsive to atropine, cardiac pacing.",
"     </li>",
"     <li>",
"      Treat ventricular tachycardia with low dose cardioversion (eg, 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       joules/kg)",
"      </span>",
"      and ventricular fibrillation with low dose defibrillation (eg, 2",
"      <span class=\"nowrap\">",
"       joules/kg,",
"      </span>",
"      maximum dose 100 joules).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38616930\">",
"    <span class=\"h2\">",
"     Cyanide poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many fruit pits and seeds (eg, cherry, apricot, peach, plum, pear, almond, apple) contain cyanogenic glycosides such as amygdalin that are converted to hydrogen cyanide by gut bacteria after ingestion of masticated seeds or pits (",
"    <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"     table 1",
"    </a>",
"    ). Cyanide poisoning also complicates ingestion of amygdalin and laetrile (a chemical congener of amygdalin) sold as alternative treatments for cancer.",
"   </p>",
"   <p>",
"    The clinical findings of cyanide poisoning are delayed several hours after toxic ingestion of amygdalin-containing seeds or herbal preparations and include cherry-red skin, vomiting, abdominal pain, tachypnea, tachycardia, ventricular arrhythmias, confusion, coma, and seizures. Severe lactic acidosis can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=see_link&amp;anchor=H13413138#H13413138\">",
"     \"Clinical manifestations and evaluation of potentially toxic plant ingestions in children\", section on 'Cyanide poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that children who have ingested cyanogenic plants and have findings of cyanide poisoning should receive IV",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/32/27141?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    (70",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose 5 grams)",
"    <strong>",
"     and",
"    </strong>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/56/1924?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    25 percent (1.65",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    [412.5",
"    <span class=\"nowrap\">",
"     mg/kg]).",
"    </span>",
"    This recommendation is based upon direct evidence of benefit of this combined regimen for the treatment of cyanide poisoning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/18/7466?source=see_link&amp;anchor=H25#H25\">",
"     \"Cyanide poisoning\", section on 'Probable cyanide intoxication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38617045\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38617053\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potentially toxic plant ingestions occur frequently in children, but serious toxicity is rare. (See",
"      <a class=\"local\" href=\"#H38616816\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many exploratory plant ingestions in young children involve consumption of small amounts of nontoxic or minimally toxic species that require no therapy (",
"      <a class=\"graphic graphic_table graphicRef52103 \" href=\"mobipreview.htm?30/14/30957\">",
"       table 2",
"      </a>",
"      ). Mucosal and minor gastrointestinal irritations are the most common clinical effects associated with toxic plant ingestion in children. (See",
"      <a class=\"local\" href=\"#H38616832\">",
"       'Supportive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38616864\">",
"       'Mucosal irritation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38616840\">",
"       'Gastroenteritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious poisoning is associated with large ingestions of highly toxic plant species (",
"      <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"       table 1",
"      </a>",
"      ). Clinical findings and identification of the ingested plant are essential for determining specific management. A regional poison control center should be contacted to assist with likely plant species ingested based upon clinical findings, identification of any available plant material, and treatment of specific toxic effects. Most poison control centers maintain active call lists of botanists who are knowledgeable concerning local prevalence of plant species and can assist in identification. To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38616832\">",
"       'Supportive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38617045\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who are alert and present for care within one hour of a highly toxic plant ingestion (",
"      <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"       table 1",
"      </a>",
"      ) receive",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38616906\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children who ingest nontoxic or minimally toxic plants (",
"      <a class=\"graphic graphic_table graphicRef52103 \" href=\"mobipreview.htm?30/14/30957\">",
"       table 2",
"      </a>",
"      ) not receive",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38616906\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who ingest potentially toxic plants",
"      <strong>",
"       not",
"      </strong>",
"      undergo gastric emptying by gastric lavage or syrup of ipecac (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38616906\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most serious plant poisonings, supportive care is the mainstay of treatment. However, antidotal therapy may be life-saving in selected patients with anticholinergic, cardiac glycoside, or cyanide poisoning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that children who ingest toxic plants and develop anticholinergic poisoning and delirium that are not responsive to treatment with benzodiazepines receive",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"       physostigmine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Because physostigmine is uncommonly used and unfamiliar to many clinicians, practitioners may choose to consult with a medical toxicologist or regional poison center. In the United States, the nearest available poison control center can be reached by calling 1-800-222-1222. The World Health Organization provides a listing of international poison centers at its website (",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38616922\">",
"       'Anticholinergic poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children who ingest cardiac glycoside-containing plants (",
"      <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"       table 1",
"      </a>",
"      ) and develop life-threatening arrhythmias (eg, atrioventricular node",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe sinus node block) or serum potassium &gt;5.0 to 5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      receive",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      -specific Fab fragments (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3215304\">",
"       'Indications for digoxin-specific Fab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3215311\">",
"       'Dose of digoxin-specific Fab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children who have ingested cyanogenic plants and have findings of cyanide poisoning should receive IV",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/32/27141?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      (70",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose 5 grams)",
"      <strong>",
"       and",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/56/1924?source=see_link\">",
"       sodium thiosulfate",
"      </a>",
"      25 percent (1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      [412.5",
"      <span class=\"nowrap\">",
"       mg/kg])",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38616930\">",
"       'Cyanide poisoning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient management and disposition after toxic plant ingestion depends upon the plant ingested, amount ingested, and clinical findings (see",
"      <a class=\"local\" href=\"#H3216162\">",
"       'Approach and disposition'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asymptomatic children with ingestions of small amounts of confirmed nontoxic (",
"      <a class=\"graphic graphic_table graphicRef52103 \" href=\"mobipreview.htm?30/14/30957\">",
"       table 2",
"      </a>",
"      ) or minimally toxic plant species do",
"      <strong>",
"       not",
"      </strong>",
"      require any specific treatment.",
"     </li>",
"     <li>",
"      Asymptomatic children with ingestions of unknown or potentially highly toxic plants (",
"      <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"       table 1",
"      </a>",
"      ), particularly consumption of large amounts, warrant medical evaluation, gastrointestinal decontamination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      if accomplished within one hour, and observation for four to six hours. Most patients will remain asymptomatic and can be discharged home. (See",
"      <a class=\"local\" href=\"#H38616906\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic patients with ingestions of highly toxic plants (",
"      <a class=\"graphic graphic_table graphicRef69016 \" href=\"mobipreview.htm?35/32/36366\">",
"       table 1",
"      </a>",
"      ) should receive timely supportive care, gastrointestinal decontamination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      if accomplished within one hour of ingestion, antidotal therapy if appropriate, and hospital admission. In addition to medical management, patients who ingest highly toxic plants with suicidal intent or for recreational purposes warrant evaluation for mental illness or drug abuse. (See",
"      <a class=\"local\" href=\"#H38616832\">",
"       'Supportive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38616906\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38616914\">",
"       'Antidotes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/1\">",
"      Mrvos R, Dean BS, Krenzelok EP. Philodendron/dieffenbachia ingestions: are they a problem? J Toxicol Clin Toxicol 1991; 29:485.",
"     </a>",
"    </li>",
"    <li>",
"     Palmer, M, Betz, JM. Plants. In: Goldfrank&rsquo;s Toxicologic Emergencies, 9th edition, Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE (Eds), McGraw-Hill, New York 2011. p.1537.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/3\">",
"      Cumpston KL, Vogel SN, Leikin JB, Erickson TB. Acute airway compromise after brief exposure to a Dieffenbachia plant. J Emerg Med 2003; 25:391.",
"     </a>",
"    </li>",
"    <li>",
"     Smolinske SC, Daubert GP, Spoerke DG. Poisonous plants. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th edition, Shannon MW, Borron SW, Burns MJ.  (Eds), Saunders Elsevier, Philadelphia 2007. p.473.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/5\">",
"      Gunduz A, Turedi S, Russell RM, Ayaz FA. Clinical review of grayanotoxin/mad honey poisoning past and present. Clin Toxicol (Phila) 2008; 46:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/6\">",
"      Festa M, Andreetto B, Ballaris MA, et al. [A case of Veratrum poisoning]. Minerva Anestesiol 1996; 62:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/7\">",
"      Froberg B, Ibrahim D, Furbee RB. Plant poisoning. Emerg Med Clin North Am 2007; 25:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/8\">",
"      Tekol Y, Kameyama M. [Electrophysiology of the mechanisms of action of the yew toxin, taxine, on the heart]. Arzneimittelforschung 1987; 37:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/9\">",
"      Tai YT, But PP, Young K, Lau CP. Cardiotoxicity after accidental herb-induced aconite poisoning. Lancet 1992; 340:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/10\">",
"      Pierog J, Kane B, Kane K, Donovan JW. Management of isolated yew berry toxicity with sodium bicarbonate: a case report in treatment efficacy. J Med Toxicol 2009; 5:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/11\">",
"      Adaniya H, Hayami H, Hiraoka M, Sawanobori T. Effects of magnesium on polymorphic ventricular tachycardias induced by aconitine. J Cardiovasc Pharmacol 1994; 24:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/12\">",
"      Gottignies P, El Hor T, Tameze JK, et al. Successful treatment of monkshood (aconite napel) poisoning with magnesium sulfate. Am J Emerg Med 2009; 27:755.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/13\">",
"      Panzeri C, Bacis G, Ferri F, et al. Extracorporeal life support in a severe Taxus baccata poisoning. Clin Toxicol (Phila) 2010; 48:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/14\">",
"      West PL, Horowitz BZ, Montanaro MT, Lindsay JN. Poison hemlock-induced respiratory failure in a toddler. Pediatr Emerg Care 2009; 25:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/15\">",
"      McBride JS, Altman DG, Klein M, White W. Green tobacco sickness. Tob Control 1998; 7:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/16\">",
"      McKnight RH, Spiller HA. Green tobacco sickness in children and adolescents. Public Health Rep 2005; 120:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/17\">",
"      Swinker M, Meredith JT. A seizure in the tobacco field. Green tobacco sickness. N C Med J 2000; 61:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/18\">",
"      Ballard T, Ehlers J, Freund E, et al. Green tobacco sickness: occupational nicotine poisoning in tobacco workers. Arch Environ Health 1995; 50:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/19\">",
"      Barceloux DG. Akee fruit and Jamaican vomiting sickness (Blighia sapida K&ouml;enig). Dis Mon 2009; 55:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/20\">",
"      From the Centers for Disease Control and Prevention. Water hemlock poisoning--Maine, 1992. JAMA 1994; 271:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/21\">",
"      Wax PM, Cobaugh DJ, Lawrence RA. Should home ipecac-induced emesis be routinely recommended in the management of toxic berry ingestions? Vet Hum Toxicol 1999; 41:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/22\">",
"      Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 2008; 371:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/23\">",
"      de Silva HA, Fonseka MM, Pathmeswaran A, et al. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet 2003; 361:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/24\">",
"      Amlo H, Haugeng KL, Wickstr&oslash;m E, et al. [Poisoning with Jimson weed. Five cases treated with physostigmine]. Tidsskr Nor Laegeforen 1997; 117:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/25\">",
"      Glatstein MM, Alabdulrazzaq F, Garcia-Bournissen F, Scolnik D. Use of physostigmine for hallucinogenic plant poisoning in a teenager: case report and review of the literature. Am J Ther 2012; 19:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/26\">",
"      Krenzelok EP, Jacobsen TD, Aronis J. Is the yew really poisonous to you? J Toxicol Clin Toxicol 1998; 36:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/27\">",
"      Bandara V, Weinstein SA, White J, Eddleston M. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon 2010; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/28\">",
"      Eddleston M, Rajapakse S, Jayalath S, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet 2000; 355:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/29\">",
"      Camphausen C, Haas NA, Mattke AC. Successful treatment of oleander intoxication (cardiac glycosides) with digoxin-specific Fab antibody fragments in a 7-year-old child: case report and review of literature. Z Kardiol 2005; 94:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/30\">",
"      Barrueto F Jr, Jortani SA, Valdes R Jr, et al. Cardioactive steroid poisoning from an herbal cleansing preparation. Ann Emerg Med 2003; 41:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/31\">",
"      Safadi R, Levy I, Amitai Y, Caraco Y. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Arch Intern Med 1995; 155:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40233/abstract/32\">",
"      Rich SA, Libera JM, Locke RJ. Treatment of foxglove extract poisoning with digoxin-specific Fab fragments. Ann Emerg Med 1993; 22:1904.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16521 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40233=[""].join("\n");
var outline_f39_18_40233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38617053\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38616816\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3216162\">",
"      APPROACH AND DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38616832\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616864\">",
"      Mucosal irritation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616840\">",
"      Gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616877\">",
"      Cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3925410\">",
"      - Bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3925800\">",
"      - Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616885\">",
"      Nicotinic poisoning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15407390\">",
"      - Green tobacco sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616848\">",
"      Agitation, delirium, and/or hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3926807\">",
"      Hypoglycemia and encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616892\">",
"      Status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38616906\">",
"      GASTROINTESTINAL DECONTAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3927241\">",
"      ELIMINATION ENHANCEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38616914\">",
"      ANTIDOTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616922\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616938\">",
"      Cardiac glycoside poisoning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3215304\">",
"      - Indications for digoxin-specific Fab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3215311\">",
"      - Dose of digoxin-specific Fab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38616930\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38617045\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38617053\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/16521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16521|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/12/42178\" title=\"algorithm 1\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/37/11860\" title=\"algorithm 2\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/30/42470\" title=\"algorithm 3\">",
"      Pediatric cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16521|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/32/36366\" title=\"table 1\">",
"      Highly toxic plants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/14/30957\" title=\"table 2\">",
"      Commonly ingested nontoxic plants and minimally toxic plants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/26/17837\" title=\"table 3\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/54/42860\" title=\"table 4\">",
"      Procedure table child endotracheal intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/20/30029\" title=\"table 5\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=related_link\">",
"      Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=related_link\">",
"      Clinical manifestations and evaluation of mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/10/29865?source=related_link\">",
"      Clinical manifestations and evaluation of potentially toxic plant ingestions in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/18/7466?source=related_link\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23043?source=related_link\">",
"      Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44584?source=related_link\">",
"      Intoxication from LSD and other common hallucinogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42615?source=related_link\">",
"      Management of mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/44/20168?source=related_link\">",
"      Poison ivy (Toxicodendron) dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_18_40234="Treatment of psoriatic arthritis";
var content_f39_18_40234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of psoriatic arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40234/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40234/contributors\">",
"     Dafna D Gladman, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40234/contributors\">",
"     Christopher Ritchlin, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40234/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/18/40234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/18/40234/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/18/40234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of psoriatic arthritis (PsA) involves the use of a variety of medications, including some agents used for the treatment of the cutaneous manifestations of psoriasis and others that are also employed for the management of patients with other forms of inflammatory arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of PsA is discussed in this topic review. Treatment of psoriatic skin involvement, the pathogenesis of PsA, the clinical manifestations of PsA, and the diagnosis of PsA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23608?source=see_link\">",
"     \"Pathogenesis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriatic arthritis (PsA) was once considered a mild disease for which clinicians were reluctant to use disease-modifying antirheumatic drugs (DMARDs); however, it has since become clear that the disease is more severe than previously described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/1\">",
"     1",
"    </a>",
"    ]. Two years after disease onset in an early disease cohort, 47 percent of patients had radiographic erosions in the hands and feet, and 56 percent were taking DMARDS. In another prospective cohort study of 100 PsA patients, the majority of patients showed progression in the number of joints involved, and 68 percent manifested radiographic progression at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinical and genetic risk factors for disease progression have been identified. Such information can help to prospectively identify patients who will benefit from aggressive early treatment. Severe disease may adversely affect survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors for progressive joint damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic literature review and consensus process has identified the following factors predicting a poor prognosis with respect to progression of peripheral joint injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing number of actively inflamed joints",
"     </li>",
"     <li>",
"      An elevated erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      Failure of previous medication trials",
"     </li>",
"     <li>",
"      The presence of joint damage (clinically or radiographically)",
"     </li>",
"     <li>",
"      Loss of function (by Health Assessment Questionnaire [HAQ])",
"     </li>",
"     <li>",
"      Diminished quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observations that support these findings above and that identify other prognostic factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyarticular rather than oligoarticular presentation, higher tender and swollen joint counts, a high number of joint effusions, and the damage present predict progression of clinical and radiologic damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/5-9\">",
"       5-9",
"      </a>",
"      ]. Of 129 patients with PsA identified in an early arthritis clinic, the number of patients with at least one erosion in the hands or feet increased from 27 percent at baseline to 47 percent by the two-year follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A high level of past medication use (particularly glucocorticoids) predicts progression of clinical damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A low ESR generally indicates that the patient is at low risk for progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/8\">",
"       8",
"      </a>",
"      ]. In addition, each",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      increase in the ESR is associated with a 2 percent increased risk of progression of both clinical and radiological damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Human leukocyte antigen (HLA) typing provides important predictive information. In univariate analysis, patients who are HLA-B27, -B39, or -DQw3 positive are at a higher risk for progression of clinical damage; these antigens are stronger prognostic factors than the clinical variables [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/11\">",
"       11",
"      </a>",
"      ]. The presence of HLA-DR7 appears to be &ldquo;protective,&rdquo; predicting less progression. The best multivariate model identified the HLA-B27, when -DR7 is present, and -DQw3, when -DR7 is not present, as predicting disease progression. HLA-B39 was associated with progression in early disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/11\">",
"       11",
"      </a>",
"      ]. HLA-B22 is protective when all HLA antigens are added to the model [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/12\">",
"       12",
"      </a>",
"      ]. We do not perform such testing routinely in our practice, although, with further developments, HLA testing may have greater potential to provide clinically useful prognostic information.",
"     </li>",
"     <li>",
"      The presence of a variant of the interleukin (IL)-4 receptor gene is associated with greater severity of erosive disease in patients with psoriatic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of antibodies to cyclic citrullinated peptides (anti-CCP) is associated with an increased prevalence of polyarthritis and of erosive joint disease in a cross-sectional study of patients with psoriatic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/14\">",
"       14",
"      </a>",
"      ]. In one study of 588 patients with PsA, anti-CCP antibodies were detected in 7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/15\">",
"       15",
"      </a>",
"      ]. It is not known whether these antibodies are present in early disease and could help predict disease course or if they develop later in the illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete relief of joint tenderness and swelling may occur in a substantial minority of treated patients. As an example, among 391 patients, 69 (18 percent) achieved a remission, and nearly one-half remained free of active joint disease without continued use of medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/16\">",
"     16",
"    </a>",
"    ]. Periods of remission lasted an average of approximately 2.5 years. However, the majority experienced at least one relapse, after a mean duration of remission of 2.6 years. Male gender, milder disease, and less disability at presentation were each associated with a greater likelihood of achieving a remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with psoriatic arthritis may be at increased risk for cardiovascular disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, there was a significant increased risk of myocardial infarction, angina, and hypertension in those with psoriatic arthritis (PsA) versus the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/17\">",
"       17",
"      </a>",
"      ]; the increased risk was associated with severe psoriasis as well as other conventional risk factors.",
"     </li>",
"     <li>",
"      Conflicting data exist concerning the association between psoriatic arthritis and increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. Survival appears to have improved since the late 1970s and early 1980s, possibly related to more effective therapeutic approaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/18\">",
"       18",
"      </a>",
"      ]. A study of 453 patients with PsA in the United Kingdom (UK) entered in the database of a single center between 1985 and 2007 found no increase in mortality risk among this cohort compared with the general population of the UK [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENTS FOR PSORIATIC ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the treatment of PsA includes therapy for both skin and musculoskeletal disease aimed at controlling inflammation and preventing discomfort and damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Musculoskeletal manifestations include not only peripheral joint inflammation but also axial disease, dactylitis, and enthesitis; more than one of these features may occur in a single patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/24\">",
"     24",
"    </a>",
"    ]. Whenever possible, the treatment should be coordinated between the rheumatologist and the dermatologist since some of the medications used to treat the arthritis may have a deleterious effect on the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/25\">",
"     25",
"    </a>",
"    ], and there are differences in response between skin and joints with some agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of PsA usually begins with nonsteroidal antiinflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These include both selective cyclooxygenase-2 (COX-2) inhibitors and nonselective NSAIDs (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"mobipreview.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ). A randomized trial of nimesulide showed that 200 mg and 400 mg doses were more effective than placebo in PsA at 24 weeks, but a similarly designed trial with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (200 and 400 mg doses) failed to show significant improvement over placebo at 12 weeks. Moreover, comparative studies did not find any difference in efficacy between different NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/26\">",
"     26",
"    </a>",
"    ]. As a result, the choice of an NSAID depends upon the individual clinician&rsquo;s familiarity with a particular drug and, in some cases, the patient&rsquo;s preference. Drugs such as enteric-coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    require frequent administration, whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    and slow-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    may be given in a once daily routine and may be preferred by some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several selective COX-2 inhibitors have been developed and may be the optimal agents in those at risk for gastrointestinal toxicity with NSAIDs. There are no controlled trials evaluating these agents in PsA. The efficacy of the COX-2 selective inhibitors is not better than that of conventional NSAIDs, and agents in this class may increase the risk of adverse cardiovascular events such as myocardial infarction and stroke. These drugs are best avoided in individuals already at risk for coronary artery disease, in whom medications such as enteric-coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    may be more appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combining a non-selective NSAIDs and an anti-ulcer drug is another approach that may reduce the risk of gastroduodenal damage. A discussion of agents that have demonstrated efficacy in preventing ulceration or ulcer complications when used prophylactically is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NSAIDs can control the mild inflammatory symptoms of PsA and may also lessen pain and stiffness in spondylitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. While there has been some concern that NSAIDs may aggravate the skin psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/25,27\">",
"     25,27",
"    </a>",
"    ], in one placebo-controlled trial of the COX-2 selective inhibitor nimesulide, there was no significant difference in an index of skin involvement between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Second-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-line therapies are employed when the arthritis does not respond to NSAIDs. Since progressive joint damage is more likely in patients with a larger number of inflamed joints at the outset, patients with polyarticular involvement may benefit from early introduction of disease-modifying antirheumatic drugs (DMARDs). It must be emphasized, however, that no DMARDs have been demonstrated to slow or prevent radiographic damage. Thus, the role of these agents for patients with baseline damage is of questionable value but is often required when access to anti-tumor necrosis factor (TNF) agents is limited.",
"   </p>",
"   <p>",
"    Thus, DMARDs should be considered in patients who do not respond to NSAIDs and in those patients with aggressive disease (ie, with progression of deformities or radiologic evidence of erosive disease) who cannot take or obtain anti-TNF agents. The choice of the DMARD depends, in part, upon whether the patient has active or severe psoriasis as well as arthritis.",
"   </p>",
"   <p>",
"    Medications used for control of psoriasis should be considered in individuals in whom the psoriasis and arthritis are of roughly equal severity. Drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , photochemotherapy with psoralen plus ultraviolet A (PUVA), use of retinoic acid derivatives, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A have been shown to improve both the joint and skin manifestations of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/22,23,25,29,30\">",
"     22,23,25,29,30",
"    </a>",
"    ]. However, it should be noted that none of these medications has actually been shown to prevent or retard progression of joint damage. Inhibitors of tumor necrosis factor (TNF)-alpha may also be effective for both skin and joint disease. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'TNF inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other medications may be used in individuals with PsA in whom the psoriasis does not pose a particular problem. Included in this group are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , antimalarials, gold,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Long-term effect of DMARDs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is the most commonly used drug in clinical practice, despite the paucity of randomized trials and only limited observational data showing efficacy in PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/31\">",
"     31",
"    </a>",
"    ]. Examples that illustrate the available data include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial comparing MTX with placebo in 221 MTX naive patients with PsA described no significant treatment effect with any composite outcome measure (PsARC, ACR20, or DAS28) at three or six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/24\">",
"       24",
"      </a>",
"      ]. Patient and physician global scores and skin score did show statistically significantly greater improvement with MTX at six months. Important limitations of this trial were the use of MTX at a lower dose (15",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      administered orally) than the maximal doses typically used in clinical practice (up to 20 to 25",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      sometimes administered parenterally), a high drop-out rate in both groups, and the low number of involved joints. Further study would be required to determine whether the higher doses of MTX often used in practice are effective.",
"     </li>",
"     <li>",
"      A randomized trial, involving 115 patients with PsA compared the efficacy of MTX combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      with MTX alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/32\">",
"       32",
"      </a>",
"      ]. At week 16, at least 20 percent improvement was found significantly more often in patients receiving MTX plus infliximab (ACR20 response in 86 versus 67 percent). At least 75 percent improvement in the Psoriasis Area and Severity Index (PASI) was significantly more likely among patients whose baseline PASI was 2.5 or greater in those patients who received infliximab plus MTX (97 versus 54 percent). The results with both combination therapy and MTX monotherapy are most impressive but should be interpreted with caution because of the absence of placebo- and infliximab-only arms and because the skin responses for MTX far exceed those previously reported in the one placebo-controlled trial of MTX in psoriasis (PASI 75 of 36 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Only minimal efficacy of low-dose MTX was suggested in a trial in which 37 patients with PsA were randomly assigned to either MTX (7.5 to 15",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/30\">",
"       30",
"      </a>",
"      ]. Clinician evaluators scored those receiving MTX as having less active arthritis after 12 weeks of treatment. However, no significant differences were noted in tender or swollen joint counts. Although one of the few randomized trials of MTX in PsA, this trial had several limitations, including using relatively low doses of MTX compared with usual practice and being underpowered due to the very small size of the trial.",
"     </li>",
"     <li>",
"      One of the largest studies demonstrating the benefit of MTX in PsA compared the effectiveness and retention rates of MTX treatment (mean dose at six months of 14",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      in 430 patients with PsA and 1218 patients with rheumatoid arthritis (RA); patients were enrolled in the Norwegian registry of patients with inflammatory arthropathies starting a new DMARD regimen (NOR-DMARD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/34\">",
"       34",
"      </a>",
"      ]. At six months, improvement in the DAS28 was seen in both groups, although the reduction was significantly less in patients with PsA (-1.13 versus -1.38). Similar degrees of improvement were seen in both groups in the erythrocyte sedimentation rate, C-reactive protein, and physician global assessment score. After two years, a similar proportion of patients with PsA and RA remained on MTX (65 and 66 percent, respectively). An observational study of 59 patients treated with MTX for at least two years between 1994 and 2004 identified several factors associated with the likelihood of responding to the medication by comparing these patients with a group treated between 1978 and 1993 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/35\">",
"       35",
"      </a>",
"      ]. Over the period of time covered by the two studies, changes occurred in how the drug was used clinically, facilitating this analysis. The historical control group had been evaluated previously in a nested case-control study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/36\">",
"       36",
"      </a>",
"      ]. This older study, which included 24 patients who received MTX for two years and matched controls, showed no benefit at two years on clinical or radiologic progression. This study was limited by small sample size. In the group treated more recently, there were a higher response rate (68 versus 47 percent of patients experiencing &gt;40 percent reduction in joint count) and a reduced rate of radiographic progression over two years of observation (increase of 1.5 versus 2.3 in modified Steinbrocker score). Patients in the more recently treated group received higher doses of MTX (mean dose 16.2 versus 10.8",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      and had a shorter duration of disease at the time of initiation of therapy (8 versus 11.5 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral MTX has an advantage in that it is only given once a week, at doses ranging from 7.5 to 25 mg as a single dose or divided into three doses within a 24 hour period. With the correct dose, the response begins within four to six weeks. It has been suggested that, in doses above 15 mg per week, oral absorption is unpredictable, and parenteral administration should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who require more than 17.5",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    of MTX should be switched to parenteral administration. The subcutaneous route may be more beneficial than the intramuscular route and is more convenient for patients who can self-administer the medication. Parenteral MTX can be pushed to 25 to 30",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    is usually prescribed starting the day after MTX is taken. Dose frequency ranges from once a week to six days a week. There are no randomized controlled trials to determine the optimal dose. Patients who do not tolerate folic acid may be prescribed folinic acid, 5 mg the day after MTX.",
"   </p>",
"   <p>",
"    Patients who do not respond to MTX 25",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    for six to eight weeks are unlikely to respond to more prolonged therapy. On the other hand, discontinuation of MTX in responders is often associated with severe flares of both skin and joint disease. We, thus, suggest that patients who wish to discontinue MTX do so using a slow taper. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most serious potential side effects of MTX include liver toxicity, interstitial lung disease, and bone marrow suppression. Data are not available for prevalence of liver toxicity in PsA. However, in a study of 71 psoriasis patients on MTX, 169 serial biopsies were analyzed, and type 2 diabetes and obesity were major risk factors for progressive fibrosis even at lower doses of MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/38\">",
"     38",
"    </a>",
"    ]. The role of liver biopsy in monitoring hepatotoxicity in patients treated with MTX has been controversial. One study of 54 patients with psoriasis or psoriatic arthritis treated with MTX for a mean of 6.9 years found that the use of laboratory tests alone could adequately identify liver toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    National organizations have published different recommendations concerning the role of liver biopsies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Dermatology (AAD) and the National Psoriasis Foundation do NOT require liver biopsies in all patients administered MTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. There are no specific guidelines for patients with PsA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H32#H32\">",
"       \"Treatment of psoriasis\", section on 'Hepatotoxicity and liver biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The American College of Rheumatology (ACR) has recommended pretreatment liver biopsies only for patients with a significant history of alcohol consumption, with persistently elevated liver enzymes, or with a history of chronic hepatitis B or C infection, with repeat biopsies as indicated by liver test abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/44\">",
"       44",
"      </a>",
"      ]. The latter guidelines were made specifically for patients with rheumatoid arthritis, who may have different liver sensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      than patients with PsA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally follow the guidelines of the American College of Rheumatology with regard to pretreatment biopsies but tend to perform repeat biopsies more commonly in patients with PsA than in those with rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link&amp;anchor=H5#H5\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\", section on 'Guidelines in other rheumatic diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caution is necessary in patients with impaired renal function. Patients with severely reduced glomerular filtration rates (eg, GFR &lt;20",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    serum creatinine &gt;3.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [300",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    should not receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ; those with less marked impairment may take the drug at a reduced dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H21#H21\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    is no longer considered an important medication in the treatment of PsA, given the availability of other more effective and well-tolerated agents. Sulfasalazine (sulphasalazine, salazopyrin) was developed specifically for the treatment of rheumatoid arthritis. Controlled studies suggested that it may be effective for extraaxial arthritis in the seronegative spondyloarthropathies, particularly PsA, when compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Sulfasalazine may also improve skin lesions in patients with PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/45,46,48,49\">",
"     45,46,48,49",
"    </a>",
"    ]. A year 2000 systematic review concluded that sulfasalazine had &ldquo;well-demonstrated published efficacy in PsA&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/50\">",
"     50",
"    </a>",
"    ]. However, in a 2006 systematic review of agents used in the treatment of PsA, while the dose and number of patients studied were quite adequate, the level of benefit was very modest (effect size for sulfasalazine of only 0.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/31\">",
"     31",
"    </a>",
"    ]. The following are some illustrative studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one small study, 24 patients with PsA were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/45\">",
"       45",
"      </a>",
"      ]. Both patient and physician assessment showed improvement at four and eight weeks in such variables as morning stiffness duration, joint scores, and 50-foot walking time. Disease activity returned to baseline after withdrawal of therapy, while the initiation of therapy in placebo patients led to clinical improvement. Skin lesions also improved in sulfasalazine treated patients.",
"     </li>",
"     <li>",
"      A large double-blind trial randomly assigned 351 patients with spondyloarthropathies, including patients with PsA, either to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/45\">",
"       45",
"      </a>",
"      ]. Although sustained beneficial effects were mild, the response rate in patients with peripheral arthritis at the last clinical visit (36 weeks) was significantly higher among patients treated with sulfasalazine than among those treated with placebo (59 versus 43 percent). Sulfasalazine was more effective in reducing pain in patients with PsA than in patients with reactive arthritis.",
"     </li>",
"     <li>",
"      The largest study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      in PsA randomly assigned 221 patients with PsA to sulfasalazine (2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/48\">",
"       48",
"      </a>",
"      ]. The outcome measure was a newly developed instrument, the Psoriatic Arthritis Response Criteria (PsARC), which requires improvement in two of four items: tender joints count, swollen joint count, patient global, and physician global. However, at least one of the two items must be a joint count, and there can be no worsening in the any of the four. Using these criteria, favorable responses were more frequent in the sulfasalazine group than in the placebo group (response rates of 58 versus 45 percent). However, there was no response in the individual components. Thus, this response can at best be classified as modest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all studies have found significant benefits with this agent. As an example, a systematic review demonstrated only a modest benefit with PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, in one report of 36 patients with PsA, no benefit to either skin or joints was observed compared with controls, and 40 percent of patients discontinued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    within three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/49\">",
"     49",
"    </a>",
"    ]. Moreover there was no advantage of sulfasalazine in prevention of joint damage. Also, sulfasalazine appears to have no beneficial effects on symptoms related to axial involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    required to control PsA may be higher than that used in rheumatoid arthritis; as a result, many patients with PsA do not tolerate sulfasalazine, despite the fact that it may be effective in those patients who are able to take it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/45,46,48,49\">",
"     45,46,48,49",
"    </a>",
"    ]. The major reasons for discontinuation of therapy are gastrointestinal side effects. In addition, the onset of drug-induced lupus and toxic epidermal necrolysis has been described in patients with psoriasis treated with sulfasalazine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Prior to instituting therapy with sulfasalazine, it is important to ascertain that the patient does not have an allergic history to sulfa drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Promising results with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    were noted in an uncontrolled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/53\">",
"     53",
"    </a>",
"    ]. A larger, multicenter, international study randomly assigned 190 patients to either leflunomide (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days followed by 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for 24 weeks. Those who received leflunomide had significantly more improvement in skin and joint disease than the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/54\">",
"     54",
"    </a>",
"    ]. The primary endpoint for the study was improvement PsARC, an index of PsA activity, which was achieved by 59 percent of the leflunomide-treated patients compared with 30 percent of the placebo-treated patients. Leflunomide was also effective in controlling skin disease, as measured by an improvement in Psoriasis Area and Severity Index (PASI) scores of 22 percent in the leflunomide-treated group, compared with 2.2 percent in the placebo-treated group. Unfortunately, the trial did not include assessment of radiographic progression.",
"   </p>",
"   <p>",
"    Diarrhea and increased serum aminotransferase levels were more frequent in the group receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , toxicities that have been noted in clinical trials of leflunomide in rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .) It is unknown whether leflunomide prevents progression of joint damage, as radiographs were not included in the assessment of patients in the study.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    can, therefore, be used in the management of patients with PsA. Our experience with leflunomide is that it is effective in about 40 percent of the patients. We use leflunomide in patients who have not adequately responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or who had adverse effects to methotrexate. In a number of jurisdictions, one is expected to use methotrexate and leflunomide before prescribing anti-tumor necrosis factor (TNF) agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is used in lower doses for psoriasis and PsA than for organ transplantation. Most patients receive between 2.5 and 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, usually in divided doses. The time to response is three to four months. Randomized, double-blind, controlled trials of cyclosporine A (CSA) are lacking. Evidence for the efficacy of CSA comes from two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One was a multicenter, prospective, open-label, uncontrolled trial in 55 patients treated for six months (mean dose of CSA, 2.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/55\">",
"       55",
"      </a>",
"      ]. Pain, number of painful and swollen joints, and duration of morning stiffness all decreased from baseline by 30 to 50 percent. A 50 percent decrease in psoriasis skin score and a 52 percent fall in serum C-reactive protein level were also noted.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      also appeared to be beneficial in an open-label study of 99 patients with PsA randomly assigned to CSA (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, initially, with an increase to a maximum of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (2000 mg per day), or to usual care (NSAIDs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &le;5 mg per day, and analgesics) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/56\">",
"       56",
"      </a>",
"      ]. After six months of observation, pain decreased more in those receiving CSA than in the sulfasalazine or usual care groups (-27, -17, and -12 mm on visual analog scale, respectively, p &lt;0.05 for CSA versus sulfasalazine and usual care). Tender and swollen joint counts were lower at the end of the study in those receiving CSA than in the usual care group, but CSA was not significantly better than sulfasalazine for these disease manifestations. Hypertension (5 of 36 patients), declining renal function (10 of 36 patients), and a variety of neurologic complaints (7 of 36 patients) were common in the CSA treated group. Skin disease improved more in those receiving CSA than in those receiving usual care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As illustrated above, CSA has significant renal toxicity, even in lower doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/23,57\">",
"     23,57",
"    </a>",
"    ]. Care is required to establish a pretreatment baseline for renal function, and ongoing monitoring of serum creatinine is needed during treatment with this agent. Dose reductions or discontinuation may be necessary to prevent irreversible renal damage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to the regimen of patients who have had an incomplete response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may result in additional improvement. This was the conclusion of a published trial in which 72 patients with PsA continued methotrexate and were randomly assigned to receive CSA or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/58\">",
"     58",
"    </a>",
"    ]. At 48 weeks of study, significantly more improvement in swollen joint counts, in skin involvement index (PASI), and in ultrasonographically detected synovitis was seen in the methotrexate plus cyclosporine group than in the methotrexate plus placebo group; less radiographic progression of joint damage occurred in those receiving the active combination than in the methotrexate plus placebo group (change in Larsen score of radiographs of +7.4 versus +1.7, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antimalarials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been anecdotal reports of exacerbation of skin lesions by the antimalarials. However, this concern was not confirmed in a case-controlled study, and it is not considered to be a problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/59\">",
"     59",
"    </a>",
"    ]. Either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , at a dose &le;3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , at a dose &le;6.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, may be used. Hydroxychloroquine is preferred in the United States because it is considered to have less of a risk of causing retinal toxicity. It takes up to three months for antimalarials to exert a therapeutic response. Patients should be advised to avoid the sun, and they must have their eyes checked at regular intervals by an ophthalmologist to permit early detection of retinal toxicity. Although used in the past, these medications are no longer recommended for use in the treatment of PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4,60\">",
"     4,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H16#H16\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Monitoring for toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gold compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular gold has been shown to be more effective than oral gold for the treatment of PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/61\">",
"     61",
"    </a>",
"    ]. Intramuscular gold is administered once a week at a dose of 50 mg for at least 20 weeks. Lower doses of 10 mg and 25 mg are usually given in the first two weeks to test for allergic reactions. Major side effects include bone marrow suppression and the nephrotic syndrome due to membranous nephropathy. Thus, blood and urine tests are done to look for these complications. The oral preparation comes in 3 mg tablets and is administered twice daily. The response usually occurs at five to six months. Although used in the past, these medications are no longer recommended for use in the treatment of PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4,60\">",
"     4,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25319?source=see_link\">",
"     \"Use of gold compounds in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19525?source=see_link\">",
"     \"Major side effects of gold\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is only one controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/62\">",
"     62",
"    </a>",
"    ]. This was a double-blind crossover study for 12 months, with patients randomly assigned to drug or to placebo for the first six months. Marked improvement in joint counts, grip strength, and morning stiffness was recorded in four of six patients studied, and moderate response was recorded in the other two. Complete clearing of skin lesions was noted in two of the six patients, and partial clearing was noted in four of the six. No improvement in skin or joint disease was noted in those on placebo. In our clinical experience, we have found this drug to be effective even in individuals unresponsive to other drugs. Indeed, in an uncontrolled study of 28 patients using azathioprine in our clinic, the drug was well-tolerated, and an improvement in actively inflamed joints was noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Psoralen and ultraviolet light (PUVA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggestion of benefit from PUVA therapy in PsA was noted in an uncontrolled series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/64\">",
"     64",
"    </a>",
"    ]. Although the arthritis improved, it seemed to do so primarily in those patients whose psoriasis improved. Thus, PUVA is used primarily in patients with severe psoriasis.",
"   </p>",
"   <p>",
"    Many patients receive the combination of PUVA and a DMARD. The efficacy and side effects associated with this approach are unclear. In our clinic, we have not noted any unusual adverse events combining PUVA with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . A group of experts has recommended that aggressive immunosuppression should not follow extensive phototherapy, especially PUVA, because of a heightened risk of malignant melanoma and of nonmelanoma skin cancer in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Retinoic acid derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoic acid derivatives take about four months to produce a response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/65\">",
"     65",
"    </a>",
"    ]. They are given in doses of 25 to 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    in either single or divided daily doses. Their main side effects include extreme dryness of the skin and mucous membranes and hyperlipidemia. Clinical trials were performed with etretinate, an agent that has been withdrawn from the market due to toxicity. The value of the retinoic acid derivative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    in PsA is uncertain. It should be noted that retinoic acid derivatives can produce extraskeletal bone deposition and can lead to joint pain in patients with psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor necrosis factor (TNF)-alpha is a potent cytokine that is critically involved in the inflammatory pathway and joint damage in PsA. The downregulation or inhibition of the effector functions of this cytokine reduces its direct action as well as the action of other proinflammatory cytokines. Clinical trials have proven the efficacy of TNF inhibition in psoriatic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23608?source=see_link\">",
"     \"Pathogenesis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    , a soluble p75 TNF-alpha receptor fusion protein that binds TNF, is approved for the treatment of patients with psoriatic or rheumatoid arthritis in Europe and the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have documented the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (25 mg twice weekly) compared with placebo for both skin and joint disease in patients with psoriatic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In one of the larger and longer trials, 205 patients with PsA were randomly assigned to receive either etanercept (25 mg subcutaneously twice weekly) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/69\">",
"     69",
"    </a>",
"    ]. Approximately one-half of the patients were also receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , which was continued during the study. Only seven subjects had a &ldquo;spondylitis-like subtype,&rdquo; and three had arthritis mutilans. The major results were the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACR20 responses at 12 and 24 weeks occurred in a significantly greater proportion of those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      than of those receiving placebo (59 versus 15 percent and 50 versus 13 percent, respectively).",
"     </li>",
"     <li>",
"      ACR50 and ACR70 responses at 24 weeks were more common in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      -treated patients (37 and 9 percent versus 4 and 1 percent, respectively).",
"     </li>",
"     <li>",
"      Function as assessed by Health Assessment Questionnaire (HAQ) Disability Index improved significantly more in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      -treated group than in the placebo group; the mean HAQ score declined by 54 versus 6 percent, respectively, by 24 weeks, with a mean absolute reduction of 0.6 points in patients on etanercept. Health-related quality of life as assessed by the physical component subscore of the SF-36 instrument also improved significantly more in those receiving etanercept (8 versus 1 percent).",
"     </li>",
"     <li>",
"      Psoriasis improved significantly more in those who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      than in the placebo group (mean improvement in the Psoriasis Area and Severity Index [PASI] score of 42 percent versus an 8 percent worsening, respectively).",
"     </li>",
"     <li>",
"      There was significantly less radiographic progression in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      group over one year of observation (mean change of -0.03 versus +1.0 in total Sharp radiographic score, respectively). During a subsequent year of open-label treatment with etanercept, the rate remained low in those initially treated with etanercept (mean adjusted change in total Sharp score of -0.38 from baseline to two years), and the rate of progression decreased for those who received placebo during the first year (mean adjusted change of -0.22 from one year to two years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There were four serious adverse events in each group. In the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      -treated patients, these were noncardiac chest pain, nephrolithiasis, multiple sclerosis, and syncope, occurring in one patient each.",
"     </li>",
"     <li>",
"      A three-year follow-up of patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      demonstrated that over 80 percent continued the medication and that 48 percent of the patients were in remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/71\">",
"       71",
"      </a>",
"      ]. These patients also exhibited improvement in dactylitis and enthesitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher initial doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    than are required for the joint disease may be of benefit for treatment of the skin manifestations. In a trial involving 752 patients with psoriasis and psoriatic arthritis, initial treatment with etanercept 50 mg twice weekly for 12 weeks led to more rapid clearing of skin disease than 50 mg once weekly, but the higher dose did not appear to offer greater benefit for the arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/72\">",
"     72",
"    </a>",
"    ]. Both groups were then treated from week 12 through 24 with 50 mg once weekly. Similar rates of serious adverse events and serious infections were seen in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    , a human and mouse chimeric anti-TNF-alpha antibody given parenterally via intravenous infusion, is effective in the management of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .) Benefits from infliximab in short-term, uncontrolled studies in patients with PsA have been encouraging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Patients refractory to other DMARDs may respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/78\">",
"     78",
"    </a>",
"    ]. A single intravenous dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    resulted in a substantial decrease in synovial macrophage infiltration and in a modest decrease in T cells in synovium when assessed by biopsy 48 hours following the infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    from three double-blind, controlled clinical trials in PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. In the two largest of these, the Infliximab Multinational Psoriatic Arthritis Controlled Trials (IMPACT and IMPACT 2 trials), 104 patients and 200 patients were randomly assigned to infliximab (5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IMPACT &mdash; The ACR20 response rates after 16 weeks of treatment were significantly better in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      group compared with the placebo group (65 versus 10 percent, respectively). Significantly more patients in the infliximab group also responded, as judged by the PsARC (75 versus 21 percent) and by the Disease Activity Score (DAS) (89 versus 25 percent). Dactylitis and enthesitis also improved with infliximab.",
"      <br/>",
"      <br/>",
"      Cutaneous psoriasis responded remarkably well, with 68 percent of the infliximab-treated patients achieving &ge;75 percent improvement in the Psoriasis Area and Severity Index (PASI), which was not achieved by any of the placebo-treated patients. Skin improvement was sustained to week 50. Seven patients withdrew due to adverse effects including infusion reaction, septic arthritis, tendon rupture, hepatic enzyme elevations, asthma, and discovery of a meningioma.",
"     </li>",
"     <li>",
"      IMPACT 2 &mdash; ACR20 response rates were significantly greater in those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      when assessed at 14 weeks (58 versus 11 percent) compared with placebo. The infliximab group also had a significantly greater proportion of patients who experienced &ge;75 percent improvement in PASI (64 versus 2 percent), and the proportion of patients with active dactylitis (18 versus 30 percent) and enthesitis (22 versus 34 percent) was significantly smaller.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic progression was less in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    -treated patients in both of the IMPACT and IMPACT 2 trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/25,83\">",
"     25,83",
"    </a>",
"    ]. Health-related quality of life and physical function were significantly improved in those treated with infliximab in the IMPACT 2 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/25\">",
"     25",
"    </a>",
"    ]. These benefits were maintained at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/84\">",
"     84",
"    </a>",
"    ] and at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , a fully humanized monoclonal anti-tumor necrosis factor (TNF) antibody, is also effective in patients with PsA. This has been shown in several randomized trials, in observational studies, and in a meta-analysis of individual patient data from trials in patients with moderate to severe psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/86-91\">",
"     86-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials illustrate the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest randomized trial, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      Effectiveness in Psoriatic Arthritis Trial (ADEPT), 315 patients were randomly assigned to adalimumab (40 mg every other week subcutaneously) or to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/86\">",
"       86",
"      </a>",
"      ]. A significantly greater proportion of patients receiving adalimumab achieved an ACR20 response after six months of treatment (57 versus 15 percent). Skin disease was also better controlled by adalimumab (PASI 75 achieved in 59 versus 1 percent). Additionally, adalimumab treatment was associated with less radiologic progression, with better quality of life, and with improvement in fatigue.",
"      <br/>",
"      <br/>",
"      Alanine aminotransferase (ALT) elevations occurred more frequently among the adalimumab-treated subjects; most were transient and returned to normal during continued treatment. In a 48-week open-label extension of this study, 151 patients experienced improvement in joints, skin manifestations, reduced disability, and inhibited radiographic progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/87\">",
"       87",
"      </a>",
"      ]. Independent predictors for radiological progression in the ADEPT trial were the baseline serum C-reactive protein (CRP) level and degree of damage, while use of adalimumab was protective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benefit in patients who had previously failed a disease-modifying antirheumatic drug (DMARD) was shown in a randomized trial of 100 patients, which compared treatment using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (40 mg every other week) with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/89\">",
"       89",
"      </a>",
"      ]. At week 12, a significantly greater proportion of patients receiving adalimumab achieved an ACR20 (39 versus 16 percent) or a PsARC response (51 versus 24 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Golimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    , a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, was effective for treating psoriasis and PsA in the multinational, double-blind, placebo-controlled GO-REVEAL trial involving 405 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/92\">",
"     92",
"    </a>",
"    ]. Stable doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , nonsteroidal antiinflammatory drugs (NSAIDs), and glucocorticoids in a dose equivalent to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &le;10 mg daily were allowed.",
"   </p>",
"   <p>",
"    After 14 weeks,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    (50 mg or 100 mg subcutaneously every four weeks through week 20) was more effective than placebo in achieving both an ACR20 response (51 and 45 versus 9 percent) and, in patients with over 3 percent body surface area affected by psoriasis at baseline, a 75 percent reduction in the PASI (40 and 58 versus 3 percent). Significant improvement in nail symptoms, dactylitis, and enthesitis were observed, as were improvements in other secondary end points.",
"   </p>",
"   <p>",
"    At one year, the drug was well-tolerated, and patients maintained skin and joint responses, improved physical function, and inhibition of structural progression reported at 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20086242\">",
"    <span class=\"h3\">",
"     Long-term effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained benefit from these drugs has been shown among patients with PsA studied using several drug registries and several other studies. The Spanish registry (BIOBADASER) included 570 patients, the majority of whom were taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    . Drug survival was 73 percent at three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/94\">",
"     94",
"    </a>",
"    ]. The Norwegian registry included 172 patients with PsA, of whom 75 percent continued on anti-TNF agents for at least a year. Concomitant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was associated with persistence with the anti-TNF agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the British registry (BSRBR), 566 patients were started on anti-TNF agents, the majority on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . The mean follow-up for all patients was 2.3 patient-years, reflecting the time that each drug became readily available. Of all PsA patients on anti-TNF agents, 422 completed at least 12 months of follow-up, 75 percent remaining on the initial drug. The main reasons for discontinuations included inefficacy and toxicity. Patients who switched remained on their second drug. Overall ACR20 response was 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Danish registry of 764 PsA patients treated with their first TNF-alpha inhibitor in clinical practice, the median drug survival was 2.9 years. The ACR50 response rate was 45 percent. Increased CRP at baseline was associated both with good treatment responses and with continued treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/3\">",
"     3",
"    </a>",
"    ]. However, it should be noted that CRP should not be used as the only indicator for use of anti-TNF agents in PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 95 patients treated with anti-TNF agents for at least one year demonstrated that most of the PsA patients (more than 70 percent) responded to TNF-alpha blockers within three months. Among the non-responders at three months, a significant proportion (65 percent) achieved clinical response after 12 months of treatment. First use of TNF-alpha blockers and number of swollen joint count at onset of the treatment predicted response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/97\">",
"     97",
"    </a>",
"    ]. A five-year open-label study of 65 patients (30 on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , 25 on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and 10 on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ) also showed significant improvements in PsARC, PASI 70, PASI 90, DAS28, and ACR50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of experimental approaches have been tried in PsA:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Alefacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alefacept, the lymphocyte function-associated",
"    <span class=\"nowrap\">",
"     antigen-3/immunoglobulin",
"    </span>",
"    G fusion protein (LFA3-Ig), is beneficial for plaque psoriasis and has also been effective in patients with psoriatic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H28956885#H28956885\">",
"     \"Treatment of psoriasis\", section on 'Alefacept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benefit in psoriatic arthritis was shown in a randomized trial that assigned 185 patients in a 2:1 ratio to receive intramuscular alefacept (15 mg per week) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) or placebo plus MTX. A greater proportion of patients in the alefacept-MTX group achieved an ACR20 response at week 24 compared with those in the placebo-MTX group (54 versus 23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/100\">",
"     100",
"    </a>",
"    ]. The drug was well-tolerated, with a similar incidence and severity of side effects in both treatment groups. Nasopharyngitis and upper respiratory tract infections were the most frequent adverse events, and there were no serious infections in either group.",
"   </p>",
"   <p>",
"    Additional benefit was seen in an open-label extension of the study, in which the number of patients receiving alefacept who achieved ACR50 and ACR70 increased after their second course of treatment, although there was no further increase in the number of patients who achieved an ACR20 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Efalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efalizumab, an antibody directed against CD11a, is another agent that interferes with T-cell function and that works well in psoriasis. In contrast, efalizumab was not more effective than placebo in a multicenter randomized control trial of patients with PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/102\">",
"     102",
"    </a>",
"    ]. Further evidence of lack of efficacy is the observation that PsA develops in patients treated successfully with efalizumab for psoriatic skin disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efalizumab has been voluntarily withdrawn from the United States market because of a potential risk to patients of developing progressive multifocal leukoencephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/104\">",
"     104",
"    </a>",
"    ]. Its use has also been suspended in other countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Ustekinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     Ustekinumab",
"    </a>",
"    is a human monoclonal antibody to the shared p40 subunit of interleukin (IL)-12 and IL-23, which interferes with receptor binding to immune cells, and has shown benefit in both psoriasis and psoriatic arthritis. IL-23 is important in triggering the production of IL-17, which has a role in immune regulation and in joint injury mediation.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    in psoriatic arthritis was assessed in a study that randomly assigned 146 patients to receive either ustekinumab or placebo (76 and 70 patients, respectively) once weekly for four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/105\">",
"     105",
"    </a>",
"    ]. A greater number of patients who received ustekinumab achieved the primary outcome measure, an ACR20 response at 12 weeks (42 versus 14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/105\">",
"     105",
"    </a>",
"    ]. In the majority of the patients, the improvement was maintained through 36 weeks. There were no opportunistic infections or deaths, and a small number of serious adverse events were seen in both groups.",
"   </p>",
"   <p>",
"    Phase III trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    in patients with PsA who are na&iuml;ve to anti-TNF agents (the Summit 1 trial) and in patients with an inadequate response to an anti-TNF agent (the Summit 2 trial) will provide additional information regarding this agent when they are reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7013395\">",
"    <span class=\"h3\">",
"     IL-17 blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several monoclonal antibodies that target the interleukin (IL)-17 pathway are under study for the treatment of psoriasis and psoriatic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/106-109\">",
"     106-109",
"    </a>",
"    ]. Preliminary findings suggest that at least two of these three reagents, the monoclonal anti-IL-17A monoclonal antibodies ixekizumab and secukinumab, may be of benefit in the treatment of psoriatic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/106,109\">",
"     106,109",
"    </a>",
"    ]. Further trials are required to establish the efficacy and safety of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20086343\">",
"    <span class=\"h3\">",
"     Abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    (CTLA4-Ig), a selective T-cell costimulation modulator used for the treatment of rheumatoid arthritis, has also shown benefit for patients with PsA. In a phase II trial, 170 patients with an inadequate response to a nonbiologic disease-modifying antirheumatic drug (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), a biologic agent (usually a TNF inhibitor), or both were randomly assigned to receive one of three doses of abatacept or placebo; an ACR20 response was achieved significantly more often after six months of therapy among patients treated with abatacept (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered intravenously in three initial doses at two week intervals and then every four weeks) compared with those receiving placebo (48 versus 19 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal treatment response was at the same dose used for rheumatoid arthritis in adults and for juvenile idiopathic arthritis (10",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    Modest improvements in skin disease were also seen, as were improvements in findings on magnetic resonance imaging of affected joints in the hands or feet. Safety profiles and drug discontinuation rates were similar among treatment and placebo groups. Additional study is needed, given the limited size and duration of the trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Other experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional medications and other modalities have been studied, with the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conflicting results have been noted for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      treatment. Two controlled studies with random patient assignment have been reported; in one, there was benefit, while, in the other, there was not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/111,112\">",
"       111,112",
"      </a>",
"      ]. A systematic review concluded that further trials were needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Controlled trials of fish oil or a combination of fish and plant seed oils have not shown benefit in psoriatic arthritis or psoriasis, despite promising results in observational studies and measurable alterations in prostaglandin metabolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/113-115\">",
"       113-115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apremilast is a novel orally administered phosphodiesterase-4 inhibitor that suppresses multiple proinflammatory mediators and cytokines involved in the innate and adaptive immunity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/116\">",
"       116",
"      </a>",
"      ]. In a preliminary report of a phase II trial, an ACR20 was achieved more frequently with active drug than with placebo treatment (44 versus 12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/117\">",
"       117",
"      </a>",
"      ]. Most side effects were mild; diarrhea was the most prominent. Additional studies are required.",
"     </li>",
"     <li>",
"      Small observational studies or case reports have suggested benefit with various agents that require further evaluation. These include oral vitamin D3,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      , extracorporeal photochemotherapy, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/118-121\">",
"       118-121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The addition of balneotherapy (mud packs and sulfur baths) to bathing in the Dead Sea and sun exposure provides additional benefit to that seen with bathing and sun alone in three- or four-week treatment programs, particularly for inflammatory back pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/122,123\">",
"       122,123",
"      </a>",
"      ]. Benefits can still be observed in arthritis and back pain, regardless of the addition of balneotherapy, six months following treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a patient with psoriatic arthritis (PsA) is to first assess the degree of disease activity and damage and to identify comorbidities (diabetes, metabolic syndrome, fatty liver, coronary artery disease) that may affect overall health and treatment selection. Specifically, screening for cardiovascular risk factors (lipids, blood pressure, and smoking), weight loss counseling for patients with elevated body mass index (BMI), and ultrasound of the liver for patients with liver function tests (LFTs) greater than three times the upper limit of normal should be performed in each patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/124\">",
"     124",
"    </a>",
"    ]. All patients should be referred for physical and occupational therapy, should be encouraged to exercise, and, if needed, should be referred for orthotics. Patients should be educated as to the nature of their condition and to the effect of stress on their disease. They should also be instructed about the use of topical and oral medications, about the need for regular administration, and about joint protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Mild disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mild disease, we administer nonsteroidal antiinflammatory drugs (NSAIDs). We tend to use enteric-coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    for patients with peripheral arthropathy, and we tend to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33512?source=see_link\">",
"     tolmetin",
"    </a>",
"    for patients with axial disease. The experience with the COX 2 selective inhibitors suggests that they are neither better tolerated nor more effective than the other NSAIDs. Concerns with the cardiovascular toxicity of these drugs have led to the removal of both valdecoxib and rofecoxib from the market. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , a sulfonamide-containing agent, should not be given to individuals with a known severe allergy to sulfonamide-containing antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Use of DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A traditional disease-modifying antirheumatic drug (DMARD) is given if the arthritis remains active despite NSAIDs. If the patient demonstrates five or more swollen joints at the first visit,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    (LEF) are introduced and are increased to tolerance or to the maximum recommended dose (25",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    for MTX and 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for LEF). If doses of MTX greater than 17.5",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    are required, the subcutaneous route, which can be self-administered, is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/125\">",
"     125",
"    </a>",
"    ]. MTX is the preferred agent. However, there are patients who refuse to take MTX because they consider it &ldquo;chemotherapy,&rdquo; and there are others who refuse to give up alcohol intake. In such patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may be used if there is no known allergy to sulfa drugs. None of these medications has been shown to prevent progression of clinical or radiological damage.",
"   </p>",
"   <p>",
"    For patients whose joint count does not improve after three months of treatment with MTX, we use LEF if it is required by the funding agency. However, we treat with a TNF inhibitor if LEF is contraindicated or if there are no financial issues. Other DMARDs that may be used include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . There is consensus among experts that TNF inhibitors should be used after the failure of an adequate therapeutic trial of one traditional DMARD.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    have regulatory approval for the treatment of PsA. Etanercept (50",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    subcutaneously [SQ]) or adalimumab (40 mg SQ every other week) may be preferred by some patients for convenience; others prefer not to have frequent injections and prefer infliximab, which is given by infusion at eight-week intervals. In contrast to RA, MTX can be discontinued in PsA patients who respond to anti-TNF therapy, and it is not uncommon for patients to be on anti-TNF monotherapy and to experience sustained responses in the skin and joints. One important exception is patients treated with infliximab, who may require concomitant MTX to lessen the likelihood of tolerance to infliximab.",
"   </p>",
"   <p>",
"    Other modalities are reserved for patients who either do not respond to or demonstrate toxic reactions to the above medications. Thus, we have smaller numbers of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , PUVA, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    All anti-TNF agents may be added to ongoing MTX therapy, although no published studies have demonstrated synergy with these agents in patients with PsA. Screening for latent tuberculosis (TB) prior to beginning therapy with anti-TNF agents is necessary, and those with evidence of prior tuberculous chest infection or with a positive skin test for TB will usually require prophylactic antituberculous therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An expert panel has noted the comparable effectiveness of the three TNF inhibitors listed above in the treatment of peripheral arthritis and in the inhibition of radiographic progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4\">",
"     4",
"    </a>",
"    ]. Similar observations were noted in a meta-analysis of randomized, controlled trials with anti-TNF agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     GRAPPA recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international group of rheumatologists and dermatologists, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), has made treatment recommendations for psoriasis and PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4,60\">",
"     4,60",
"    </a>",
"    ]. These recommend that therapeutic decisions be based upon the severity of the disease manifestations, including involvement of peripheral joints, skin, and nails; axial disease; enthesitis; and dactylitis. For each patient, the most severe manifestation dictates the therapeutic decision. Our recommendations are generally consistent with these guidelines.",
"   </p>",
"   <p>",
"    As examples, the GRAPPA guidelines recommend the use of TNF inhibitors in the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with greater than five actively inflamed joints who have functional disability and radiographic changes",
"     </li>",
"     <li>",
"      Patients with axial involvement that is not responsive to NSAID treatment",
"     </li>",
"     <li>",
"      Patients with a high PASI score and a severely affected quality of life",
"     </li>",
"     <li>",
"      Patients who have enthesitis and dactylitis that do not respond to NSAIDs and locally injected glucocorticoids and for whom there is no evidence for nonbiologic DMARD efficacy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to those requiring a TNF inhibitor, topical medications or light treatments may be sufficient for a patient with minimal psoriasis that does not affect quality of life or functional capacity.",
"   </p>",
"   <p>",
"    Gold salts and antimalarials, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , are not recommended for treatment of PsA.",
"   </p>",
"   <p>",
"    These recommendations have also been used to develop quality indicators for the management of PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191776653\">",
"    <span class=\"h3\">",
"     EULAR treatment recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the European League Against Rheumatism (EULAR) are centered on five overarching principles, 10 specific recommendations, and a treatment algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/127\">",
"     127",
"    </a>",
"    ] . Specific treatment recommendations are outlined for peripheral arthritis, axial disease, dactylitis, and enthesitis, along with a consideration of comorbidities in the treatment approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     British Society for Rheumatology TNF inhibitor guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A guideline for the use of anti-TNF therapy in PsA, developed by a working group of the British Society for Rheumatology, suggests a longer trial of nonbiologic DMARDs prior to anti-TNF therapy (six versus three months with at least two months at a &ldquo;standard target dose&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/128\">",
"     128",
"    </a>",
"    ]. In addition to the usual contraindications to the use of anti-TNF therapies, the British guideline also recommends caution in use of these agents in patients with prior PUVA therapy (&gt;1000 joules), due to an increased risk of nonmelanoma skin cancer; in",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients, due to a general lack of data on the safety of anti-TNF therapy in this setting; and in patients with heart failure of American Heart Association grade III or IV. The full text of the guideline is accessible at the following internet address:",
"    <a class=\"external\" href=\"file://rheumatology.oxfordjournals.org/content/44/3/390.full\">",
"     file://rheumatology.oxfordjournals.org/content/44/3/390.full",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Other modalities are reserved for patients who either do not respond to or demonstrate toxic reactions to the above medications. Thus, we have smaller numbers of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , PUVA, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Role of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of oral glucocorticoids in patients with PsA should be avoided, since there is a chance of developing pustular psoriasis; in addition, there appears to be interference with the effect of other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/25,129\">",
"     25,129",
"    </a>",
"    ]. Care should be taken in patients who require intraarticular glucocorticoid injections to avoid injection through psoriatic plaques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Long-term effect of DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some of the medications listed above have demonstrated the ability to reduce inflammatory joint activity in the short term, it remains to be seen whether they actually modify the disease process in the long term. Most of the investigations carried out in PsA have been short-term, with trials usually lasting from eight weeks to three to six months. Two case-controlled, retrospective studies attempted to evaluate the efficacy of gold and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for the prevention of radiological progression in PsA but were unable to demonstrate benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/36,130\">",
"     36,130",
"    </a>",
"    ]. Prospective studies with anti-TNF agents have been more promising based upon short-term trials with radiographic data and outcomes that include dactylitis and enthesitis and upon findings in rheumatoid arthritis, but long-term data on DMARDs are lacking in psoriatic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Role of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of reports concerning the epidemiology and efficacy of surgery in patients with PsA. One study of 440 patients with PsA revealed that 31 (7 percent) had undergone musculoskeletal surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/131\">",
"     131",
"    </a>",
"    ]. The probability for surgery increased with disease duration. Compared with those not requiring an operative procedure, surgery patients had more active inflammation and radiological evidence of damage. However, quality of life was similar between the two groups.",
"   </p>",
"   <p>",
"    Joint replacements have been performed when PsA leads to damage that limits movement and that impairs function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/132\">",
"     132",
"    </a>",
"    ]. A review of the types of procedures performed in a cohort of patients with PsA documented the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/133\">",
"     133",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with oligoarticular disease usually underwent hip or knee surgery.",
"     </li>",
"     <li>",
"      Those with distal joint disease usually had hand surgery.",
"     </li>",
"     <li>",
"      Patients with polyarticular disease underwent a variety of procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not clear whether PsA poses an additional risk, particularly for infection; the study reported only one infection in 71 procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While initial results for total hip replacement in one survey were noted to be good, there appeared to be excess bone proliferation with a decrease in mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/134\">",
"     134",
"    </a>",
"    ]. We have also been disappointed with small joint arthroplasty in these patients, since they appear to fibrose around the prosthesis. In general, patients with PsA do not do as well as expected with post-reconstructive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be educated as to the nature of their condition and to the effect of stress on their disease. They should also be instructed about the use of topical and oral medications, about the need for regular administration, and about joint protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RESPONSE TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus among experts is that measures that were developed to assess the response to treatment in rheumatoid arthritis can be used for PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4\">",
"     4",
"    </a>",
"    ]. Recommended response criteria include the ACR20, ACR50, and ACR70 (from the American College of Rheumatology [ACR]), as well as the Disease Activity Score using a 28 joint count (DAS28) and the European League Against Rheumatism (EULAR) response criteria. However, although the DAS28 clearly distinguishes between drug-treated and placebo-treated patients in clinical trials, it may not be appropriate for PsA patients, many of whom have foot and distal interphalangeal (DIP) joint involvement that is not recorded in the DAS28. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361032#H7361032\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Composite indices for disease activity assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361102#H7361102\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Response criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed review of assessment methods that have been used",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proposed for research purposes to guide development of drugs and biologic agents is beyond the scope of this topic. However a review published in 2004 addressed the issue and highlighted the need to develop standardized approaches to assessing the activity of disease in the following domains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/135\">",
"     135",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral arthritis (joint pain, tenderness, and swelling)",
"     </li>",
"     <li>",
"      Clinical severity of joint damage (including restricted motion, ankylosis, or unstable joints)",
"     </li>",
"     <li>",
"      Measures of spinal mobility",
"     </li>",
"     <li>",
"      Dactylitis",
"     </li>",
"     <li>",
"      Tendonitis",
"     </li>",
"     <li>",
"      Enthesitis",
"     </li>",
"     <li>",
"      Skin disease",
"     </li>",
"     <li>",
"      Functional ability (disability)",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A module from the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) on PsA recommended the following &ldquo;core set&rdquo; of domains to be included in clinical trials and observational cohort studies in PsA: peripheral joint assessment, skin assessment, patient global assessment, pain, physical function, and quality of life. The following domains were considered important but not mandatory: dactylitis, enthesitis, nail assessment, spinal assessment, radiology, physician global assessment, and acute phase reactants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indices of response to treatment that have been employed are those that have been used primarily in patients with RA which have been used in PsA clinical trials (eg, ACR20, ACR50, and ACR70), the EULAR criteria based upon the DAS, and those developed more specifically for studying treatment responses in patients with PsA (eg, the PsARC). A study analyzing the data from the first",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    randomized controlled trials demonstrated that all these indices function well in PsA. It was also shown that CRP did not function well in PsA. Although the DAS28 functioned well, a reduction of joint count to 28 would eliminate 25 percent of the patients included in the clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A simplified composite measure for evaluating clinical trial outcomes, the Psoriatic Arthritis Joint Activity Index (PsAJAI), has been developed based upon the data from phase III randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/137\">",
"     137",
"    </a>",
"    ]. The PsAJAI rated responses based upon a weighted sum of 30 percent improvement in core measures with weights of two given to the joint count measure, the CRP laboratory measure, and the physician global assessment of disease activity measure, while 30 percent improvement in measures of pain, patient global assessment of disease activity, and the HAQ are given one.",
"   </p>",
"   <p>",
"    Another outcome measure to assess response in PsA in clinical trials, the Composite Psoriatic Disease Activity Index (CPDAI), was developed, based upon the GRAPPA treatment recommendation grid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4,138,139\">",
"     4,138,139",
"    </a>",
"    ]. Numerical values were assigned to the different grades of the disease manifestations proposed by GRAPPA to up to a maximum score of 15.",
"   </p>",
"   <p>",
"    Minimal disease activity (MDA) criteria have been developed and validated in PsA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/140,141\">",
"     140,141",
"    </a>",
"    ]. To achieve MDA, a patient must demonstrate five of the seven following criteria: tender joint count &le;1; swollen joint count &le;1; Psoriasis Area and Severity Index &le;1 or body surface area &le;3; patient pain visual analogue score (VAS) &le;15; patient global disease activity VAS &le;20; health assessment questionnaire &le;0.5; or tender entheseal points &le;1.",
"   </p>",
"   <p>",
"    Plain film radiography, magnetic resonance imaging, and ultrasonography may provide useful information for responding to treatment and for assessing the effect of therapy on preventing joint destruction or ankylosis. There are no validated indices based upon these imaging techniques that can be recommended. However, in randomized controlled trials, the Sharp method for evaluating radiographs and the van der Heijde modification of that method have been used successfully [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/18/40234/abstract/142\">",
"     142",
"    </a>",
"    ]. In clinical practice, plain film radiography of clinically involved peripheral joints, the sacroiliac joints, and the spine are used to assess the extent and progression of disease at these sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/52/835?source=see_link\">",
"       \"Patient information: Psoriatic arthritis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/36/36419?source=see_link\">",
"       \"Patient information: Psoriatic arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20469265\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psoriatic arthritis (PsA) has variable disease expression; a significant proportion of patients may develop destructive and potentially disabling disease. Factors predicting a poor prognosis include a higher number of actively inflamed joints, an elevated erythrocyte sedimentation rate, failure of previous medication trials, the presence of joint damage, loss of function, and diminished quality of life. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for progressive joint damage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the treatment of PsA includes therapy for both skin and joint disease aimed at controlling inflammation and at preventing discomfort and damage. There are differences in response between skin and joints with some agents. Disease-free remissions may occur, but relapses are common within several years. Patients with psoriatic arthritis may be at increased risk for cardiovascular disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      death. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Second-line therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'TNF inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Experimental therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatments for psoriatic arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Remission'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of PsA usually begins with nonsteroidal antiinflammatory drugs (NSAIDs). There have been no systematic trials of NSAIDs in PsA, although they can control the mild inflammatory features of PsA and may also relieve symptoms of spondylitis. While there has been some concern that NSAIDs may aggravate the skin psoriasis, there are no randomized trials that have documented this phenomenon. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple agents have been used to treat PsA, including nonbiologic (traditional) disease-modifying antirheumatic drugs (DMARDs); biologic DMARDs, including tumor necrosis factor (TNF) inhibitors and other agents; and other therapies that are useful in psoriasis that is refractory to initial therapies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Second-line therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'TNF inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Experimental therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to PsA includes an assessment of the degree of disease activity and damage; referral of all patients for physical and occupational therapy, including exercise instruction, joint protection, and appropriate orthotics; education regarding the disease and the effects of stress on the illness; and instruction in the proper use of topical and oral medications. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use NSAIDs alone initially in patients with mild disease (no greater than four swollen joints), but a nonbiologic DMARD, preferably",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX), is given if the arthritis remains active despite NSAIDs.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      may be used as alternatives to MTX, if needed. None of these medications has been shown to prevent progression of clinical or radiological damage. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Mild disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Use of DMARDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients whose joint count does not improve after three months of treatment with MTX, we add a TNF inhibitor to MTX, usually",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , depending upon patient preference for route of administration. Alternatively, if use of a TNF inhibitor is precluded by regulatory or financial considerations, we will use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      or another alternative agent, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . Use of oral glucocorticoids in patients with PsA should be avoided. Long-term data are lacking regarding the ability of nonbiologic or biologic DMARDs to prevent progressive joint injury. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Use of DMARDs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Role of glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Long-term effect of DMARDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a paucity of reports concerning the epidemiology and efficacy of surgery in patients with PsA. Joint replacements have been performed when PsA leads to damage that limits movement and that impairs function. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Role of surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outcome measures used to assess treatment responses in PsA include those used in rheumatoid arthritis, although the limitations of these measures should be recognized. In clinical practice, plain film radiography of clinically involved peripheral joints, the sacroiliac joints, and the spine are used to assess the extent and progression of disease at these sites. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Assessment of response to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/1\">",
"      Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med 1987; 62:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/2\">",
"      McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/3\">",
"      Glintborg B, &Oslash;stergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor &alpha; therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/4\">",
"      Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/5\">",
"      Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2:ii14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/6\">",
"      Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999; 26:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/7\">",
"      Queiro-Silva R, Torre-Alonso JC, Tintur&eacute;-Eguren T, L&oacute;pez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/8\">",
"      Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995; 22:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/9\">",
"      Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007; 66:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/10\">",
"      Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/11\">",
"      Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995; 38:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/12\">",
"      Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998; 25:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/13\">",
"      Rahman P, Snelgrove T, Peddle L, et al. A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. Arthritis Rheum 2008; 58:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/14\">",
"      Bogliolo L, Alpini C, Caporali R, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/15\">",
"      Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/16\">",
"      Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J Rheumatol 2001; 28:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/17\">",
"      Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/18\">",
"      Ali Y, Tom BD, Schentag CT, et al. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007; 56:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/19\">",
"      Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008; 26:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/20\">",
"      Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/21\">",
"      Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol 2010; 37:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/22\">",
"      Bruce IN, Gladman DD. Psoriatic arthritis: recognition and management. BioDrugs 1998; 9:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/23\">",
"      Cu&eacute;llar ML, Citera G, Espinoza LR. Treatment of psoriatic arthritis. Baillieres Clin Rheumatol 1994; 8:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/24\">",
"      Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012; 51:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/25\">",
"      Goodfield M. Skin lesions in psoriasis. Baillieres Clin Rheumatol 1994; 8:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/26\">",
"      Ash ZR, Tinazzi I, Gallego CC, et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis 2012; 71:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/27\">",
"      Abel EA, DiCicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/28\">",
"      Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/29\">",
"      Griffiths CE. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol 1997; 36:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/30\">",
"      Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/31\">",
"      Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/32\">",
"      Baranauskaite A, Raffayov&aacute; H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012; 71:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/33\">",
"      Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/34\">",
"      Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/35\">",
"      Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008; 35:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/36\">",
"      Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995; 22:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/37\">",
"      Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/38\">",
"      Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/39\">",
"      Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009; 48:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/40\">",
"      Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/41\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/42\">",
"      Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 1996; 55:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/43\">",
"      Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/44\">",
"      Kremer JM, Alarc&oacute;n GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/45\">",
"      Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/46\">",
"      Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995; 22:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/47\">",
"      Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/48\">",
"      Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/49\">",
"      Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998; 25:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/50\">",
"      Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000; :CD000212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/51\">",
"      Veale DJ, Ho M, Morley KD. Sulphasalazine-induced lupus in psoriatic arthritis. Br J Rheumatol 1995; 34:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/52\">",
"      Jullien D, Wolkenstein P, Roupie E, et al. Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication. Arthritis Rheum 1995; 38:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/53\">",
"      Scarpa R, Manguso F, Oriente A, et al. Leflunomide in psoriatic polyarthritis. J Clin Rheumatol 2002; 8:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/54\">",
"      Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/55\">",
"      Mahrle G, Schulze HJ, Br&auml;utigam M, et al. Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol 1996; 135:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/56\">",
"      Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/57\">",
"      Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/58\">",
"      Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/59\">",
"      Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992; 19:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/60\">",
"      Kavanaugh AF, Ritchlin CT, GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006; 33:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/61\">",
"      Palit J, Hill J, Capell HA, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990; 29:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/62\">",
"      Levy JJ, Paulus HE, Barnett EV, et al. A double-blind controlled evaluation of azathioprine treatment in the rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972; 15:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/63\">",
"      Lee JC, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol 2001; 7:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/64\">",
"      Perlman SG, Gerber LH, Roberts RM, et al. Photochemotherapy and psoriatic arthritis. A prospective study. Ann Intern Med 1979; 91:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/65\">",
"      Klinkhoff AV, Gertner E, Chalmers A, et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989; 16:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/66\">",
"      Heiberg MS, Kaufmann C, R&oslash;devand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007; 66:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/67\">",
"      Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008; 35:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/68\">",
"      Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/69\">",
"      Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/70\">",
"      Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/71\">",
"      de Vlam K, Lories RJ, Janssen S. Sustained improvement in clinical measures of psoriatic arthritis in etanercept: 3-year results in an inception cohort. (Abstract) Ann Rheum Dis 2008; 67(suppl II):525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/72\">",
"      Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340:c147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/73\">",
"      Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/74\">",
"      Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/75\">",
"      Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/76\">",
"      Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/77\">",
"      Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/78\">",
"      Salvarani C, Cantini F, Olivieri I, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/79\">",
"      Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/80\">",
"      Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/81\">",
"      Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/82\">",
"      Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/83\">",
"      Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/84\">",
"      Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/85\">",
"      Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/86\">",
"      Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/87\">",
"      Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/88\">",
"      Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010; 12:R113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/89\">",
"      Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/90\">",
"      Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/91\">",
"      Mease PJ, Signorovitch J, Yu AP, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. Dermatology 2010; 220:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/92\">",
"      Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/93\">",
"      Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012; 64:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/94\">",
"      Carmona L, G&oacute;mez-Reino JJ, BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8:R72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/95\">",
"      Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/96\">",
"      Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11:R52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/97\">",
"      Eder L, Chandran V, Schentag CT, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford) 2010; 49:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/98\">",
"      Saougou I, Markatseli TE, Papagoras C, et al. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011; 40:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/99\">",
"      Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002; 46:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/100\">",
"      Mease PJ, Gladman DD, Keystone EC, Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/101\">",
"      Mease PJ, Reich K, Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009; 60:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/102\">",
"      Papp KA, Caro I, Leung HM, et al. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007; 11:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/103\">",
"      Viguier M, Richette P, Aubin F, et al. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis Rheum 2008; 58:1796.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market. file://www.fda.gov/bbs/topics/NEWS/2009/NEW01992.html (Accessed on April 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/105\">",
"      Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/106\">",
"      Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/107\">",
"      Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/108\">",
"      Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/109\">",
"      McInnes I, Sieper J, Braun J. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2011; 63:S306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/110\">",
"      Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/111\">",
"      Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987; 14:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/112\">",
"      McKendry RJ, Kraag G, Seigel S, al-Awadhi A. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 1993; 52:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/113\">",
"      Peloso P, Gladman DD. Fish oils in the treatment of psoriatic arthritis: An open study (abstract). Arthritis Rheum 1992; 35(Suppl 9):S225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/114\">",
"      S&oslash;yland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med 1993; 328:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/115\">",
"      Veale DJ, Torley HI, Richards IM, et al. A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. Br J Rheumatol 1994; 33:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/116\">",
"      Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/117\">",
"      Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/118\">",
"      Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum 1990; 33:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/119\">",
"      Buskila D, Sukenik S, Holcberg G, Horowitz J. Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia. J Rheumatol 1991; 18:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/120\">",
"      de Misa RF, Aza&ntilde;a JM, Harto A, et al. Psoriatic arthritis: one year of treatment with extracorporeal photochemotherapy. J Am Acad Dermatol 1994; 30:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/121\">",
"      Grundmann-Kollmann M, Mooser G, Schraeder P, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/122\">",
"      Sukenik S, Giryes H, Halevy S, et al. Treatment of psoriatic arthritis at the Dead Sea. J Rheumatol 1994; 21:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/123\">",
"      Elkayam O, Ophir J, Brener S, et al. Immediate and delayed effects of treatment at the Dead Sea in patients with psoriatic arthritis. Rheumatol Int 2000; 19:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/124\">",
"      Johnsson H, McInnes IB, Sattar N. Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. Ann Rheum Dis 2012; 71:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/125\">",
"      Balis FM, Mirro J Jr, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/126\">",
"      Kavanaugh A, Ritchlin C, Boehncke WH. Quality indicators in psoriatic arthritis. Clin Exp Rheumatol 2007; 25:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/127\">",
"      Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/128\">",
"      Kyle S, Chandler D, Griffiths CE, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005; 44:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/129\">",
"      Kay L, Walker D. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol 1998; 37:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/130\">",
"      Mader R, Gladman DD, Long J, et al. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med 1995; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/131\">",
"      Zangger P, Gladman DD, Bogoch ER. Musculoskeletal surgery in psoriatic arthritis. J Rheumatol 1998; 25:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/132\">",
"      Lambert JR, Wright V. Surgery in patients with psoriasis and arthritis. Rheumatol Rehabil 1979; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/133\">",
"      Zangger P, Esufali ZH, Gladman DD, Bogoch ER. Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis. J Rheumatol 2000; 27:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/134\">",
"      Kammer GM, Soter NA, Gibson DJ, Schur PH. Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/135\">",
"      Gladman DD, Helliwell P, Mease PJ, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004; 50:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/136\">",
"      Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/137\">",
"      Gladman DD, Tom BD, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index. J Rheumatol 2010; 37:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/138\">",
"      Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011; 70:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/139\">",
"      FitzGerald OM, Helliwell P, Mumtaz A, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA dataset. Arthritis Rheum 2010; 62(Suppl 10):S214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/140\">",
"      Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/141\">",
"      Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010; 62:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/18/40234/abstract/142\">",
"      Fransen J, Antoni C, Mease PJ, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65:1373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7793 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.102.30.19-B4B63FB7F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40234=[""].join("\n");
var outline_f39_18_40234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20469265\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors for progressive joint damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENTS FOR PSORIATIC ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Second-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antimalarials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gold compounds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Psoralen and ultraviolet light (PUVA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Retinoic acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Etanercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Golimumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20086242\">",
"      - Long-term effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Alefacept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Efalizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Ustekinumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7013395\">",
"      - IL-17 blockade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20086343\">",
"      - Abatacept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Other experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Mild disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Use of DMARDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - GRAPPA recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H191776653\">",
"      - EULAR treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - British Society for Rheumatology TNF inhibitor guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Role of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Long-term effect of DMARDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Role of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      ASSESSMENT OF RESPONSE TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20469265\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7793|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23608?source=related_link\">",
"      Pathogenesis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/36/36419?source=related_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/52/835?source=related_link\">",
"      Patient information: Psoriatic arthritis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25319?source=related_link\">",
"      Use of gold compounds in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_18_40235="Clin char ess thrombocythemia";
var content_f39_18_40235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial clinical characteristics in 150 patients with essential thrombocythemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent or median result (range)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        49.8 (17-98)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex, percent female",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin (g/dL)",
"       </td>",
"       <td>",
"        13.7 (9.1-16.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WBC count (x 10(3)/microL)",
"       </td>",
"       <td>",
"        9.0 (4.1-25.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet count (x 10(3)/microL)",
"       </td>",
"       <td>",
"        1000 (454-3460)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpable splenomegaly, percent",
"       </td>",
"       <td>",
"        34.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic, percent",
"       </td>",
"       <td>",
"        45.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasomotor symptoms, percent",
"       </td>",
"       <td>",
"        13.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of fetal loss (women only), percent",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of thrombosis, percent",
"       </td>",
"       <td>",
"        21.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of hemorrhage, percent",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal cytogenetics, percent",
"       </td>",
"       <td>",
"        87.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JAK2 mutation, percent",
"       </td>",
"       <td>",
"        48.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Wolanskyj, AP, et al. Br J Haematol 2005; 131:208.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40235=[""].join("\n");
var outline_f39_18_40235=null;
var title_f39_18_40236="Exercise testing in LEMS";
var content_f39_18_40236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exercise testing in Lambert-Eaton myasthenic syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exercise testing in Lambert-Eaton myasthenic syndrome, with the median nerve stimulated supramaximally at the wrist and the abductor pollicis brevis muscle recorded. (Top) Baseline. (Bottom) Immediately after 10 seconds of maximal voluntary exercise. Note marked increase in compound muscle action potential amplitude (postexercise facilitation). Preexercise and postexercise testing, looking for an increment, always is better tolerated by patients than is 50-Hz repetitive nerve stimulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders, 2nd ed, Butterworth-Heinemann, Boston 1998. Copyright &copy; 1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40236=[""].join("\n");
var outline_f39_18_40236=null;
var title_f39_18_40237="AHT drug and stroke ALLHAT";
var content_f39_18_40237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lisinopril and increased risk of stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the ALLHAT trial, cumulative event rates for the development of stroke according to primary treatment with chlorthalidone, amlodipine, or lisinopril. Compared to chlorthalidone, there was a significant increase in the six year rate of stroke with lisinopril (6.3 versus 5.6 percent, relative risk 1.15 95 percent CI 1.02 to 1.30).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The ALLHAT Officers, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40237=[""].join("\n");
var outline_f39_18_40237=null;
var title_f39_18_40238="Normal foot oblique";
var content_f39_18_40238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard oblique radiograph of foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 534px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The oblique angle provides a better view of the Lisfranc joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40238=[""].join("\n");
var outline_f39_18_40238=null;
var title_f39_18_40239="AECOPD abx inpatient";
var content_f39_18_40239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antibiotic treatment of acute exacerbations of COPD in hospitalized patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 575px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Pseudomonas risk factors:",
"     <br>",
"      &nbsp;&nbsp;- Frequent administration of antibiotics (4 or more courses over the past year)",
"      <br>",
"       &nbsp;&nbsp;- Recent hospitalization (2 or more days' duration in the past 90 days)",
"       <br>",
"        &nbsp;&nbsp;- Isolation of Pseudomonas during a previous hospitalization",
"        <br>",
"         &nbsp;&nbsp;- Severe underlying COPD (FEV1 &lt;50 percent predicted)",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_18_40239=[""].join("\n");
var outline_f39_18_40239=null;
        